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SUMMARY 
This thesis addresses the pressing concern of clinical drug-induced hearing loss (ototoxicity). 
Described herein is the mechanism by which ototoxicity emerges following drug administration 
both in a clinical setting and in an in vitro model assay system used for its investigation, 
through use of mouse cochlear cultures. The predominant nature of this research concerns the 
identification of novel otoprotectants - compounds that when co-administered alongside 
clinical drug treatments can prevent the unfortunate ototoxic side-effect from occurring.  
Here I present my research, focussing on the identification of a number of novel compounds 
that have the potential to be taken forward to in vivo screening and, ultimately, clinical trials. 
Moreover, for each identified compound I present my investigation of their mechanism of 
protection – which could arise either by preventing the entry of the ototoxicity-inducing drugs 
into the sensory hair cells of the inner ear, or prevent their induction of apoptosis once inside 
the cell. To investigate their protective mechanism I employed a variety of methods, including: 
electrophysiology, fluorescent imaging and mitochondrial respirometry. 
Conclusively, I have identified at least five novel otoprotectants with the potential for clinical 
use. I show that three of these compounds likely block the entry of the damaging drugs into 
sensory hair cells, whereas the remaining two are thought to work intracellularly. Moreover, 
the two most effective compounds that I have identified seemingly work intracellularly, 
suggesting this to be the most viable mechanism of otoprotection for further investigation. I 
also show the potential for compound modification based on their mechanism of protection as 
a way of improving a compound’s otoprotective profile. Lastly, I devised an assay for the 
screening of clinical drug effects on mitochondria and employ this as a new avenue of 
screening for otoprotection.  
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Abstract 
 
Aminoglycoside antibiotics (AGs) are extremely effective clinical agents used to treat serious 
bacterial infections such as septicaemia. They do however cause permanent hearing loss as an 
unfortunate side-effect. This is because they are known to specifically enter the sensory hair 
cells of the inner ear through an ion channel known as the mechano-electrical transducer 
(MET) channel. Once inside a cell they are thought to interact with mitochondria, causing the 
production of cytotoxic levels of reactive oxygen species (ROS). It is this process that results in 
the activation of apoptotic cell death cascades, underlying the hair cell loss and consequent 
elevation of hearing threshold associated with AG treatments. 
It is therefore of pressing concern to identify preventative measures against this side-effect. 
Presented herein is my investigation, and identification, of potential novel otoprotectants – 
compounds that when co-administered alongside AG treatment can prevent the associated 
hearing loss. At least five novel compounds have been identified from a library of ion channel 
interactors that display otoprotective properties in vitro and have the potential for clinical 
investigation.  
Following otoprotectant identification, the mechanism by which they protect was 
subsequently investigated. Broadly speaking, there are two possibilities: extracellular block of 
AG entry into hair cells via the MET channel or intracellular prevention of mitochondrial 
dysfunction and ROS accumulation. Whole-cell electrophysiological approaches were 
employed to study compound interaction with the MET channel and imaging of a fluorescent 
AG analogue to assess any prevention of its entry into sensory hair cells. The most effective 
compound identified, protecting in the low nanomolar range, was found to not prevent AG 
entry and thus assumed to have an intracellular mechanism of protection. For this reason, an 
assay was developed to investigate the effect of the AGs on mitochondrial function and 
subsequently to test whether the compound of interest was able to prevent this effect. 
AGs were found to behave as uncouplers of the mitochondrial electron transport chain, 
affecting respiratory rates by dissipating the mitochondrial membrane potential and thereby 
inhibiting ATP production. The most efficacious otoprotectant identified herein did not prevent 
this effect, meaning its mechanism of protection remains to be identified. 
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Our sense of hearing is unequivocally fundamental to our existence as we know it. Not only 
underpinning our survival, our ability to hear is crucial to the rich plethora of communicatory 
abilities that we utilise on a daily basis, without which life would certainly lose a little richness 
at the very least. Those who are unfortunate enough to lose this sensory modality suffer a 
greatly-reduced quality of life, with an almost-unavoidable impact on every aspect of their 
livelihood. Progressive and irreversible hearing loss occurs naturally as a result of aging; 
however other causes of deafness include: prolonged exposure to loud noise, infections such 
as meningitis and treatment with ototoxic compounds. The aminoglycoside antibiotics are an 
extremely effective class of clinical agent used to cure serious bacterial infections. They do, 
however, cause permanent hearing loss as an unfortunate side-effect. The aim of this thesis 
was to identify compounds that could prevent this effect and uncover their modes of action, 
thereby improving the quality of life of individuals unfortunate enough to be treated with 
these clinical agents. 
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1.1 The Anatomy and Functionality of the Ear 
 
1.1.1 The Outer and Middle ear 
 
The outer ear, consisting of the pinna, concha and external auditory meatus (ear canal), serves 
to collect and funnel airborne sound information from the external environment and direct it 
through the ear canal to the tympanic membrane, colloquially known as the ear drum (Figure 
1.1). The sound pressure of frequencies of sound around 3 kHz are passively amplified by the 
auditory meatus due to its anatomical configuration - the frequency of sound at which human 
speech distinction cues are concentrated (Purves et al., 2012).   
The middle ear serves to amplify the sound signal by acting as an impedance matching device. 
Sound stimuli in the external environment are in a low-impedance medium, air. The inner ear, 
however, is filled with the higher-impedance medium, aqueous fluid. When sounds travel 
between these two mediums in the external environment almost all of the acoustic energy is 
lost due to the process of reflection. The middle ear works to prevent the loss of the acoustic 
signal by impedance-matching and boosting the pressure measured at the tympanic 
membrane almost 200-fold by the time it reaches the inner ear (Purves et al., 2012). The 
structure achieves this amplification pressure gain by two complimentary processes. Firstly, 
the middle ear contains three bones that connect the tympanic membrane to the oval window 
(Figure 1.1). These are known as the ossicles, or the malleus, incus and the stapes; colloquially 
known as the hammer, anvil and stirrup. They are three small, specifically shaped and 
interconnected bones that serve to amplify and concentrate the sound signal on the oval 
window; maximising sound intensity with remarkable efficiency. Secondly, the focussing of the 
force from the relatively large-diameter tympanic membrane onto the much smaller-diameter 
oval window (where the middle ear bones contact the inner ear) gives a large boost in the 
pressure signal, enhancing the amplification process (Purves et al., 2012; Kandel et al., 2013). 
 
1.1.2 The Inner Ear 
 
The inner ear is a bony labyrinth comprised of the auditory and vestibular systems; highly-
specialised structures that are responsible for the phenomenon of hearing and balance 
respectively. The vestibular apparatus comprises the saccule, utricle and the semicircular 
canals; structures that are responsible for the detection of head motion, head orientation and 
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balance. The cochlea (the organ of hearing) is directly responsible for sound transduction and 
our ability to perceive sounds emerging from the external environment. It is the location at 
which sound stimuli are converted into neural impulses that can then be delivered to, and 
processed by, the auditory cortex. Alongside this, the cochlea also represents the first instance 
of frequency analysis, with complex sound stimuli waveforms being decomposed into their 
component parts by the fascinatingly intricate anatomical organisation of the structure.  
The stapes joins the cochlea at the oval window, at the base of the structure (Figure 1.1). From 
the base to the apex, the cochlea is partitioned into three fluid-filled chambers. Either side of 
this partition are two chambers known as the scala vestibuli and scala tympani, both of which 
contain perilymph; a sodium-rich fluid. Central to the cochlear partition is a distinct chamber 
known as the cochlear duct, or scala media, which contains a potassium-rich fluid known as 
endolymph. Within the scala media sits the organ of Corti – the anatomical structure that is 
situated between the basilar and tectorial membranes and is directly responsible for sound 
transduction (Figure 1.2). The cochlear partition is what allows for the flexibility in movement 
of the basilar and tectorial membrane – important structures that underlie the frequency-
selectivity of the transduction apparatus (Purves et al., 2012; Kandel et al., 2013). 
When sound stimuli are delivered to the base of the cochlea via the stapes, the basilar 
membrane resonates depending on the frequency composition of the sound. Due to the 
geometry of the basilar membrane, being wider and more flexible at the apical end and more 
narrow and stiff at the base, it vibrates maximally at different locations dependent on the 
stimulus. High-frequency stimuli induce maximal basilar membrane displacement at the base 
of the cochlea whereas low-frequency stimuli cause maximal displacement in the apex. This 
tonotopic gradient is an important characteristic enabling the decomposition of complex 
sound waveforms into their frequency components, with the basilar membrane acting as a 
mechanical frequency analyser (Purves et al., 2012; Kandel et al., 2013).  
The sensory hair cells (HCs) of the inner ear are situated atop of the basilar membrane (Figure 
1.2). On top of the HCs sits the tectorial membrane, a gelatinous structure in which the 
stereocilia of outer HCs (OHCs) are embedded. When the basilar membrane vibrates in 
response to sound stimuli, this causes movement of both the organ of Corti and the overlying 
tectorial membrane. Due to their differing pivoting points this displacement leads to a shearing 
of the two membranes. This shearing causes a displacement of the stereocilia that adjoin the 
HC’s apical surface, leading to potassium ion entry into the cell, consequent cellular 
depolarisation and the signalling of sound stimuli to the auditory nerve. Inner HCs (IHCs) are 
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not directly embedded in the tectorial membrane, but rather their stereocilia are deflected by 
movement of the fluid beneath the membrane (Kandel et al., 2013) (Figure 1.2).  
 
 
 
Figure 1.1: The anatomical organisation of the ear. Figure modified with permission from © 
University of Dundee School of Medicine, illustrated by Annie Campbell. 
The outer ear, responsible for capturing and funnelling airborne sound information, consists of 
the pinna, concha and auditory canal. The middle ear, which impedance matches and serves to 
amplify sound signals, consists of the tympanic membrane and the ossicles (the malleus, incus 
and stapes). The inner ear, which is responsible for sound transduction, consists of the 
vestibular apparatus and the cochlea. 
21 
 
 
 
Figure 1.2: The anatomical organisation of the organ of Corti. Figure modified from Pickles 
(2008). 
The organ of Corti, which is situated in the cochlear duct, is responsible for the transduction of 
sound stimuli into electrical impulses that can be interpreted by the brain. Inner HCs (IHCs) 
directly transduce sound stimuli to afferent nerve fibres, whereas outer HCs (OHCs) are 
innervated mainly by efferent nerve fibres and serve to fine-tune our hearing sensitivity and 
frequency selectivity. 
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1.2 Sensory Hair Cell Anatomy and Function 
 
Along the length of the cochlear sensory epithelium there are typically four rows of sensory 
HCs - one row of IHCs and three rows of OHCs (Figure 1.2). On average, the human organ of 
Corti contains approximately 3,500 IHCs and 11,000 OHCs (Kandel et al., 2013). The IHCs are 
the sensory receptors that are directly responsible for sound stimuli transduction and 
information transfer to the auditory nerve. They are contacted by many afferent nerve fibre 
innervations, with approximately 95% of fibres in the auditory nerve originating from the IHCs 
(Purves et al., 2012). OHCs are primarily contacted by efferent nerve fibres and serve to 
actively amplify sound signals due to their expression of the motor protein prestin. This gives 
rise to their unique characteristic of electromotility; frequency-dependent contraction and 
extension of the cell body in response to electrical stimulation (Brownell et al., 1984; Zheng et 
al., 2000; 2002; Dallos, 2008). 
Located on the apical surface of all sensory HCs is a mechanosensory hair bundle, comprised of 
multiple rows of stereocilia that are joined together with an assortment of molecular linkers, 
allowing the hair bundle to move in a cohesive manner upon deflection (Hackney and Furness, 
2013). These stereocilia are anchored in the apical membrane in an actin-rich structure known 
as the cuticular plate, and are able to pivot in response to mechanical deflection. In mammals, 
the bundle also has a larger kinocilium that disappears shortly after birth – it is absent by 
postnatal day 12 (Kikuchi and Hilding, 1965; Kimura, 1966). The stereocilia are arranged in a 
graded pattern with rows of increasing height and are connected at their apical tips by 
filamentous structures known as tip-links (Pickles et al., 1989). These are molecular structures 
comprised of cadherin-23 and protocadherin-15 (Kazmierczak et al., 2007), which are 
anchored in structures known as the upper and lower tip-link densities, alongside an 
assortment of other proteins such as myosin VIIa, harmonin-b and sans (Figure 1.3). In IHCs, 
the hair bundle shape is roughly linear, whereas OHCs have a characteristic V-shaped 
mechanosensory hair bundle located on their apical surfaces (Kandel et al., 2013).  
When a mechanical stimulus causes displacement of the stereociliary bundle in the excitatory 
direction, towards the tallest stereocilia, the tip-links are stretched and put under tension. 
Located at the lower end of the tip-link is a non-selective cation channel known as the 
mechano-electrical transducer (MET) channel. The tip-links and MET channels represent the 
transduction apparatus, in that their functionality is what allows the transformation of hair 
bundle displacement into a receptor potential. When the tip-links are put under tension in 
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response to an excitatory stimulus this causes the mechanically-gated MET channels to open 
and potassium and calcium ions from the endolymphatic fluid to flow into the HC. This process 
depolarises the cell, causing calcium ions to enter near the basolateral membrane and 
subsequent neurotransmitter release to the connecting nerve fibre, which then transmits the 
signal along the auditory pathway, eventually terminating in the auditory cortex of the brain. 
Deflection in the inhibitory direction, towards the shortest row of stereocilia, closes the MET 
channels and hyperpolarises the cell.  
Evidence of the involvement of tip-links in transduction comes from calcium chelation studies. 
When calcium chelators such as BAPTA are used to destroy tip-links, transduction disappears 
(Assad et al., 1991; Goodyear and Richardson, 2003; Marcotti et al., 2014). Upon regeneration, 
transduction is restored, indicative of tip-link control of HC mechano-transduction (Zhao et al., 
1996; Indzhykulian et al., 2013; Kendal et al., 2013).  
 
1.3 The Endocochlear Potential 
 
A crucial driving force of mechano-electrical transduction within the cochlea is the 
endocochlear potential (EP). The EP is primarily generated by the stria vascularis (SV) – a 
metabolically-active epithelium located in the lateral wall of the cochlear duct (Quraishi and 
Raphael, 2008). The SV is responsible for the two endolymphatic properties which enable such 
efficient signal transduction by mechanosensory HCs - the unusually high extracellular K+ 
concentration (˃ 150 mM) and the large electrical potential (+80 to +90 mV) relative to the 
perilymphatic fluid (Takeuchi et al., 2000; Wangemann, 2002; Hibino and Kurachi, 2006; 
Quraishi and Raphael, 2008). The cells of the SV transport and secrete K+ ions into the scala 
media compartment (Tasaki and Spyropoulos, 1959), thereby generating the properties that 
are fundamental to audition (Wangemann, 2006; Nin et al., 2008). 
The EP is essential for cochlear function, with the influx of K+ ions through the MET channel 
determined by the electrical gradient established by the sum of the EP and the resting 
potential (RP) of the HC, which is between -70 and -45 mV (Dallos et al., 1982; Dallos, 1996; 
Takeuchi et al., 2000; Purves et al., 2012). The RP of OHCs is more negative than that of IHCs 
(Dallos et al., 1982). The EP is non-uniform and increases from the apex to the base, meaning 
there is a greater electrical driving force across HC MET channels in the basal coil of the 
cochlea. 
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Following entry, K+ must be cleared from HCs to enable continuous sensory receptiveness. This 
is achieved by basolateral potassium channels that release the K+ into the perilymph that 
bathes the basolateral surface of the HCs. A number of ion channels perform this function, 
including: KCNQ4 (which mediates the current IK,n), KCNN2 (ISK2) and KCNMA1 (IK,f) (Kros, 
1996; Wangemann, 2006). 
 
1.4 The Mechano-Electrical Transducer (MET) Channel 
 
For the sensation of hearing to occur, mechanical sound stimuli must be converted into 
electrical signals that can be interpreted by the brain. This function is achieved by the sensory 
HC MET channels. The molecular characterisation of the MET channel has been described as 
the ‘holy grail’ of the field of hearing research, due to its obscurity and elusiveness of 
identification. Pursuit of its molecular identity has spanned over 20 years (Fettiplace, 2016), 
and the topic is still of controversial debate. Several candidates have been proposed, including 
members of the transient receptor potential (TRP) channel family (Corey, 2003; Fettiplace, 
2009; Lee et al., 2013); however these have since failed under scientific scrutiny (Corey, 2006). 
Many researchers now consider transmembrane channel-like (TMC) 1 and TMC2 proteins to be 
the most likely candidates as crucial molecular components of the MET channel (Kurima et al., 
2015; Fettiplace, 2016; Pan et al., 2018). 
Investigation into the molecular identification of the MET channel has led to a large body of 
information regarding its functional properties. Firstly, the MET channel is a non-specific, 
cation-selective ion channel. It primarily permits the flow of potassium, which predominantly 
underlies the MET current, and also calcium, which partly underlies the adaptation process 
(Corns et al., 2014). However, other molecules have also been shown to permeate through the 
channel (Farris et al., 2004). The entry rate of positively-charged molecules is determined by 
the electrical potential generated across the channel, primarily as a result of the combined 
sum of the EP and RP of the cell. Cellular depolarisation has been shown to reduce calcium 
entry (Eatock et al. 1987; Crawford et al. 1989), as direct evidence of this. 
Experimental evidence has suggested that there are two MET channels per stereocilium 
(Fettiplace, 2009), and although researchers remain divided, their location is largely assumed 
to be at the base of the tip-links on the second and third stereociliary rows atop cochlear HCs, 
as established by high-speed calcium imaging studies (Beurg et al., 2009) (Figure 1.3). HCs 
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exhibit adaptation properties in that upon maintained stimulation, the tension in the tip-links 
is lessened over time to enable a broader dynamic range of the sensory detection response. 
This is partly due to the non-selective nature of the MET channel. When it opens upon 
stereocilial deflection calcium ions also flow into the cell and this is what underlies at least one 
aspect of the adaption process (Vilfan and Duke, 2003; Corns et al., 2014).  
The functioning of the MET channel can be investigated with the use of a number of 
fluorescent dyes. Classically, the styryl dye FM 1-43 has been used for the study of endo- and 
exo- cytosis (Betz et al., 1996; Smith and Betz, 1996; Amaral et al., 2011). However, 
researchers have also found that it can rapidly enter HCs through the MET channel (Gale et al., 
2001), meaning it provides a reliable marker of HC MET channel function. 
 
 
Figure 1.3: The proposed anatomical localisation of the MET channel. Figure taken from Grati 
and Kachar, 2011. 
Current theories suggest that the mechano-electrical transducer (MET) channel, which is 
critical for our ability to hear, is located in the lower tip-link density, on the shorter 
neighbouring stereocilium.  
26 
 
1.5 Ototoxic Drugs 
 
1.5.1. The Use of Ototoxic Drugs 
 
Ototoxicity is defined as the property of being toxic to the ear. This can manifest as either 
cochleotoxicity (damage to the cochlea or auditory nerve) or vestibulotoxicity (damage to the 
vestibular system or nerve).  Many ototoxic substances have been identified, including: the 
aminoglycoside antibiotics (AGs), loop diuretics such as furosemide and chemotherapy agents 
such as cisplatin. Despite their ototoxic properties they are still widely prescribed due to their 
effectiveness at treating serious medical conditions and the lack of suitable alternatives.  
The AGs are one of the most commonly prescribed antibiotics worldwide due to their 
remarkable antimicrobial efficacy, their widespread availability due to their ease of storage 
and also their low cost relative to alternatives (Rizzi and Hirose, 2007; Kushner et al., 2016). 
They are widely prescribed to treat serious life-threatening bacterial infections such as 
septicaemia, tuberculosis, meningitis, respiratory infections in cystic fibrosis and complex 
urinary tract infections (Xie et al., 2011). A recent study on the prescription demographic 
revealed that the vast majority of AG prescriptions are for neonatal children and the younger 
population, between 18 and 34 years of age (Kushner et al., 2016). 
Although extremely effective clinical agents, the AGs carry the unfortunate risk of common 
adverse side-effects such as oto- and nephro- toxicity – damage to hearing ability and kidney 
function respectively (Mingeot-Leclercq and Tulkens, 1999; Forge and Schacht, 2000; 
Selimoglu, 2007; Wargo and Edwards, 2014). The damage to these tissue types specifically is 
due to the retention of the AGs within these cells. Most cells take up AGs but are able to 
efficiently clear them from their cytoplasm (De Groot et al., 1990; Imamura and Adams, 2003; 
Jiang et al., 2017). Kidney cells and cochlear sensory HCs, however, retain the AGs within their 
cytoplasm for a prolonged period of time (Imamura and Adams, 2003; Dai et al., 2006). This, 
together with the greater cellular uptake, leads to the accumulation of an intracellular 
concentration at which apoptosis is induced. Nephrotoxicity is of a lesser concern due to the 
regenerative ability of kidney cells, with dying cells replaced through cellular proliferation 
meaning kidney damage is short-lived and reversible (Heller, 1984; Xie t al., 2001; Jiang et al., 
2017). In mammals, unlike in avian species, the sensory cells of the inner ear are unable to 
regenerate (Stone and Cotanche, 2007), meaning that damage to the inner ear is permanent 
and irreversible, making AG-induced ototoxicity a much more pressing concern.  
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In terms of ototoxicity, the AGs can be both cochleo- and vestibulo- toxic, depending on which 
one is prescribed. Gentamicin (Figure 1.4) and streptomycin are primarily vestibulotoxic, 
whereas amikacin, neomycin, dihydrostreptomycin (DHS) and kanamycin are primarily 
cochleotoxic (Selimoglu, 2007; Xie et al., 2011). The likelihood of developing the symptoms of 
ototoxicity is influenced by several factors, including: the concentration of the dose, the 
frequency of administration, the duration of treatment and any genetic predisposition, 
primarily as a result of mitochondrial make-up, with the latter largely due to the A1555G 
mutation in the mitochondrial 12S rRNA gene (Wu et al., 2002; Xie et al., 2001; Qu et al., 
2015). The incidence of ototoxicity varies between studies depending on the method of 
assessment, but in patients who receive intravenous doses across multiple days, the incidence 
of ototoxicity has been reported in approximately 20% of all treated patients (Ariano et 
al., 2008; Al-Malky et al., 2015; Garinis et al., 2017; Jiang et al., 2017). Cochleotoxicity is more 
commonly observed, with incidence rates as high as 33% reported, compared with 15% for 
vestibulotoxicity (Fee, 1980; Lerner et al., 1986; Fausti et al., 1999; Kushner et al., 2016).  
 
Figure 1.4: Gentamicin is a large (465 g/mol molecular weight), polycationic molecule that is 
water soluble at physiological pH. The chemical structures for the gentamicin varieties are as 
follows: gentamicin C1: R1 = R2 = CH3; gentamicin C2: R1 = CH3, R2 = H; and gentamicin C1A: R1 = 
R2 = H. Figure modified from Jiang et al., 2017. 
 
The prescription demographic is what makes the issue of AG-induced ototoxicity a pressing 
concern. Neonatal children are the most often treated with the antibiotics due the broad-
spectrum nature of AG activity and therefore their effectiveness at curing a wide range of 
bacterial infections, especially when the underlying cause is unknown. However, neonates are 
also the most susceptible population to the debilitating consequences of the often-endured 
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ototoxic side-effect. Hearing ability is vital for the development of language and 
communication skills, education, psychosocial development and social interaction; those that 
lose their ability to hear at an early age often struggle to develop in these areas, creating a 
large socio-economic burden and a greatly-reduced quality of life. 
 
1.5.2 Mechanism of Action of the Aminoglycoside Antibiotics 
 
The way in which the AGs cause the death of bacteria is well understood, with their 
antibacterial effect attributable to their binding of the bacterial 30S ribosomal subunit. Binding 
of this subunit causes RNA to be misread, consequent disruption to protein synthesis and thus 
an accumulation of non-functional proteins leading to bacterial cell death (Cox et al., 1964; 
Davies and Davis, 1968; Xie et al., 2011). The way in which the AGs cause the death of kidney 
cells and cochlear sensory HCs is less well understood, however. The damage to these organs is 
due to the entry and subsequent inefficient clearance from these tissue types specifically, with 
endocytic and non-selective cation channel-mediated entry routes in kidneys (Nagai and 
Takano, 2014) and the MET channels in cochlear sensory HCs being proposed entry pathways 
(Marcotti et al., 2005; Alharazneh et al., 2011).  
In order to cause sensory hair cell death the AGs must first be trafficked to the endolymph (in 
which the sensory hair cell bundles are situated), where they can then proceed to enter cells 
and induce apoptosis. The AGs are usually administered systemically, and although the 
endolymph is well shielded from the circulatory system due to the blood-labyrinth barrier, 
they are still able to enter into this discrete compartment.  Endothelial cells line the capillaries 
within the stria vascularis, forming an impermeable barrier. However, evidence suggests that 
the tight junctions existing in these cell membranes can allow the passage of AGs into the 
endolymph, with AGs trafficked from the capillaries, through the marginal cells and into the 
endolymphatic compartment (Figure 1.5). For a thorough review, see Kros and Desmonds 
(2015). 
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Figure 1.5: A schematic of a cross-section through a turn of the cochlea, showing the three 
discrete compartments. AGs are able to cross the blood-labyrinth barrier and enter the 
endolymph via the marginal cells. Figure taken from Kros and Desmonds, 2015. 
 
Once inside a cell, however, the AGs are thought to have a conserved mechanism of cell death 
induction. They are believed to interact with intracellular organelles such as mitochondria, 
causing their dysfunction and the consequent initiation of apoptotic cell death pathways. The 
assumption of mitochondrial involvement in AG-induced damage has manifested as a result of 
several pieces of evidence. Firstly, the remarkable similarity of the structure of mitochondria to 
that of bacteria (the primary target of AGs) gave the first indication that they may represent a 
secondary target of the antibiotics, alongside their proposed bacterial origin (Margulis et al., 
1970; Gray et al., 2001; Gray et al., 2012). Secondly, fluorescence imaging studies showing the 
co-localisation of a fluorescent AG conjugate (gentamicin-Texas Red; GTTR) with mitochondrial 
stains such as Mitotracker (Ding et al., 1995; Steyger et al., 2003), suggested that they are 
trafficked to these organelles once inside the cell. Moreover, point mutations in mitochondrial 
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DNA leads to enhanced susceptibility to AG-induced toxicity (Prezant et al., 1993), again 
signifying mitochondrial involvement. Lastly, prior to cell death, cells treated with AGs show an 
increase in the intracellular concentration of reactive oxygen species (ROS) (Clerici et al., 1996; 
Hirose et al., 1997; Sha and Schacht, 1999a); cell signalling molecules produced primarily by 
mitochondria. Taken together these data suggest that mitochondria are a secondary target of 
the AGs, and that perhaps their dysfunction is what underlies kidney and sensory HC death 
following AG entry into these cell types. 
As well as these somewhat indirect lines of evidence, researchers have also shown a direct 
effect of the AGs on the respiratory activities of mitochondria, both in isolated mitochondrial 
assays and also intact whole-cell systems. Reports suggest that AGs can irreversibly bind to 
mitochondria in vitro (Kornguth et al., 1980), their binding induces the opening of the 
permeability transition pore (Dehne et al., 2002), this dissipates the mitochondrial membrane 
potential (Dehne et al., 2002; Miyazono et al., 2018) and leads to a reduction in the amount of 
ATP that cells can produce (Simmons et al., 1980), thereby causing the death of the cell. 
Alternative theories have suggested the involvement of ribosomes and the endoplasmic 
reticulum (ER) (Steyger et al., 2003), and potentially an extremely complex interaction 
between combinations of intracellular organelles and their interconnecting systems, including 
calcium signalling between the ER and mitochondria (Esterberg et al., 2013, 2014; Hailey et al., 
2017; O’Sullivan et al., 2017). 
31 
 
 
Figure 1.6: Crude schematics of the mechanisms by which AGs are thought to cause HC death. 
(A) Figure produced by Richard Goodyear, University of Sussex, and modified by myself. (B) 
Figure taken from Karasawa and Steyger, 2011. 
The aminoglycoside antibiotics (AGs) are known to enter the sensory HCs of the inner ear 
through the MET channel. Once inside, they are thought to interact with mitochondria, causing 
the production of cytotoxic levels of free radicals and the release of pro-apoptotic factors. 
 
1.6 Mechanisms of Otoprotection 
 
Due to the devastating consequences of AG-induced ototoxicity, especially when occurring in 
the younger demographic, a large number of researchers working in the field of hearing and 
deafness have focussed on attempting to identify otoprotectants; compounds that when co-
administered alongside AG treatment can prevent the unfortunate side-effect form occurring. 
Broadly speaking, there are two main ways in which a compound could offer protection 
against AG-induced ototoxicity, as detailed below. 
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1.6.1 MET Channel Block 
 
One potential method of otoprotection that has been extensively studied is focussed on the 
entry route of the AGs into HCs. As they are known to primarily enter sensory HCs through 
their MET channels (Marcotti et al., 2005; Alharazneh et al., 2011), numerous studies have 
investigated the potential of blocking these channels and thereby preventing AG entry, 
accumulation and consequent apoptosis-induction. However, when searching for a MET 
channel-blocking otoprotectant, the compound must show reversibility of the channel block so 
as to provide only a temporary effect. Furthermore, compounds must not permeate into HCs, 
as they themselves could cause toxic effects once they have accumulated inside a cell. 
 
1.6.2 Intracellular Protection  
 
An alternative mechanism of otoprotection that has been extensively studied is the prevention 
of intracellular apoptotic cascades. Once inside a cell, AGs are thought to cause mitochondrial 
dysfunction and the consequent production of cytotoxic levels of ROS. Intracellular approaches 
therefore aim to prevent this effect. One approach is to preserve mitochondrial function, for 
example by way of preventing AG binding to the mitochondrial membranes, preventing the 
opening of the permeability transition pore, or by preserving the mitochondrial membrane 
potential (Fu et al., 2006; Ou et al., 2009). Alternatively, these approaches could work post-
mitochondrial dysfunction, by way of reducing ROS concentrations within the cell, often by 
application of antioxidants and other ROS-scavenging molecules (Sha and Schacht, 2000; Sergi 
et al., 2004; Rybak and Whitworth, 2005; Xie et al., 2011; Negrette-Guzmán et al., 2015). 
 
1.6.3 Otoprotection Method Comparison 
 
The advantage of an intracellular approach is that there would be no interference with MET 
channel function, so patients treated with the otoprotectant would not experience short-lived 
hearing loss, as they would with MET channel-blocking approaches. However, once inside a cell 
the closely-related AGs neomycin and gentamicin have been shown to activate different 
intracellular cell-death cascades in zebrafish (Owens et al., 2009; Coffin et al., 2013a,b), so 
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perhaps a MET channel-blocking otoprotectant may be the most effective, all-encompassing 
approach. 
However, mitochondrial dysfunction is known to play a role in a variety of diseases and 
disorders, including a large number of neurodegenerative conditions such as Alzheimer’s 
disease (Reddy, 2009; Lezi and Swerdlow, 2012). Consequently, if we were to identify a 
compound that could preserve mitochondrial function, for example by way of mitochondrial 
membrane potential stabilisation, this could have huge transferable potential in terms of 
remodelling for a large number of other debilitating conditions. 
 
1.7 Zebrafish as a Model for Otoprotectant Screening 
 
Zebrafish were used for preliminary screening in this thesis as they provide a powerful pre-
screening tool when searching for otoprotectants that can prevent the ototoxic side-effect of 
the AGs in mammals. This is because the sensory HCs that are situated in the neuromasts 
located along the lateral line system are remarkably similar to those in the mammalian 
cochlea, both morphologically and functionally. Each neuromast has an aggregation of multiple 
sensory HCs. On top of each of these HCs sits a mechanosensory hair bundle, consisting of a 
single kinocilium and multiple stereocilial rows. These are the same morphological features 
present on the sensory HCs of the postnatal day 2 (P2) mice cochleae used in the subsequent 
screening experiments detailed in this thesis. Moreover, zebrafish sensory HCs are permeated 
by FM 1-43 (Seiler and Nicolson, 1999), susceptible to AG damage (Kaus, 1987; Song et al., 
1995; Harris et al., 2003) and protected by the same compounds that protect mammalian HCs 
(Kirkwood et al., 2017), further highlighting their functional similarities. 
The use of zebrafish allows for extremely high-throughput screening relative to the use of 
mammalian models, and numerous otoprotectants have previously been identified using this 
approach (Ton and Parng, 2005; Ou et al., 2009; Esterberg et al., 2013; Kruger et al., 2016). 
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1.8 Thesis Aims 
 
Ototoxicity is an extremely unfortunate and debilitating effect associated with AG treatment. 
Patients already suffering from serious bacterial infections must then also endure the 
extremely unpleasant experience of losing their hearing ability. For this reason, the main aim 
of this thesis was to identify novel otoprotectants – compounds that when co-administered 
alongside AG treatment could prevent the associated hearing loss.  
Additionally, I also aimed to establish the mechanism of protection of all of the newly-
identified protectants. This would further our knowledge of which approach to otoprotection 
may be the most viable option; whether that be blockade of the MET channel and prevention 
of AG entry or, alternatively, the prevention of mitochondrial dysfunction and the consequent 
initiation of intracellular apoptotic cascades. 
Alongside this, I have provided full characterisation of the effects of gentamicin in the mouse 
cochlear culture assay system developed by Richardson and Russell (1991), which was used for 
the screening and assessment of otoprotection throughout this thesis and elsewhere 
throughout the literature. 
Lastly, I also aimed to elucidate the effect of the AGs on mitochondrial function and develop an 
experimental assay for screening for this effect. This then enabled me to investigate the 
mechanism of protection of identified compounds in regards to preservation of mitochondrial 
function. 
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2   Methods 
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2.1 Animal Husbandry 
 
2.1.1 Mouse Husbandry 
 
CD-1 wildtype, postnatal day 2 (P2) mice of either sex were used for the majority of the 
experiments detailed herein; for cochlear culture protection screening, GTTR and FM 1-43 live 
imaging and also for electrophysiological recordings. Animals were bred in house following UK 
Home Office guidelines. Stock was originally obtained from Charles River. 
2.1.2 Rat Husbandry 
 
For the mitochondria experiments detailed in this thesis, Sprague Dawley rats of either sex 
were used. Their age ranged from 4 weeks to 3 months, with no difference detected in the 
experimental result across different ages. Rats were bought in from Charles River. Pups were 
born and raised in house following UK Home Office guidelines. 
2.2 Cochlear Culture Preparation 
 
Cochlear cultures were prepared from CD-1 wildtype mice as previously described by Russell 
and Richardson (1987). In brief, P2 pups were euthanized by cervical dislocation following 
Home Office guidelines. Decapitated heads were surface sterilised by three one minute 
washes in 80% ethanol. Sagittal incisions were made down the midline of the head and 
cochleae were removed. Subsequent dissections were performed in Hank’s Buffered Salt 
Solution (HBSS; Thermo Shandon 14025050) with 1% Hepes (Sigma H0887) (HBHBSS). The 
cartilaginous capsule surrounding the cochlea was removed, the sensory tissue was then 
detached from the central modiolus and the stria vascularis was stripped off. The exposed 
sensory epithelium was explanted onto a collagen-coated (Corning 354236) coverslip. 
Immersed in rat culture media (RCM; 93% DMEM-F12, 7% fetal bovine serum and 10 µg ml-1 
ampicillin), cochlear preparations were sealed in Maximow slide assemblies and left to adhere 
for 24 hours in a 37°C, 5% CO2 incubator. All cochlear culture screening was performed after 
one day (P2 + 1) incubation. Electrophysiology experiments were conducted after one or two 
(P2 + 2) days incubation time. All procedures described in this thesis complied with the UK 
Animals (Scientific Procedures) Act 1986. 
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2.3 Mouse Protection Assay 
 
Following 24 hours incubation, cochlear cultures were quality-checked using differential 
interference contrast (DIC) optics on an inverted Zeiss IM35 microscope, to assess culture 
viability. They were then removed from the Maximow slide assemblies, placed in 35 mm petri 
dishes (Greiner Bio-One 627161) and incubated for 48 hours in the presence of 1 ml 
RCM:DMEM-F12 (1:4) alongside 5 µM gentamicin (Sigma G3632) and either 0.5% dimethyl 
sulfoxide (DMSO) or selected concentrations of the compounds of interest, often starting with 
a dose-response experiment for the parent compound from which subsequent concentrations 
were chosen. Following 48 hours incubation, cultures were washed once with 2 ml phosphate 
buffered saline (PBS) and fixed for 1 hour with 3.7% formaldehyde (Sigma F1635) in 0.1 M 
sodium phosphate buffer (pH ~ 7.3). After fixation, cultures were washed three times with PBS, 
trimmed off of the coverslips with their adherent collagen and permeabilised with 0.1% Triton 
X-100 in PBS, in the presence of 10 % horse serum and 1 mM sodium azide. Cultures were then 
stained with TRITC-phalloidin (Sigma P1951) at a concentration of 1:1000 for at least 24 hours. 
Additionally, myosin VIIa (1:400) rabbit primary antibody (2B Scientific) followed by Alexa 488 
goat α rabbit secondary antibody (1:500) (Invitrogen) were used to specifically stain the HC 
bodies in some experiments.  Cultures were mounted on glass slides with Vectashield (Vector 
Laboratories) and imaged using a Zeiss Axioplan II microscope and Spot RT digital camera. 
 
2.4 Live Cell Imaging of Gentamicin-Texas Red (GTTR) and FM 1-43 
Loading into Sensory Hair Cells 
 
2.4.1 Block of GTTR Loading by 5 minutes Compound Incubation 
 
Coverslips with their adherent cochlear cultures were removed from the Maximow slide 
assemblies and placed in a Perspex viewing chamber with a glass bottom. They were immersed 
in 500 µl of HBHBSS and the cultures were then treated with either 100 µM of the potential 
otoprotectant or 1% DMSO as a control, with all parent compounds and their derivatives being 
dissolved in this solvent. After 5 minutes incubation time at room temperature (20-25°C), GTTR 
(obtained from P.S. Steyger, Oregon Hearing Research Center, Oregon Health & Science 
University, Portland, Oregon, USA) was added at a final concentration of 0.2 µM and incubated 
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for a further 10 minutes. Cultures were then washed three times with 500 µl HBHBSS, before 
live imaging on a Zeiss Axioplan II microscope. A 60x water immersion lens, numerical aperture 
(NA) 0.90, was used to take images of both the mid-apical and mid-basal regions of cochlear 
cultures across a time range from T = 20 to T = 31 minutes post-GTTR application. Both 
Nomarski DIC and fluorescence images were taken. Three repeats were conducted and 
quantification of the intracellular GTTR fluorescence intensity was derived from selected time 
point images of the basal region, approximately 20% along from the basal end. 
A structural comparison of gentamicin and GTTR is not presented here due to the complexity 
and variability of the conjugation process. Both gentamicin and GTTR come in many different 
varieties, as detailed in Woiwode et al., 2015. 
 
2.4.2 Block of GTTR Loading by 24 hours Compound Incubation 
 
For the experiments presented in Chapter 4 (4.2.5.5.1 - 4.2.5.5.3), cultures were incubated 
with 50 µM of selected compounds or 0.5% DMSO for 24 hours before testing the loading of 
GTTR into HCs. Following incubation, the cultures were placed in a Perspex viewing chamber 
and washed three times with 500 µl HBHBSS. GTTR was then added at a concentration of 0.2 
µM and incubated for 10 minutes, after which the culture was washed with three 500 µl 
HBHBSS additions. Images were taken of the mid-apical and mid-basal regions of the cochlear 
culture on a Zeiss Axioplan II microscope with a 60x objective, across a time range from T = 20 
to T = 31 minutes post-GTTR application. 
 
2.4.3 Block of FM 1-43 Loading by 24 hours Compound Incubation 
 
As with the 24 hours compound, GTTR live imaging experiments presented above (2.4.2), 
coverslips with adherent cultures that had been exposed to 50 µM of selected compounds or 
0.5% DMSO for 24 hours were placed in a Perspex viewing chamber and immersed in 500 µl of 
HBHBSS. They were washed three times and then FM 1-43 was added to a final concentration 
of 0.3 µM and incubated for 10 minutes. After washing off FM 1-43 with three 500 µl HBHBSS 
additions to remove any unbound dye, images of the mid-apical and mid-basal regions were 
taken on a Zeiss Axioplan II microscope with a 60x objective at 10 and 15 minute time points 
post-FM 1-43 application. 
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2.5 Cell Culture Data Analysis 
 
2.5.1 Protection Assay Analysis 
 
Images of the apical and basal region were obtained using a Zeiss Axioplan II microscope with a 
40x objective, with the focal plane adjusted to focus on the mechanosensory hair bundles. 
When two fluorescence stains were used, images were taken at the level of the hair bundles 
(TRITC phalloidin) and cell bodies (Alexa 488, for myosin VIIa) through separate fluorescent 
channels. For quantification of HC survival in otoprotection screening experiments, images 
from the mid-basal region were analysed. OHCs in a 300 µm-long segment of the cochlea were 
quantified in most instances, approximately 20% along the length of the cochlea from the 
basal end. The observable presence of a hair bundle was the criterion used as a marker of HC 
survival. Although HCs can survive without a stereociliary bundle (Gale et al., 2002; Majumder 
et al., 2017) their presence would be vital for sound transduction, so provide a useful marker 
of HC viability when screening for suitable otoprotectants.  
For the purposes of the data presented in Chapter 3, OHC numbers in the mid-apical region 
were also quantified, as well as IHCs in both cochlear regions of interest. 
 
2.5.2 Live Cell Imaging (GTTR and FM 1-43) Analysis 
 
For quantification of intracellular GTTR and FM 1-43 fluorescence, images analysed were from 
the mid-basal region at selected time points after GTTR or FM 1-43 addition, as detailed in 
each chapter (between 15 and 27 minutes post-fluorescent compound application). Ten cells 
from the first row of OHCs central to the 160 μm-long image were analysed in Adobe 
Photoshop CS2 (OHC I; Figures 2.1A* and 2.2), obtaining cell cytoplasm fluorescence intensity 
values from a 30x30 pixel region of interest (ROI) (the square in Figure 2.1B shows the size of 
this ROI relative to the cell) using the Histogram tool to generate a mean grey level intensity 
value. Three background fluorescence intensity ROIs were measured, averaged and subtracted 
from each individual cell value, and the remaining grey level intensity values were then 
averaged as an indication of intracellular fluorescence. One background ROI was taken from 
non-sensory HC cellular space to account for any endocytic loading. At least three 
experimental replicates were conducted in every instance. 
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Figure 2.1: The 10 first row (most inner) OHCs that were analysed to generate GTTR and FM 1-
43 fluorescence intensity values.  
(A) The fluorescence intensity values (arbitrary units) of 10 first row OHCs (closest to the IHCs)  
in the centre of the image were analysed to establish whether the compounds of interest 
reduced the loading of the fluorescent compounds GTTR and FM 1-43 (*). (B) A 30x30 pixel ROI 
was used to generate mean intracellular fluorescence intensity values (). Scale bar is 50 μm. 
 
2.5.3 Statistics 
 
GraphPad Prism 7 was used for the generation of all statistical data. All graphical 
representations display the mean ± S.E.M values. Numbers above bars represent the number 
of independent experimental replicates. 
For the significance testing of zebrafish and mouse cochlear culture protection assays, 1-way 
analysis of variance (ANOVA) was applied followed by either Dunnett’s or Tukey’s post-hoc 
test.  
For GTTR and FM 1-43 live imaging experiments, 1-way ANOVA or unpaired t tests were used 
depending on the number of experimental conditions, followed by Tukey’s post hoc test if an 
ANOVA was used. 
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For the generation of the dose-response curve in Chapter 4, the percentage of OHC survival in 
the gentamicin plus compound conditions was compared with that in control cultures. Curves 
were fit to the equation: 
𝑂𝐻𝐶 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 =  
𝐵 + (100 − 𝐵)[𝐶]
(𝐾 + [𝐶])
 
Where B is the percentage of OHCs surviving in the gentamicin alone conditions, [C] is the 
compound concentration and K is the concentration at which 50% protection is observed. 
Significance was set at p ˂ 0.05. On all graphical representations, * = p ˂ 0.05, ** = p ˂ 0.01, 
*** = p ˂ 0.001. 
Compounds were considered completely protective if the HC count was significantly higher 
than the gentamicin-treated condition but not significantly different from the control. They 
were considered partially protective if significantly different from both the control and 
gentamicin-treated conditions.  
Data were tested for normality in Prism with four tests: D’Agostino & Pearson, Anderson-
Darling, Shapiro-Wilk and Kolmogorov-Smirnov. The majority of data sets passed the normality 
tests. 
 
 
2.5.4 Figure Preparation 
 
All protection assay figures, GTTR and FM 1-43 live imaging figures were created using 
Photoshop CS2. When using a 40x objective, the Spot RT camera takes images at 1600 x 1200 
pixels. A 1200 x 600 pixel region central to the image was extracted in every instance and used 
to create the final figures, correlating to a 220 μm length of the cochlear culture. 
Quantification and statistical, graphical representations were created in GraphPad and 
imported into Photoshop. Electrophysiology figures were produced in Origin 2018.  
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2.6 Confocal Imaging 
  
Confocal microscopy was used for high magnification, high resolution imaging of the 
mechanosensory hair bundles (Chapter 6) in order to assess any morphological disruption 
induced by the compounds of interest. 
Slides were imaged on a Leica SP8 confocal microscope, using the 561 nm laser (at 3% 
intensity) and a x100 1.44 NA oil-immersion lens. Images were captured at a resolution of 
736x400 (and a zoom of x 2.0 with a x4 line average), using a low detector gain (511) in order 
to reduce noise and improve image quality. Z-projections were created in ImageJ.  
 
2.7 Electrophysiology 
 
2.7.1 Equipment for Electrophysiology 
 
The sensory HCs of cochlear cultures, adherent to collagen-coated cover slips, were visualised 
using an upright light microscope (Leica DM LFSA) equipped with a 63x water-immersion 
objective and a 15x eyepiece, using Nomarski DIC optics. Coverslips were placed in a Perspex 
bath chamber connected to inflow and outflow tubing, with a constant perfusion of fresh 
extracellular solution (ECS) over the cochlear culture. The ECS was pre-filtered before entering 
the bath using a Millipore Millex syringe filter unit and was perfused using a peristaltic pump 
(Cole-Palmer, IL, USA). To prevent the peristaltic pump from generating additional noise in the 
set-up, the chamber was grounded using a 63 μF capacitor, connected to the inflow tube, 
connected to the headstage. The recording chamber was positioned on top of a rotating stage, 
to allow access to HCs along the cochlear preparation from different angles. The entire setup 
was placed on an anti-vibration air table that was kept levitated by an air pump (JunAir), inside 
a Faraday cage to minimise movement and electrical noise within the system; allowing for 
cleaner recordings with a greater signal to noise ratio.  
HC currents were recorded using a patch-clamp amplifier. The patch electrode used was a 
polycarbonate electrode holder with a pin headstage connector, containing a silver chloride 
wire for current detection. It was connected to a Cairn Optopatch headstage and an Optopatch 
patch-clamp amplifier. Before the signal was input to a Power1401 data acquisition interface, 
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it was filtered at 2.5 kHz through an 8-pole Bessel filter, which allowed for analogue to digital 
data conversion.  
An upright glass puller (Narishige, Tokyo, Japan) was used to pull glass pipettes. Patch pipettes 
were pulled from soda glass capillaries. Cleaning and fluid jet pipettes were pulled from 
borosilicate glass capillaries. For patch pipettes, the temperature of the second pull was 
adjusted (~39.5 - 41.0°C) to ensure that the resistance of the pipette tip was between 2 and 
3.5 MΩ - a resistance that ensured reliable patch formation. The shaft of the patch pipette was 
coated with a thin layer of wax (Mr Zogs SexWax), from halfway down the shaft to 
approximately 100 μm away from the pipette tip. This was in order to reduce the fast 
capacitive transients across the wall of the patch pipette, created by the pipette tip entering 
the bath solution.  
For compound application to the cochlear cultures, a gravity-fed system was used. The system 
comprised of syringes (that were filled with compounds in solution), connected to fine tubing 
that met at a point and were bound together in an end-piece using parafilm and dental 
cement. The end-piece contained all solution tubes that were then funnelled into one final, 
relatively wide-ended tube (~200 μm) that was then placed in the bath in order to deliver the 
compounds of interest to the cochlear culture. The tube was placed 2 and a half turns of the 
focussing dial above the culture to ensure reliable, consistent compound administration and 
local manipulation of the external conditions. Selective solution application was achieved by 
having taps connected to the compound-filled syringes. When a tap was turned to the open 
position, solution was dispensed from the end-piece. Manual control of the taps allowed for 
fast, effective changes between the solutions. Control solution was initially superfused after a 
gigaohm (GΩ) seal had been formed, followed by the compound of interest and then the re-
superfusion of the control solution to assess the washout of the compound and the 
reversibility of any observed block.  
 
2.7.2 Solutions for Electrophysiology 
 
2.7.2.1 Extracellular Solution (ECS): 
 
Cochlear cultures were bathed in high sodium extracellular solution that mimicked perilymph 
composition, containing (in mM): 135 NaCl, 5.8 KCl, 1.3 CaCl2, 0.9 MgCl2, 0.7 NaH2PO4, 5.6 D-
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glucose, 10 HEPES-NaOH, 2 sodium pyruvate. Eagle’s minimum essential medium (MEM) 
amino acids solution (50X), and MEM vitamins solution (100X) were added from concentrates 
to a final concentration of 1X (Fisher Scientific). The pH of the solution was adjusted to 7.48 
using 1M NaOH. The osmolality of the solution was 307.6 (± 0.7) mOsmol kg-1 (n=7). 
2.7.2.2 Caesium Intracellular Solution (Cs ICS): 
 
When recording MET currents, patch pipettes were filled with a caesium chloride-based 
solution. This was used in order to block potassium channels, so as to investigate MET 
channels independently without the interference of potassium currents. The solution 
contained (in mM): 137 CsCl, 2.5 MgCl2, 1 EGTA-CsOH, 2.5 Na2ATP, 10 sodium 
phosphocreatine, 5 HEPES-CsOH. The pH of the solution was adjusted to 7.3 using 1M CsOH. 
The average osmolality of the solution was 291.6 (± 0.7) mOsmol kg-1 (n=5), approximately 10-
15 mOsm kg-1 below that of the extracellular solution. 
2.7.2.3 Potassium Intracellular Solution (K+ ICS): 
 
When recording the basolateral potassium channel currents, patch pipettes were filled with a 
potassium-rich intracellular solution that contained (in mM): 131 KCl, 3 MgCl2, 5 Na2ATP, 1 
EGTA-KOH, 5 HEPES, 10 sodium phosphocreatine. The pH of the solution was adjusted to 7.28 
using 1M KOH. The average osmolality of the solution was 291 (± 0.6) mOsmol kg-1 (n=5). 
2.7.2.4 Control ECS: 
 
Control extracellular solution was used to dilute compounds and also as a superfusion control 
condition, being superfused before and after each compound application. The solution 
contained (in mM): 145 NaCl, 5.8 KCl, 1.3 CaCl2, 0.9 MgCl2, 0.7 NaH2PO4, 5.6 glucose, 10 HEPES-
NaOH, 2 sodium pyruvate. The pH of the solution was adjusted to 7.48 with 1M NaOH. The 
average osmolality of the solution was 308.2 (±0.7) mOsmol kg-1 (n=5). 
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2.7.3 Whole-Cell MET and Basolateral K+ Channel Current Recording  
 
Both potassium and MET channel currents were recorded from the third (most outer) row of 
OHCs of mouse organotypic cochlear cultures, as depicted below (OHC III; Figure 2.2). All 
recordings were made from P2 CD-1 wildtype mice of either sex, after being maintained for 1 – 
2 days in vitro in a 37°C, 5% CO₂ incubator. Coverslips with adherent cultures were removed 
from their Maximow slide assembly and placed in a Perspex microscope chamber, which was 
continuously perfused with ECS at an approximate rate of 14 ml/hour. All experiments were 
performed at room temperature (20-25°C). 
 
 
Figure 2.2: The experimental setup used for electrophysiological recording of MET currents 
from mouse cochlear culture OHCs. Figure modified from Kros et al., 1992.  
The pipette entering from the left-hand side of the image is the fluid jet, used to stimulate the 
HC bundle and open the MET channels. The pipette entering from the right-hand side is the 
patch pipette, forming the seal on the HC membrane and recording the MET currents. Scale 
bar is 10 μm. 
 
The location of the OHCs that were patched along the length of the coil was mostly confined to 
the mid-coil region. In order to expose OHC membranes, a cleaning pipette was used. This was 
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a glass pipette connected to a syringe system, which allowed for manual suction to occur. 
Support cells were removed as well as any cellular debris, exposing cell membranes and 
allowing patch formation.  
Whole-cell patch clamp recordings were performed using an Optopatch (Cairn Research) 
patch-clamp amplifier. In order for MET currents to be elicited, the stereociliary hair bundle on 
top of the OHC was stimulated using a fluid jet from a glass pipette (tip diameter in the range 
of 6-12 μm), which was driven by a piezoelectric disc (Kros et al., 1992; Marcotti et al., 2005). 
Mechanical stimuli (filtered at 1.0 kHz, 8-pole Bessel) were applied as 45 Hz sinusoidal waves 
that were sufficient in order to elicit large, saturating MET currents. 
To investigate the extracellular block of potassium and MET channels, compounds of interest 
were dissolved in a solution with a composition similar to ECS and superfused over the 
cochlear cultures. Control solution was superfused after a GΩ seal on the cell membrane was 
formed, but before the whole-cell patch configuration was achieved, and was continuously 
superfused during the initial control recordings. After three recordings were obtained in 
control solution the drug of interest was superfused over the cells, three more recordings were 
taken, control solution was re-superfused and three more recordings obtained. This was done 
in order to wash away the compound from the channels of interest and gain washout 
recordings – indicative of the reversibility of the channel block. A slight negative pressure was 
continuously applied to the tip of the fluid jet, in order for the superfused compound-
containing solution to be slightly sucked into the pipette tip. This enabled the prevention of 
any dilution of the desired compound concentration with the extracellular bath solution 
expelled from the fluid jet when it was used for hair bundle stimulation. 
Before recording, a note of the series resistance (Rs) and membrane capacitance (Cm) of the 
cell was noted, and series resistance compensation was applied, anywhere between 30-60% 
depending on the stability of the preparation. 
 
 
2.7.4 Data Acquisition and Analysis 
 
The acquisition of electrophysiological data was performed using Signal 4.3 software 
(Cambridge Electronic Design) and was stored on computer for off-line analysis. Off-line 
analysis was performed using Origin 2018 (Origin Lab) data analysis software. When analysing 
electrophysiological data, the three traces in each condition (control, during drug and 
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washout) were first converted from the data acquisition software Signal in to a file type 
readable by the data analysis software Origin (text files), where they were then averaged. This 
was in order to generate an average of the current sizes during each condition, thereby 
minimising any noise picked up in the system.  
For MET channel current recordings, protocols were written in Signal in order to set the 
command voltages and simultaneously deliver a sine-wave stimulus from the fluid jet to the 
HCs. The holding potential of the cells was set to -84 mV at the beginning of recordings using 
an external voltage calibrator. During experiments, cells were stepped in 20 mV increments 
between -164 and +96 mV, whilst a sine-wave stimulus was simultaneously applied at each 
voltage step in order to control the piezo-driven fluid jet. The sampling rate was 10 kHz. 
For the determination of MET current size, the difference between the minimum current in the 
inhibitory phase (the trough; the leak current) of the sinewave and the maximum steady-state 
current (peak) in the excitatory phase of the sinewave was calculated. There was no fixed time 
point for this but rather peaks and troughs were analysed manually, due to variability in the 
shape of the MET currents obtained. The first of the four sinewave cycles was excluded in 
every instance. Current-voltage (I-V) curves were created in Origin, by plotting MET current 
size against every membrane potential. Fractional block curves were derived by plotting the 
ratio of control current to current in the presence of the compound of interest, across all 
membrane potentials from multiple cells. 
For basolateral potassium channel current analysis, protocols were written in Signal in order to 
set the command voltages. The holding potential of the cells was set to -84 mV at the 
beginning of recordings. During experiments, cells were stepped in 10 mV increments between 
-154 and +46 mV. Current amplitudes were measured from the steady-state current towards 
the end of the voltage step, before the tail currents emerged.  
 
2.8 Compound Preparation and Storage 
 
The parent compounds tested in this thesis are all commercially available and bought in from 
sources such as Tocris Biosciences, HelloBio and MilliporeSigma. Purity was ≥ 95%. Some 
compound derivatives were commercially bought depending on their availability; however, 
some specific compound modifications were synthesised in house by the chemists assigned to 
this project - Marco Derudas or Rosemary Huckvale at the University of Sussex.  
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All compounds were dissolved in DMSO at a stock concentration of 10 mM (or 50 mM for FM 
1-43 derivatives). They were aliquoted and stored at -80°C. Aliquots were not used more than 
three times, to minimise any effect of freeze-thawing cycles.  
 
2.9 d-Tubocurarine-Texas Red Conjugation 
 
To a solution of d-Tubocurarine (dTC) (1.09 mg) in dimethylformamide (0.5 mL), Texas Red 
sulfonyl chloride (1 mg) was added and the reaction mixture was stirred at room temperature 
(20-25°C) in the dark for 4 hours. After this period, the solvent was removed under reduced 
pressure to give the desired compound which was used without any further purification.   
 
2.10 Mitochondria 
 
2.10.1 Isolation of Rat Liver and Kidney Mitochondria 
 
Sprague-Dawley rats were euthanized by two methods depending on their weight, due to 
Home Office guidelines. If weighing less than 150 grams then cervical dislocation was used, or 
if over 150 grams, the rat was euthanized by 10 minutes incubation in a CO₂ chamber. No 
difference in the mitochondrial function under investigation was detected between the two 
methods of euthanasia. The liver was used due to the ease of mitochondrial isolation from this 
tissue type and the kidney was used because this is an organ susceptible to AG-induced 
(nephro)-toxicity. 
The liver or kidney was dissected and transferred to ice cold Milli-Q water before being placed 
in buffer solution containing (in mM): 1 EGTA, 30 MOPS, 250 sucrose, 3.5 L-cysteine and 0.1% 
BSA, pH adjusted to 7.6 using NaOH. The tissue of interest was homogenised with 10 passes in 
a loose-fitting homogeniser, followed by 10 passes in a tight-fitting homogeniser. After filtering 
through muslin, the homogenate underwent differential centrifugation at 4°C – being spun 
once at 1000 g (after which the supernatant was kept and pellet discarded) and then twice at 
10,000 g, each for 10 minutes, after each of which the supernatant was discarded and the 
mitochondrial pellet re-suspended in buffer solution. Isolated mitochondria were kept on ice 
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before being transferred to the Oroboros Oxygraph-2K oxygen electrode chambers upon the 
initiation of experimentation. Mitochondrial protein content was estimated using the Bradford 
method (He, 2011) using Bio-Rad protein assay dye. 
 
2.10.2 Investigating the Electron Transport Chain (ETC) Complexes (C) I-V 
using an Oroboros Oxygraph-2K Oxygen Electrode 
 
Oxygen consumption rates of isolated mitochondria were measured using an Oroboros 
Oxygraph-2K oxygen electrode, with the electron transport chain (ETC) complexes investigated 
independently with the addition of various substrates and inhibitors. Assays were performed 
in media containing (in mM): 200 sucrose, 25 KCl, 11 MgCl₂, 5 KH₂PO₄, 5 MOPS, pH adjusted to 
7.4 using NaOH. Approximately 600 μg of protein from the crudely-isolated mitochondria 
sample was added to the chamber containing 2 ml assay media, and allowed to equilibrate for 
10 minutes either in the presence or absence of selected concentrations of gentamicin. The 
reaction was then initiated with both 5 mM pyruvate and 2 mM malate for complex I (CI), or 
10 mM succinate in the presence of rotenone for complex II (CII)-dependent respiration. 
Uncoupled respiration was investigated with the addition of 0.5 - 2 µM carbonyl cyanide m-
chlorophenyl hydrazine (CCCP), and complex IV (CIV) respiration was investigated by addition 
of ascorbate (8 mM) and TMPD (4 mM).  All experiments were performed at 32°C. 
 
2.10.3 Investigating the Mitochondrial Membrane Potential (MtMP) and 
Reactive Oxygen Species (ROS) Production in Isolated Mitochondria using 
Safranin and Amplex Red 
 
The mitochondrial membrane potential (MtMP) can be investigated with the use of Safranin, a 
biological stain with an excitation wavelength of 495 nm and an emission wavelength of 587 
nm.  An initial calibration of the safranin concentration was performed on each day of 
experimenting. This was achieved by performing a titration of the safranin fluorophore, 
between 0.1 and 2.0 µM final concentrations (Krumschnabel et al., 2014). Following calibration 
2.0 µM safranin was added to the chambers followed by the MtMP effectors of interest. Most 
often, 10 mM succinate was added in order to generate a proton gradient and hyperpolarise 
the membrane, followed by serial additions of gentamicin to assess its dose-dependent effect 
on the MtMPs. 
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Mitochondrial ROS (MtROS) production can be measured using Amplex Red, a dye with a peak 
excitation wavelength of 563 nm and a peak emission wavelength of 587 nm. Initial 
calibrations were performed in both chambers by first adding Amplex (10 μM), horseradish 
peroxidase (HRP) (f.c. 1 U/ml) and superoxide dismutase (SOD) (f.c. 5 U/ml). Then 0.1 μM H₂O₂ 
was added in order to calibrate the fluorescent signal, after which endogenous ROS levels 
were measured by the addition of succinate (10 mM). Gentamicin addition was used to assess 
the effect of AGs on endogenous ROS production. 
The materials used in all of the experiments detailed were purchased from Sigma. 
 
2.10.4 Investigating MtMP Changes in Mouse Cochlear Culture HCs using 
Rhodmaine-123 
 
Rhodamine-123 (1mg/ml; Vector Laboratories, USA) was diluted 1:200 in ECS. Cochlear 
cultures prepared from P2 CD-1 mice, and maintained for 24 hours in vitro, were rinsed three 
times in PBS and then incubated in 1 ml of the Rhodamine-123 solution for 15 minutes at 37°C. 
Cultures were subsequently rinsed three times in PBS and placed in the microscope chamber 
containing ECS. The OHCs were observed with an upright microscope (Olympus) with a 60x 
water-immersion objective. Fluorescence images were obtained using the Visitech VT-
infinity3-based confocal system and VoxCell Scan software. Gentamicin (50mg/ml; Sigma) was 
added to the recording chamber to a final concentration of 5 mM. Fluorescence images were 
obtained at regular intervals (2 – 10 minutes). Experiments were performed at room 
temperature (20-22 °C). 
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Figure 2.3: The Oroboros Oxygraph machine used for recording oxygen consumption rates from 
isolated mitochondria. Image © OROBOROS INSTRUMENTS. 
Removable injection ports are located atop of the machine (A), incubation chambers centrally 
(B) and the oxygen sensors on the sides (C).   
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3   Characterising the Ototoxic Effects of Gentamicin on 
Mouse Cochlear Cultures 
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3.1 Introduction 
 
3.1.1 Aminoglycoside Choice  
 
Of all of the aminoglycoside antibiotics (AGs) that are Food and Drug Agency (FDA) approved 
for clinical use (of which there are at least nine: amikacin, gentamicin, kanamycin, neomycin, 
netilmicin, paromomycin, spectinomycin, streptomycin and tobramycin) (Xie et al., 2011; Jiang 
et al., 2017), gentamicin is the most commonly prescribed in the United Kingdom, the United 
States of America, and potentially worldwide (Eltahawy and Bahnassy, 1996; Gonzalez et al., 
1998; Xie et al., 2011). This is due to its low cost, ease of storage and its reliability in treating a 
wide range of bacterial infections as a result of its broad-spectrum antimicrobial activity. For 
this reason, gentamicin was used in all of the experiments detailed in this thesis: in the search 
for clinically-relevant otoprotective compounds in mammalian models, and also in the 
investigation of the effect of AGs on mitochondrial function. Furthermore, the availability of a 
fluorescently-conjugated gentamicin analogue (gentamicin-Texas Red (GTTR)) (Steyger et al., 
2003) allowed for greater ease of investigation of AG uptake into sensory HCs, so as to further 
elucidate the mechanisms of protection of the novel compounds that have been identified 
herein. 
 
3.1.2 Aims 
 
In this chapter the effect of gentamicin on mouse cochlear cultures will be characterised, 
drawing comparisons between the cochleotoxic effects induced in our in vitro assays and those 
observed in the clinic. Our standard gentamicin-kill assay used for otoprotectant detection will 
be described in detail and an extension of this experimental paradigm will also be provided. I 
aim to characterise the effects of higher gentamicin concentrations and a longer exposure 
time, whilst again drawing analogous comparisons with what is observed clinically. 
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3.2 Results 
 
3.2.1 Standard Otoprotection Assay – 5 μM Gentamicin for 48 Hours 
 
When used clinically, the reported hearing loss in patients treated with AGs follows a 
distinctive pattern, with high-frequency hearing being affected first followed by the more low-
frequency ranges. This occurs in a dose and time-dependent fashion, with higher doses or 
prolonged exposure time leading to more severe hearing loss (Conly et al., 1994; Huth et al., 
2011). The assay that was used for the assessment of otoprotection by novel compounds 
adhered to this pattern in an attempt to replicate and mimic real-world scenarios, with the 
gentamicin-induced damage confined primarily to the basal section of the cochlear cultures. 
Organotypic cochlear cultures (Figure 3.1A) that were incubated with 5 µM gentamicin for 48 
hours showed pronounced loss of OHCs from the basal (high-frequency) region of the cochlea 
(Figure 3.1E) with far fewer, if any, being lost from the apical (low-frequency) region (Figure 
3.1D). However, apical OHCs did often display a perturbed morphology of their characteristic 
V-shaped mechanosensory hair bundles when treated with this concentration of the antibiotic 
(Figure 3.1D).  
On average, incubation with 5 µM gentamicin for 48 hours caused a loss of 88% of OHCs from 
the mid-basal region of the cochlear cultures, with an average of 112.9 (± 1.4) (n=68) OHCs 
present in a 300 µm-long segment of the controls and 14.0 (± 1.3) (n=68) in the gentamicin-
treated conditions (p ˂ 0.001) (Figure 3.1F). These statistics are a culmination of all of the HC 
counts from the otoprotection experiments conducted in Chapters 4–7, with the significance 
here derived from an unpaired t test.  
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Figure 3.1: Exposing postnatal day 2 mouse cochlear cultures to 5 μM gentamicin for 48 hours 
results in a significant loss of OHCs from the mid-basal region. 
(A) A whole mouse cochlea explanted onto a collagen-coated cover slip and incubated with 5 
μM gentamicin for 48 hours. (B) The mid-apical and (C) the mid-basal region of a control 
cochlear culture. (D) The mid-apical and (E) mid-basal region of a gentamicin-treated culture. 
(F) Quantification of OHC survival in a 300 μm-long segment of the mid-basal region. Scale bar 
in A is 1 mm, and in E is 50 μm. 
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3.2.2 Assay Extension: 2.5, 5, 7.5, 10 and 12.5 μM Gentamicin for 48 Hours 
 
Additional experiments were conducted in order to further assess the toxicity profile of 
gentamicin when administered to mouse cochlear explants. I first investigated the ototoxic 
effect of various gentamicin concentrations. The result of 48 hours incubation with a range of 
concentrations of gentamicin (2.5, 5, 7.5, 10 and 12.5 μM) was investigated, with the 
additional premise that if the otoprotective compounds identified in this thesis could protect 
against the higher concentrations of the antibiotic then we could eliminate the dose-limiting 
aspect of AG treatment (Conly et al., 1994), at least in terms of the ototoxic side-effect. This is 
because the dose of AGs that is given to patients is restricted due to the adverse oto- and 
nephro- toxic effects that they can induce. If a co-administered compound was able to prevent 
the undesirable side-effects, this AG dose restriction would become obsolete.  
Furthermore, the concentration of gentamicin that accumulates in and around the cochlear 
sensory epithelium when used in a clinical setting is not fully known. At the onset of ototoxic 
symptoms, the AG concentration in rat endolymph has been estimated to be approximately 1 
μM (Tran Ba Huy et al., 1981; Li and Steyger, 2009); however, uncertainty in the 
endolymphatic concentration when used clinically is due to the difficulty in accurately 
measuring concentrations in the endolymph due to the extremely small size of the fluid-
containing compartment. Moreover, additional ambiguity arises in the clinic because of the 
uncertainties in the amount of the AG crossing into the endolymphatic compartment post-
administration, and the numerous variables that may affect this across different patients being 
treated with the antibiotics. For example, those exposed to high levels of sustained noise (Li 
and Steyger, 2009), treated with loop diuretics (Tao et al., 2014) or with cases of inflammatory 
responses (Koo et al., 2015), have all been shown to have an enhanced susceptibility to AG-
induced ototoxicity (Jiang et al., 2017). Each aforementioned attribute may contribute to 
ototoxicity by altering AG trafficking into the endolymph, potentially enhancing the 
endolymphatic AG concentration. Consequently, identifying compounds that can provide 
otoprotection against a range of AG concentrations would be desirable.  
Figure 3.2A-F shows examples of the basal region of cochlear cultures exposed to increasing 
concentrations of gentamicin for 48 hours. Quantitative data obtained from apical and basal 
regions in at least 3 independent experiments is shown in Figure 3.2G-J (experimental replicate 
numbers range from 3 to 68). When organotypic cochlear cultures were incubated with 2.5 μM 
gentamicin for 48 hours, there was a sporadic loss of HCs in some experiments; however, there 
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was no significant difference in the number of HCs remaining when compared to the control in 
any of the four criteria examined (the number of OHCs or IHCs in the apical or basal coil) 
(Figures 3.2G-J). However, disruption of the mechanosensory hair bundle morphology (as 
indicated by a deviation from the characteristic V-shaped OHC hair bundle) was observed in 
three of the four trials (Figure 3.2B). 
When incubated with 5 μM gentamicin for 48 hours, there was a loss of OHCs from the basal 
region, as detailed in section 3.2.1. There was no significant difference in any other measure. 
With 7.5 μM gentamicin for 48 hours, a similar response was seen as with 5 μM, primarily with 
a loss of OHCs from the basal coil of the cochlea. However, a one-way ANOVA revealed that 
there was also a significant loss of basal IHCs, with an average of 34.0 (± 0.5) (n=40) in control 
cultures, 32.9 (± 0.4) (n=43) in those treated with 5 μM gentamicin and 22.8 (± 3.9) (n=6) in 
those treated with 7.5 μM gentamicin (p < 0.001) (Figures 3.2D and H).  
With 10 μM gentamicin incubation for 48 hours, the toxicity profile was markedly different. 
Almost all of the OHCs from the mid-basal region were lost in every experiment, with an 
average of 6.4 (± 2.7) (n=5) OHCs remaining compared with 14.0 (± 1.3) (n=68) in the 5 μM-
treated condition. However, this difference was non-significant (Figure 3.2J). There was a 44% 
reduction in the number of OHCs in the mid-apical region of the cochlea, with an average of 
112.3 (± 1.5) (n=60) in the control cultures and 63.8 (± 12.1) (n=4) in the 10 μM gentamicin-
treated conditions (Figure 3.2I). A one-way ANOVA revealed that this difference was significant 
(p < 0.001). With IHCs, there was a reduction in numbers in both the mid-apical and mid-basal 
regions. In the base, IHC numbers fell from 34.03 (± 0.5) (n=43) in the control conditions to 
10.8 (± 2.7) (n=5) in those treated with 10 μM gentamicin (Figure 3.2E and H). In the apex, IHC 
numbers fell from 33.4 (± 0.6) (n=35) to 23.6 (± 3.7) (n=5) (Figure 3.2G). Both reductions in IHC 
numbers were statistically significant (p < 0.001).  
When incubated with 12.5 μM gentamicin for 48 hours, there were further reductions in all 
but one of the four criteria detailed above when compared to 10 μM gentamicin-treated 
conditions (Figures 3.2G-J). However, none of these differences were statistically significant. 
All statistical comparisons in this section were made using a one-way ANOVA, followed by 
Tukey’s multiple comparisons test. 
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Figure 3.2: HC survival in the mid-apical and mid-basal regions of mouse cochlear cultures, 
treated with a range of gentamicin concentrations (2.5-12.5 μM) for 48 hours. 
(A-F) The mid-basal region of mouse cochlear cultures treated with (A) HBHBSS as a control or 
(B) 2.5 μM, (C) 5 μM, (D) 7.5 μM, (E) 10 μM or (F) 12.5 μM gentamicin for 48 hours. (G-J) 
Quantification of HC survival: (G) IHCs in the apex, (H) IHCs in the base, (I) OHCs in the apex, (J) 
OHCs in the base. Scale bar is 50 μm. 
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3.2.3 Assay Extension: 2.5, 5, 7.5, 10 and 12.5 μM Gentamicin for 72 Hours 
 
When the gentamicin incubation time was extended by an additional 24 hours, to 72 hours in 
total, a much more severe effect was observed. Even when gentamicin was tested at 2.5 μM, 
there was a complete loss of all of the OHCs from the basal region, whereas IHCs mostly 
survived (Figure 3.3B). This result was strikingly similar to the ototoxicity pattern observed 
when cultures were treated with 5 μM gentamicin for 48 hours (Figure 3.2C).  
 
Figure 3.3: The mid-basal region of mouse cochlear cultures treated with a range of gentamicin 
concentrations (2.5-12.5 μM) for 72 hours. 
(A-F) The mid-basal region of mouse cochlear cultures treated with (A) HBHBSS as a control or 
(B) 2.5 μM, (C) 5 μM, (D) 7.5 μM, (E) 10 μM or (F) 12.5 μM gentamicin for 72 hours. Scale bar is 
50 μm. 
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3.3 Summary 
 
Incubation of P2 mouse cochlear cultures with 5 μM gentamicin for 48 hours resulted in a 
toxicity profile remarkably similar to that observed in the clinic; with the basal, high-frequency 
sound-encoding sensory HCs being damaged first, followed by a progressive loss of the more 
apical HCs with increased dose or exposure time. This dose-dependent ototoxicity profile has 
been observed previously (Richardson and Russell, 1991; Forge and Richardson, 1993) and 
closely matches what is observed when AGs are used clinically (Chen et al., 2007; Schacht et 
al., 2012; Cannizzaro et al., 2014; Petersen and Rogers, 2015). In the standard gentamicin-kill 
assay using 5 μM gentamicin (Figure 3.1), there was an average loss of 88% of OHCs from the 
mid-basal region of the cochlea, whereas apical OHCs and IHCs along the length of the 
cochlear coil were largely preserved. As the concentration of gentamicin was increased, there 
was a progressively larger number of IHCs lost from the basal region, followed by OHCs from 
the apical region and lastly, once the concentration was doubled to ≥ 10 μM, a loss of IHCs 
from the apical region was also observed (Figure 3.2). A longer incubation time of 72 hours 
exacerbated this effect, causing an increase in the loss of each aforementioned HC type at 
every concentration tested (2.5 – 12.5 μM) (Figure 3.3). 
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3.4 Discussion 
The reason for the observed pattern of OHC loss is presumably due to a number of factors that 
are all related to the intracellular accumulation of the antibiotics, with basal HCs accumulating 
gentamicin at a faster rate compared to those in the apex. Maturation of sensory HCs 
proceeds from the basal end upwards to the apex along a decreasing tonotopic gradient (from 
high to low-frequency); with MET currents present in basal HCs at birth and developing later 
along the apical coil (Alharazneh et al., 2011). A greater unitary conductance of the basal HC 
MET channels has been shown, ranging from 110 pS in the basal cells of the mouse cochlea to 
62 pS in the HCs from the apical region (Beurg et al., 2014; Beurg and Fettiplace, 2017), and 
300 pS versus 100 pS in the HCs of turtle cochleae (Fettiplace, 2009). Moreover, the resting 
open probability of the channel decreases from base to apex (Dallos et al., 1982; Johnson et 
al., 2011), as does the number of stereocilia on the cell’s apical surface in the organ of Corti of 
rats (Roth and Bruns, 1992; Beurg et al., 2006). All of the aforementioned attributes will lead 
to a greater rate of entry of the antibiotics into basal HCs compared to those in the apex, 
meaning a more rapid accumulation of an intracellular concentration at which apoptotic cell-
death pathways are initiated. This is a potential explanation for the clinical scenario, alongside 
the results of our in vitro assays. An alternative explanation for the disparity in apical and basal 
AG-induced cell death could be in the variable production of apoptosis-inducing ROS in a basal-
apical gradient (Xie et al., 2011), or perhaps a combination of these factors. 
IHCs are also largely preserved in the standard experimental assay detailed above and, again, 
this is likely due to a number of factors relating to the intracellular accumulation of the AGs. 
The conductance and peak amplitude of IHC MET channel currents along the tonotopic axial 
length of the cochlea is invariant (Beurg et al., 2006; Jia et al., 2007; Fettiplace, 2009; Kim and 
Fettiplace, 2013); however, IHCs are larger than their OHC counterparts, they have fewer MET 
channels (Jia et al., 2007), these channels have a smaller single-channel unitary conductance 
than basal OHCs (Beurg et al., 2006), a smaller macroscopic MET current (Kros et al., 1992) and 
the electrical driving force across the MET channel is reduced due to the RP of the cell being 
less negative in IHCs than it is in OHCs – approximately -45 mV compared to -70 mV (Russell 
and Sellick, 1983). This means that in the same 48 hours assay time window the intracellular 
accumulation of gentamicin would not reach levels as high as in OHCs, consequently not 
reaching a concentration at which apoptosis is triggered. With prolonged exposure time or 
higher concentrations of gentamicin, a loss of IHCs and apical OHCs (Figures 3.2 and 3.3) was 
also observed, confirming the postulation that it is the accumulation of AGs within a HC that 
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determines its fate, with apoptosis initiating after a certain intracellular concentration is 
reached. 
The observed pattern of ototoxicity, both concentration and time-dependent, is due to the 
entry rates of the antibiotics into HCs, dictated by diffusion constants. By performing 
volumetric calculations of OHC size relative to the ionic concentration gradients across the 
MET channel, studies have shown that DHS, a semisynthetic AG, when at an endolymphatic 
concentration of 1 μM, can reach an intracellular concentration of 1 μM within 80 seconds 
(Marcotti et al., 2005) highlighting the rapid entry rates of the AGs into HCs. The underlying 
calculations offer explanations as to why increasing the extracellular concentration of the 
antibiotic, or prolonging the time of exposure, will lead to enhanced HC death – explainable by 
an enhanced achievement of an intracellular concentration that is sufficient to induce 
apoptosis in all of the aforementioned cell types and regions. 
Although it is the IHCs that are directly responsible for sound transduction and information 
transfer to the auditory nerve, the OHCs serve as active amplifiers of the signal, fine-tuning our 
frequency sensitivity (Dallos and Harris, 1978; Purves et al., 2001; Dallos, 2008). Therefore, loss 
of OHCs alone would be sufficient to result in the loss of hearing ability, or the evident increase 
in hearing threshold that is frequently observed in a clinical setting when patients are treated 
with AGs (McRorie et al., 1989; Fausti et al., 1992; Stavroulaki et al., 2002).  
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4   Assessing the Otoprotective Potential of the Tocris Ion 
Channel Library 
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4.1 Introduction 
4.1.1 Library Choice 
 
The Tocris Ion Channel library (Tocriscreen Custom Collection Ion Channel Set) is a 
commercially-available chemical library of 160 small molecules that are known to behave as 
agonists or antagonists of various different ion channels.  
The AGs have been shown to enter the sensory HCs of the inner ear through their MET 
channels (Marcotti et al., 2005; Alharazneh et al., 2011); non-selective cation channels that are 
capable of being blocked by numerous compounds known to interact with various other ion 
channels. Consequently, it was assumed that a library of ion channel interactors may provide 
the most suitable option for screening in the search for viable otoprotectants that could 
potentially block the MET channel and prevent the entry of the AGs into sensory HCs, thereby 
preventing their death and the unfortunate ototoxic side-effect associated with AG treatment. 
 
4.1.2 Aims 
 
We sought to screen the entire Tocris library in an attempt to identify novel otoprotectants in 
vivo in zebrafish and in vitro in mouse cochlear cultures, which could then be transferred to a 
mammalian in vivo model before potentially being taken forward to clinical trials. 
We also sought to investigate the mechanism of protection of all of the protectants identified. 
This would inform us of several things, including, but not exclusive to: the most frequently 
successful mechanism of otoprotection (whether that be preventing AG entry into HCs or 
alternatively an intracellular protective process); how reliable zebrafish pre-screening is for 
this purpose; and whether we can modify compounds based on their mechanism of protection 
in order to generate more efficacious otoprotectants.  
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4.2 Results 
 
4.2.1 Screening for Otoprotection 
 
4.2.1.1 Zebrafish Pre-Screening 
 
* All zebrafish research detailed in this section was conducted by Emma Kenyon, University of 
Sussex. 
 
The entire set of 160 compounds was initially tested in three different zebrafish assays, as 
detailed in Kenyon et al., 2017. Briefly, the three assays investigated whether each Tocris 
compound was able to consistently: 
1. Block or reduce the loading of FM 1-43FX (a dye known to permeate through sensory 
HC MET channels) into neuromast HCs.  
2. Prevent the loading of a fluorescently-conjugated AG (neomycin-Texas Red) into 
neuromast HCs.  
3. Prevent the neuromast HC loss caused by 1 hour incubation with neomycin.  
Compounds that were successful in any of the three zebrafish assays were taken forward to 
mouse cochlear cultures for further screening. Additional compounds that did not hit any of 
the zebrafish assays were also tested in mice, as they shared a similar chemical signature to 
compounds that were successful in at least one of the three assays. This was in order to 
increase the number of possible hits whilst also assessing and reducing the number of false 
negatives in the initial zebrafish screen, concurrently gaining further insight regarding the 
usefulness and viability of preliminary zebrafish screens as a prerequisite to mammalian 
testing. 
Of the 160 compounds screened in zebrafish, 72 were effective in at least one of the three 
assays. These 72, alongside 6 other structurally-related compounds, were then brought 
forward for additional testing in mouse cochlear cultures. 
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4.2.1.2 Cochlear Culture Screening 
 
4.2.1.2.1 Protection at 50 μM 
 
In mouse cochlear cultures, compounds that were brought forward from zebrafish screening 
were initially tested for their ability to provide protection against the damage caused by 5 μM 
gentamicin over a period of 48 hours. As previously detailed in Chapter 3, this concentration of 
the antibiotic caused an average loss of 88% of the OHCs from the mid-basal region of P2 mice 
cochleae (Figure 3.1). All of the Tocris compounds that were brought forward were initially 
tested at a concentration of 50 μM, to assess whether they could prevent the observed OHC 
loss. Any compounds that did not provide protection in this initial screen, or had any 
observable toxic effect, were excluded from further testing. Any compounds that did provide 
protection were re-tested at this concentration at least an additional two times, to ensure the 
reliability of their protective efficacy. The number of repeats when tested at a concentration of 
50 μM ranged from 3 to 11. 
Of the 78 compounds screened, 12 consistently provided complete protection against the 
gentamicin-induced loss of OHCs when tested at 50 μM (13087, 13097, 13104, 13142, 13143, 
13150, 13154, 13170, 13190, 13196, 13218 and 13228). One compound (13222) provided 
partial protection, working effectively in some experiments and failing on others (protecting in 
5 out of 11 trials). To note, one of these 13 compounds (13150) was not identified as being 
successful in the zebrafish screening procedure, but instead was selected on the basis of 
structural similarity to one that was successful. 
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Figure 4.1: When tested at a concentration of 50 μM, 12 of the 78 compounds consistently 
protected against 5 μM gentamicin damage and 1 provided partial protection. 
Cochlear cultures were treated with either (A) 0.5% DMSO (n=67), (B) 5 μM gentamicin and 
0.5% DMSO (n=67), or (C–O) 5 μM gentamicin and 50 μM compound (C) 13087 (n=5), (D) 
13097 (n=9), (E) 13104 (n=5), (F) 13142 (n=8), (G) 13143 (n=8), (H) 13150 (n=4), (I) 13154 
(n=5), (J) 13170 (n=5), (K) 13190 (n=3), (L) 13196 (n=5), (M) 13218 (n=10), (N) 13222 (n=11) 
and (O) 13228 (n=4). Images in A and B are representative of 67 experiments. Images in C–O 
are representative of 3–11 experiments. A compound was considered protective if it protected 
in ≥ 60% of tests and partially protective if the success rate was > 20% < 60%. Asterisks identify 
cultures with damaged hair bundles; arrows indicate specific examples of damaged bundles. 
Scale bar is 50 μm. Figure taken from Kenyon et al., 2017. 
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4.2.1.2.2 Protection at 10 μM 
 
All 13 compounds were then screened for their ability to protect against gentamicin damage 
when tested at a concentration of 10 μM, to assess the lower limit of their protective efficacy. 
A compound with a lower protective concentration would be preferable due to a reduction in 
the likelihood of it causing any unwanted, off-target side-effects following administration of 
the compound in a clinical setting. When tested at this concentration, 3 compounds remained 
consistently protective (13097, 13143 and 13170), 6 were partially protective (13104, 13142, 
13154, 13196, 13222 and 13228), and 4 provided no protection (13087, 13150, 13190 and 
13218). The number of repeats when tested at a concentration of 10 μM ranged from 5 to 10. 
 
Figure 4.2: When tested at a concentration of 10 μM, 3 of the 13 compounds protected against 
5 μM gentamicin damage, 6 were partially protective and 4 provided no protection. 
Cochlear cultures were treated with either (A) 0.5% DMSO (n=67), (B) 5 μM gentamicin and 
0.5% DMSO (n=67), or (C–O) 5 μM gentamicin and 10 μM compound (C) 13087 (n=6), (D) 
13097 (n=6), (E) 13104 (n=7), (F) 13142 (n=8), (G) 13143 (n=8), (H) 13150 (n=6), (I) 13154 
(n=5), (J) 13170 (n=5), (K) 13190 (n=6), (L) 13196 (n=5), (M) 13218 (n=7), (N) 13222 (n=10) and 
(O) 13228 (n=7). Images are representative. Asterisks identify compounds that damaged hair 
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bundles (only compound 13170 in this assay) while arrows indicate specific examples of 
damaged bundles. Scale bar is 50 µm. Figure taken from Kenyon et al., 2017. 
 
 
4.2.1.2.3 The Effect of Otoprotectants on Sensory Hair Bundle Morphology 
 
As a further screening precaution, all of the protective screens that had been conducted in the 
presence of gentamicin were analysed to assess whether any of the compounds caused any 
observable damage to the mechanosensory hair bundle that is located on top of sensory HCs. 
The hair bundle is directly responsible for auditory transduction, so any morphological 
disruption may lead to negative effects on hearing ability. Moreover, any compounds that did 
protect but caused bundle damage may have only protected due to malformation of the hair 
bundle to such an extent so as to render the MET channel non-functional. As this study was 
aimed at protecting our hearing, any observable impact on the morphology of the 
characteristic V-shaped OHC hair bundle led to their exclusion from being taken forward as a 
lead compound. 
Of the 13 compounds screened in the presence of gentamicin, 8 caused some degree of 
disruption to the morphology of the mechanosensory hair bundle when tested at 50 μM 
(13087, 13104, 13142, 13150, 13170, 13190, 13196 and 13228), and 1 when tested at 10 μM 
(13170). Examples of morphological hair bundle disruption are indicated by the arrows in 
Figures 4.1 and 4.2. 
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4.2.1.2.4 The Intrinsic Toxicity of Otoprotectants when tested Alone in the Absence of 
Gentamicin 
 
As an additional precaution all 13 compounds were also screened for their intrinsic toxicity 
when tested alone in the absence of gentamicin, at 50 μM and also at a higher concentration 
of 100 μM. Due to the uncertainty of the concentrations of these compounds when they reach 
the endolymphatic compartment of the cochlea, within which the sensory HCs are situated, it 
is essential for any potential otoprotectant to have a broad non-toxic concentration range. For 
this reason, all of the compounds were screened in the absence of gentamicin to assess their 
intrinsic toxicity at a concentration of 50 and 100 μM. When tested at 50 μM, 5 of the 
compounds caused some disruption to hair bundle morphology (13087, 13150, 13170, 13196 
and 13228). When tested at 100 μM, 4 of the compounds were generally cytotoxic to the 
cochlear culture, causing a loss of the neurosensory epithelium and other supporting cells 
(13087, 13150, 13218 and 13228). An additional 4 compounds caused damage to the 
morphology of the hair bundles (13104, 13170, 13190 and 13196). Only 5 of the 13 
compounds showed no adverse effects on the cochlear culture when tested at 100 μM (13097, 
13142, 13143, 13154 and 13222). In Figures 4.3 and 4.4, disruption to hair bundle morphology 
is indicated by a singular asterisk (*) and general cytotoxicity is indicated by a double asterisk 
(**). 
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Figure 4.3: When tested at 50 μM in the absence of gentamicin, 5 compounds caused 
disruption to the morphology of the mechanosensory hair bundle. 
Cochlear cultures were treated for 48 hours with either (A) 0.5% DMSO (n=2) or (B-N) 50 μM 
compound as indicated (n=2 for all compounds). Asterisks identify compounds that damage 
hair bundles. Scale bar is 50 μm. Figure taken from Kenyon et al., 2017. 
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Figure 4.4: When tested at 100 μM in the absence of gentamicin, 4 compounds were generally 
cytotoxic and an additional 4 caused disruption of the hair bundle morphology. 
Cochlear cultures were treated for 48 hours with either (A) 0.5% DMSO (n=2) or (B-N) 100 μM 
compound as indicated (n=2 for all compounds). Asterisks identify compounds that damage 
hair bundles, with arrows indicating examples of damaged bundles. Double asterisks identify 
compounds that were generally cytotoxic. Scale bar is 50 μm. Figure taken from Kenyon et al., 
2017. 
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4.2.1.2.5 Dose-Response Experiments assessing the Minimal Protective Concentration of 
the Lead Compounds 
 
After the exclusion of any compounds that had negative intrinsic characteristics, such as 
generalised cytotoxicity at higher concentrations or any impact on the morphology of the 
mechanosensory hair bundle at any concentration, just 3 compounds remained (13097, 13142 
and 13143). Of these 3, only 2 provided protection against gentamicin damage when tested at 
10 μM (13097 and 13143). These 2 were therefore taken as our lead compounds and dose-
response experiments were conducted to assess the limit of their protective efficacy by 
ascertaining their minimum protective concentration. Compound 13143 (commonly known as 
linopirdine) was protective down to 1 μM (with a half-protecting concentration K of 840 nM), 
and a 95% CI of 210-1,480 nM. Compound 13097 (commonly known as XE 991) provided 
complete protection at concentrations as low as 10 nM (with a half-protecting concentration K 
of 4.9 nM), and a 95% CI of 2.2-7.7 nM. Both compounds had a remarkable protective efficacy 
relative to other otoprotectants previously identified both in zebrafish and mammalian 
systems (Ou et al., 2009; Kirkwood et al., 2017; Majumder et al., 2017), with 13097 protecting 
at a 1000-fold greater efficacy than any other previously identified otoprotectant reported in 
the literature (nM versus μM). 
 
Figure 4.5:  Dose-response experiments for our two lead compounds. The half-protecting 
concentration for 13143 was 840 nM and for 13097 it was 4.9 nM. 
Cochlear cultures were treated with (A) 0.5% DMSO (n=67), (B) 5 μM gentamicin (n=67), 5 μM 
gentamicin and 13143 at (C) 5 μM (n=5), (E) 3 μM (n=5), (G) 1 μM (n=4), and (I) 0.5 μM (n=3) 
or 5 μM gentamicin and 13097 at (D) 30 nM (n=5), (F) 10 nM (n=5), (H) 3 nM (n=4), and (J) 1 
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nM (n=4). Images in A and B are representative of 67 experiments. Images in C–J are 
representative of 3–5 experiments. (K) Dose-response curves showing the percentage survival 
of basal-coil OHCs in cultures treated with gentamicin and either compound 13097 (red) or 
compound 13143 (blue) compared with that in control cultures. Error bars are SEM from 3–8 
independent tests. Curves are fit to the equation: OHC survival (%) = B + (100–B)[C]/(K + [C]), 
where B is the percentage of OHCs surviving in gentamicin alone, [C] is the concentration of 
the compound, and K is the compound concentration at which 50% protection occurs. For 
13097, K = 4.9 nM and B = 12.6%; for 13143, K = 840 nM and B = 11.5%. Scale bar is 50 μm. 
Figure taken from Kenyon et al., 2017. 
 
4.2.1.2.6 Lead Compound Protection against a Higher Gentamicin Concentration or a 
Longer Exposure Time 
 
I further investigated the protective ability of our most effective compound, 13097, when 
tested against a higher gentamicin concentration and a longer exposure time. As previously 
mentioned, having a broad protective range would be a desirable characteristic of an 
otoprotective compound. For this reason, I initially investigated the ability of 13097 to protect 
against the HC loss caused by 10 μM gentamicin incubation. I tested the compound at 100, 200 
and 300 μM – at a high molar excess of its minimum protective concentration in the standard 5 
μM protection assay. At 100 μM, no protection was seen (data not shown). At 200 μM, partial 
protection was observed as some HCs were protected. When tested at 300 μM, HCs were 
protected however the morphology of the OHC hair bundles was greatly disturbed (Figure 4.6). 
One cochlear culture was tested for each specified concentration.  
 
Figure 4.6: 13097 protected against 10 μM gentamicin damage when tested at 300 μM. 
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Cochlear cultures were treated for 48 hours with (A) 0.5% DMSO,  (B) 10 μM gentamicin and 
0.5% DMSO or 10 μM gentamicin and 13097 at (C) 200 or (D) 300 μM (n=1 for all conditions). 
Scale bar is 50 μm. 
 
I subsequently investigated the ability of 13097 to protect against the damage caused by 5 µM 
gentamicin over a longer time course of 72 hours. When tested at 1 and 50 μM, the compound 
showed no protection against the damaging effects of gentamicin (Figure 4.7).  One cochlear 
culture was tested for each specified concentration.  
 
Figure 4.7: 13097 did not protect against 72 hours exposure to 5 μM gentamicin when tested 
at 1 or 50 μM. 
Cochlear cultures were treated for 72 hours with either (A) 0.5% DMSO or (B) 5 μM gentamicin 
and 0.5% DMSO or 5 μM gentamicin and 13097 at (C) 50 or (D) 1 μM (n=1 for all conditions). 
Scale bar is 50 μm. 
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4.2.2 Compound Modifications 
 
Following our screening for mammalian otoprotectants, 2 compounds were selected for 
modification (13087 and 13143) in an attempt to synthesise more effective derivatives. 
Compound 13087 was selected due to its structural similarity to another compound that was 
identified as an effective mammalian otoprotectant within this thesis, which is already FDA 
approved for the treatment of hypertension (Carvedilol; Chapter 6). Compound 13143 was 
selected as it is our second most effective otoprotectant and our most effective (13097) was 
originally identified as an improved derivative of 13143 for use as a cognitive enhancer, with a 
similar chemical structure (Zaczek et al., 1998; Greene et al., 2017).  
The 13087 derivatives were: 28663, 28664, 28665 and 28666. All were initially tested for their 
protective ability against 5 μM gentamicin when tested at a concentration of 50 μM; the limit 
of the parent compound’s protective efficacy. Of the 4, only 1 was protective (28664) (Figure 
4.8A-F). However this was the lower limit of its protective efficacy. When tested at 20 and 10 
μM 28664 provided no HC protection (Figure 4.8G). 
The 13143 derivatives were: 21166, 21170, 21172, 21173 and 21174. All of these compounds 
were tested at 10 μM, in high excess of the parent compound’s minimum protective 
concentration. None of the derivatives provided any protection when tested at this 
concentration (Figure 4.8H-L), suggesting that our chemical modifications were unsuccessful at 
improving otoprotective efficacy. 
 
 
 
78 
 
 
Figure 4.8: Two Tocris compounds (13087 and 13143) were structurally modified to improve 
their otoprotective ability. None of the derivatives were more protective than the parent 
compounds. 
Cochlear cultures were treated for 48 hours with either (A) 0.5% DMSO, (B) 5 μM gentamicin 
and 0.5% DMSO, (C-F) 5 μM gentamicin and 50 μM (C) 28663, (D) 28664 (n=3), (E) 28665 or (F) 
28666, (G) 5 μM gentamicin and 20 μM 28664 or (H-L) 5 μM gentamicin and 10 μM (G) 21166, 
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(H) 21170, (I) 21172, (J) 21173 or (K) 21174 (n=1 for all compounds unless otherwise stated). 
Scale bar is 50 μm. 
 
4.2.3 The effect of Tocris Compounds on the Antimicrobial Activity of 
Gentamicin 
 
All 13 compounds were tested in a bacterial cell viability assay, to ensure that they do not 
compromise the antimicrobial activity of gentamicin, as this would then void their usefulness 
as a potential otoprotectant. This research was conducted by Daire Cantillon, University of 
Sussex, and is thoroughly detailed in Kenyon et al., 2017. However, in brief, when co-incubated 
with gentamicin, 2 Tocris compounds of interest (13170 and 13228) increased gentamicin’s 
antimicrobial effect on bacterial cell survival.  
 
 
4.2.4 Candidate Otoprotectants 
 
From all of the results detailed above, 5 compounds emerged as potential otoprotectants that 
should be investigated further for clinical use (13097, 13142, 13143, 13154 and 13222). These 
5 are potential candidates due to their ability to protect basal OHCs against 5 μM gentamicin-
induced damage when tested at 50 μM (or considerably less in some cases). They do not cause 
any HC death of hair bundle disruption when tested alone at 100 μM and they do not 
compromise the antimicrobial actions of gentamicin. Three of the 5 compounds are MET 
channel blockers (13142, 13154 and 13222), so may be protecting by blocking this primary 
entry route into HCs. All 5 compounds are blockers of the OHC potassium channel IK,neo, so 
could potentially depolarise the cell membrane and in this way reduce the electrical driving 
force that is one determinant of AG entry into HCs. 
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4.2.5 Mechanisms of Protection 
 
4.2.5.1 The Effect of Otoprotectants on MET Channel Currents 
* The electrophysiology presented in this chapter was performed by Nerissa Kirkwood, 
University of Sussex. 
 
The MET channel is a known entry route of the AGs into HCs (Marcotti et al., 2005; Alharazneh 
et al., 2011). For this reason, all of the otoprotectants that we identified were tested for their 
ability to block MET channel currents, on the assumption that they may be protecting HCs by 
blocking the channel and impeding the entry, and accumulation, of the antibiotics. MET 
channel currents were recorded from the third row of OHCs of P2 mouse cochleae before, 
during and after the superfusion of the compounds, tested at a concentration of 50 μM. 
Whole-cell voltage clamp experiments were conducted in order to test the effect of the 
compounds on the MET channel currents when the cell was stepped between membrane 
potentials ranging from -164 mV to +96 mV, to assess the voltage-dependency of any observed 
channel block. 
Of the 13 compounds tested, 7 had no effect on the MET channel current size at any 
membrane potential tested, indicating a lack of interaction with the channel. The remaining 6 
(13087, 13104, 13142, 13154, 13218 and 13222) all showed a voltage-dependent block of the 
channel. Shown in Figure 4.10 are two examples of MET channel current traces recorded 
before (black), during (red) and after (blue) the superfusion of 2 of the Tocris compounds of 
interest. Compound 13143 is shown in A and 13222 in B. Compound 13143 had no interaction 
with the channel whereas 13222 caused a reduction in the recorded current sizes, indicative of 
channel block. In Figure 4.10C and D, current-voltage (I-V) curves were derived by plotting the 
peak MET channel current amplitude at each voltage step, providing further evidence of the 
lack of interaction of 13143 with the MET channel (Figure 4.10C) and the reduction in MET 
channel current size by superfusion with 13222 (Figure 4.10D), at all membrane potentials 
tested. Evidently this block is reversible, as shown by the complete restoration of current size 
following re-superfusion of control solution (blue).  
Average fractional block curves can be derived by plotting the ratio of the control MET channel 
current to the current in the presence of the compound against all membrane potentials; 
averaging the I-V curves across multiple cells. Shown in Figure 4.10E are fractional block curves 
for all 7 compounds that had no interaction with the channel. Shown in Figure 4.10F are all 6 
compounds that interacted with the channel. All 6 compounds display a voltage-dependent 
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block, with all but one (13087) showing maximal block at the intermediate, slightly negative 
potentials. Furthermore, all of the MET channel blocking compounds showed a release of the 
block at the extreme depolarised and extreme hyperpolarised potentials, indicating that they 
all behaved as permeant blockers of the MET channel, similarly to DHS (a semisynthetic AG 
derived from streptomycin) (Marcotti et al., 2005) and FM 1-43 (Gale et al., 2001), a stryl dye 
commonly used as a marker of MET channel function. 
 
Figure 4.10: Interactions of otoprotectants with the MET channel. 
Representative MET currents from OHCs in cultures prepared from P2 pups recorded before, 
during, and after exposure to (A) 50 μM 13143 (n=12) and (B) 50 μM 13222 (n=6). MET 
currents were recorded at membrane potentials from -164 mV to +96 mV in response to a 
sine-wave stimulus. Current-voltage curves for the peak MET currents derived from the 
recordings shown in A and B demonstrate (C) the lack of interaction of 13143 with the channel 
and (D) the voltage-dependence of block by 13222. (E) Fractional block of the MET currents at 
all membrane potentials reveals that 7 compounds, including 13143, do not interact with the 
channel. (F) 6 compounds, including 13222, provide a voltage-dependent block that is in most 
cases strongest at moderately negative potentials. Error bars are SEM. Numbers of 
independent tests are shown after each compound number in graphs (E and F). Figure taken 
from Kenyon et al., 2017. 
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4.2.5.2 The Effect of Otoprotectants on Basolateral K+ Channel Currents 
 
Of the 13 compounds that provided protection against gentamicin-induced loss of OHCs, 4 of 
them are known to be potassium channel blockers (13087, 13097, 13143 and 13154). Two of 
these are Kv7 channel blockers (13097 and 13143) but do not block the MET channel, whereas 
the remaining two (13087 and 13154) do. We tested all 13 otoprotective compounds for their 
block of the potassium channels expressed by P2 mouse OHCs. In the first postnatal week, a 
slow outward K+ current (IK,neo) is expressed in OHCs which activates at potentials positive 
to -50 mV (Marcotti and Kros, 1999). Block of IK,neo may result in depolarisation of the cell 
membrane and in this way reduce AG entry by reducing the driving force across the MET 
channel, which is determined by the sum of the EP and the RP of the cell. All 13 compounds 
were tested for their effect on Ik,neo at a concentration of 30 μM. K
+ currents were elicited by 
applying a series of hyperpolarising and depolarizing voltage steps, stepping from a holding 
potential of -84 mV. These results are thoroughly documented in Kenyon et al., 2017, however, 
in brief, of the 13 compounds tested, 11 showed some block of the K+ current and only 2 
(13170 and 13196) showed no interaction with the IK,neo channel.  
The common effect of the compounds on both of the ion channel types expressed in OHCs that 
could influence AG entry into HCs suggested that our otoprotectants may be protecting by 
reducing the loading and intracellular accumulation of gentamicin. For this reason, we then 
tested our 5 lead compounds for their ability to depolarise HC membranes and also for their 
ability to block the loading of a fluorescently-conjugated AG (GTTR) into HCs.  
 
4.2.5.3 The Effect of Otoprotectants on the Resting Membrane Potential 
 
The AGs are drawn into the MET channel due to the negative charge within the channel pore 
and are then pulled into the HC due to the negative potential inside relative to the 
extracellular environment. If a compound depolarised the cell membrane there would be less 
of an electrical driving force pulling the AGs into the cell, so their entry rates and consequent 
intracellular accumulation would be reduced, perhaps providing an otoprotective effect. The 5 
lead compounds (13097, 13142, 13143, 13174 and 13222) were tested for their effect on the 
resting membrane potential of the cell, as detailed in Kenyon et al., 2017. Briefly, none of the 
compounds caused any shift in cellular resting potential, eliminating membrane depolarisation 
as a potential mechanism of protection. 
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4.2.5.4 The Effect of Otoprotectants on Gentamicin-Texas Red Loading into 
HCs 
 
To further assess whether any of our lead compounds may be protecting by preventing AG 
entry into HCs, short-term fluorescence assays were used. A fluorescently-conjugated AG is 
available, known as gentamicin-Texas Red (GTTR). GTTR has often been used to study the 
loading of AGs into HCs (Steyger et al., 2003), so we utilised this experimental technique. P2 
mice cochleae were incubated with 0.2 μM GTTR for a period of 10 minutes, a concentration 
and time frame known to lead to HC loading. Prior to this, they were incubated for 5 minutes 
either with 100 μM of the Tocris compound of interest or 1% DMSO – the solvent in which the 
compounds were dissolved, as a control. By quantifying the intracellular GTTR florescence in 
the absence of presence of the compound, we were able to determine whether any of the 
compounds caused any reduction of AG loading into HCs. 
As detailed in Kenyon et al., 2017, only 1 of our 5 lead compounds (13143) caused a significant 
reduction in GTTR loading, despite showing no block of the MET channel or any shift in cellular 
resting potential. Compound 13170, found to block TR-Neo and FM 1-43FX loading in the 
zebrafish assays but disregarded as a potential lead compound due to negative effects on hair 
bundle morphology, caused a considerable decrease in loading and was used as a positive 
control in this assay. 
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Figure 4.13: Effects of lead otoprotectants on gentamicin-Texas Red (GTTR) loading in mouse 
cochlear cultures. 
Representative (A, C, E, G, I, K, and M) DIC and (B, D, F, H, J, L, and N) fluorescent images of 
cultures from P2 pups that were exposed to 0.2 μM GTTR for 10 minutes in presence of (A and 
B) 1% DMSO (n=21), (C and D) 100 μM 13097 (n=5), (E and F) 100 μM 13142 (n=6), (G and H) 
100 μM 13143 (n=4), (I and J) 100 μM 13154 (n=3), (K and L) 100 μM 13170 (n=6), and (M and 
N) 100 μM 13222 (n=6). Scale bar is 50 μm. (O) Box-and-whisker plot of background-corrected 
intensity values for fluorescence intensity (arbitrary units) in first-row OHCs in cultures 
exposed to GTTR in presence of DMSO, 13097, 13142, 13143, 13154, 13170, and 13222. Thick 
line = median; boxes = interquartile range (IQR). Whiskers extend an additional 1.5× IQR 
beyond the boxes. Outliers are shown as white circles. Figure taken from Kenyon et al., 2017. 
 
 
4.2.5.5 The Effect of Hair Bundle Disruption on Transduction Ability 
 
Many of the compounds that we identified as being otoprotective were found to cause some 
disruption of the mechanosensory hair bundle morphology. For this reason, I investigated 
whether it was this bundle disruption that underlay the protectiveness of the compound, due 
to this effect then rendering the MET channels non-functional. In order to assess this 
hypothesis I developed a new experimental paradigm with several experimental conditions, to 
investigate whether the compounds caused the observed hair bundle damage after only 24 
hours exposure time and whether if the compound was then washed away, this bundle 
damage was sufficient to prevent the HC loss caused by subsequent exposure to 5 μM 
gentamicin for 48 hours. Additionally, I investigated the loading of GTTR (and occasionally FM 
1-43) into HCs from cultures treated with the compound for 24 hours, to see if AG loading was 
reduced by this amount of compound exposure. Of the 8 compounds that caused some 
disruption to bundle morphology when tested at 50 μM in the presence of gentamicin (13087, 
13104, 13142, 13150, 13170, 13190, 13196 and 13228), I tested 5 in this experimental 
paradigm (13087, 13142, 13150, 13170 and 13196). Compounds 13104, 13190 and 13228 
were not tested due to time restrictions. 
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4.2.5.5.1 UoS 13087 (AM 92016), 13142 ((±)-1-(1,2-Diphenylethyl) piperidine) and 13196 
(m-Chlorophenylbiguanide) 
 
Cochlear cultures treated with 0.5% DMSO for 24 hours followed by HBHBSS for 48 hours 
maintained control characteristics of V-shaped OHC bundles (Figure 4.14A). When treated with 
0.5% DMSO for 24 hours followed by 5 μM gentamicin for 48 hours, there was a significant loss 
of basal OHCs (Figure 4.14B), similarly to the standard experimental paradigm presented in 
Chapter 3 (Figure 3.1). Following incubation with 50 μM 13087 or 13142 for 24 hours, the 
morphology of the mechanosensory hair bundle appeared unperturbed (Figures 4.14C and 
4.15C). With 50 μM 13196, however, the morphology of the mechanosensory hair bundle 
appeared slightly disrupted (Figure 4.16C). 
When 13087 was washed off of the cochlear culture after 24 hours (three 1 minute washes in 
2 ml HBHBSS) and 5 μM gentamicin then applied for 48 hours, the compound still provided 
anterograde protection against the gentamicin-induced loss of OHCs (Figure 4.14D). The HCs 
were extremely grown out of position and the morphology of the hair bundle was disrupted 
but the OHCs were still present. When 13142 and 13196 were washed off of the cochlear 
cultures after 24 hours and 5 μM gentamicin applied for 48 hours, the compounds still 
provided partial anterograde protection against the gentamicin-induced loss of OHCs (Figures 
4.15D and 4.16D). 
Despite the hair bundle morphology appearing undisrupted by 24 hour incubation with 13087, 
when tested for the loading of GTTR or FM 1-43 into HCs after 24 hour exposure, there was a 
significant reduction in the loading of both transduction markers (Figure 4.14F-J). The average 
cellular fluorescence in the control condition, after 24 hour incubation in 0.5% DMSO followed 
by 20 minutes exposure to GTTR, was 202.0 (± 6.1) (n=10, from one animal). When treated 
with 13087 for 24 hours prior to GTTR exposure, the average cell fluorescence reduced by 33% 
to 133.3 (± 7.7) (n=10, from one animal). An unpaired t test revealed that this difference was 
statistically significant (p < 0.001). The average cellular fluorescence in the control condition, 
after 24 hour incubation in 0.5% DMSO followed by 5 minutes exposure to FM 1-43, was 244.8 
(± 0.3) (n=10, from one animal). When treated with 13087 for 24 hours prior to FM 1-43 
exposure, the average cell fluorescence reduced by 32% to 166.8 (± 10.3) (n=10, from one 
animal). An unpaired t test revealed that this difference was significant (p < 0.001).  
When tested for the loading of GTTR into HCs after 24 hour exposure to 13142, there was a 
significant reduction in its loading.  The average cellular fluorescence in the control condition, 
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after 24 hour incubation in 0.5% DMSO followed by 20 minutes exposure to GTTR, was 69.3 (± 
2.2) (n=10, from one animal). When treated with 13142 for 24 hours prior to GTTR exposure, 
the average cell fluorescence reduced by 30% to 48.4 (± 1.9) (n=10, from one animal) (Figure 
4.15F-H). An unpaired t test revealed that this difference was statistically significant (p < 
0.001).   
When tested for the loading of GTTR into HCs after 24 hour exposure to 13196, there was a 
significant reduction in its loading (Figure 4.16F-H). The average cellular fluorescence in the 
control condition, after 24 hour incubation in 0.5% DMSO for 24 hours followed by 20 minutes 
exposure to GTTR, was 101.2 (± 2.0) (n=10, from one animal). When treated with 13196 for 24 
hours prior to GTTR exposure, the average cell fluorescence reduced by 85% to 15.2 (± 0.8) 
(n=10, from one animal). An unpaired t test revealed that this difference was statistically 
significant (p < 0.001).  
Taken together, these data implied that there was some block or disruption of MET channel 
function after 24 hour exposure to 13087, 13142 and 1396, reducing AG entry into HCs. 
Furthermore, this reduction in loading was sufficient to prevent at least some degree of HC 
loss by delaying the accumulation and consequent onset of AG-induced HC death. 
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Figure 4.14: 24 hours incubation with 50 μM 13087 led to hair bundle disruption, a reduction in 
FM 1-43 and GTTR loading into HCs, and subsequent protection from OHC loss following 
washout and 48 hours, 5 μM gentamicin exposure. 
Cochlear cultures were treated with 50 μM 13087 for 24 hours. The compound was then 
washed off and the culture was tested for (A-E) protection against subsequent 5 μM 
gentamicin incubation for 48 hours or (F-J) reduction of FM 1-43 and GTTR loading. (A-E) 
Cultures incubated with (A) 0.5% DMSO for 24 hours followed by HBHBSS for 48 hours, (B) 
0.5% DMSO for 24 hours followed by 5 μM gentamicin for 48 hours, (C-E) 50 μM 13087 for 24 
hours followed by (C) fixation, (D) 5 μM gentamicin for 48 hours or (E) HBHBSS for 48 hours. 
(F-J) Live imaging of fluorescent dye loading into cochlear culture HCs, incubated in 0.5% 
DMSO or 50 μM 13087 for 24 hours. Control (F) FM 1-43 or (G) GTTR loading. 24 hour 
incubation with 50 μM 13087 followed by (H) FM 1-43 or (I) GTTR exposure. (J) Quantification 
of HC fluorescence. Scale bars are 50 μm. 
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Figure 4.15: 24 hours incubation with 50 μM 13142 led to a reduction in GTTR loading into HCs 
despite no obvious hair bundle disruption, and subsequently partial protection from OHC loss 
following washout and 48 hours, 5 μM gentamicin exposure. 
Cultures were treated with 50 μM 13142 for 24 hours. The compound was then washed off 
and the culture was tested for (A-E) protection against subsequent 5 μM gentamicin 
incubation for 48 hours or (F-H) reduction of GTTR loading. (A-E) Cultures incubated with (A) 
0.5% DMSO for 24 hours followed by HBHBSS for 48 hours, (B) 0.5% DMSO for 24 hours 
followed by 5 μM gentamicin for 48 hours, (C-E) 50 μM 13142 for 24 hours followed by (C) 
fixation or 48 hour incubation with (D) 5 μM gentamicin or (E) HBHBSS. (F-H) Live imaging of 
fluorescent dye loading into cochlear culture HCs, incubated with HBHBSS or 50 μM 13142 for 
24 hours. GTTR loading into HCs following 24 hour incubation with (F) HBHBSS or (G) 50 μM 
13142. (H) Quantification of HC fluorescence. Scale bars are 50 μm. 
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Figure 4.16: 24 hours incubation with 50 μM 13196 led to hair bundle disruption, a reduction in 
GTTR loading into HCs, and subsequently partial protection from OHC loss following washout 
and 48 hours, 5 μM gentamicin exposure. 
Cultures were treated with 50 μM 13150 for 24 hours. The compound was then washed off 
and the culture was tested for (A-E) protection against subsequent 5 μM gentamicin 
incubation for 48 hours or (F-H) reduction of GTTR loading. (A-E) Cultures incubated with (A) 
0.5% DMSO for 24 hours followed by HBHBSS for 48 hours, (B) 0.5% DMSO for 24 hours 
followed by 5 μM gentamicin for 48 hours, (C-E) 50 μM 13150 for 24 hours followed by (C) 
fixation or 48 hour incubation with (D) 5 μM gentamicin or (E) HBHBSS. (F-H) Live imaging of 
fluorescent dye loading into cochlear culture HCs, incubated with HBHBSS or 50 μM 13150 for 
24 hours. GTTR loading into HCs following 24 hour incubation with (F) HBHBSS or (G) 50 μM 
13150. (H) Quantification of HC fluorescence. Scale bars are 50 μm. 
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4.2.5.5.2 UoS 13150 - FPL 64176 
 
When treated with 50 μM 13150 for 24 hours, the morphology of the mechanosensory hair 
bundle was greatly disrupted, with no evidence of the characteristic V-shaped OHC bundles 
along the entirety of the cochlear coil (Figure 4.17C). When 13150 was then washed off of the 
cochlear culture and 5 μM gentamicin applied for 48 hours, the compound still provided 
complete protection against the gentamicin-induced loss of OHCs (Figure 4.17D). Interestingly, 
when 13150 was washed off of the cochlear culture and HBHBSS applied for 48 hours, there 
was a loss of IHCs (Figure 4.17E), dissimilarly to what was observed following the application of 
gentamicin (Figure 4.17D). This result is likely explained by the fact that 13150 is a calcium 
channel agonist. As IHCs have a larger number of voltage-gated calcium channels than OHCs, 
the IHCs presumably loaded with a large intracellular calcium concentration over 24 hours. 
Following compound washout and gentamicin application, calcium loading into IHCs was 
reduced due to competition for entry through the MET channel, whereas when HBHBSS was 
applied calcium loading was not inhibited.  This postulation is supported by the comparison of 
IHC loss when cochlear cultures were treated with 50 μM 13150 alone (Figure 4.3) and the 
preservation of IHCs when co-incubated with gentamicin (Figure 4.1). 
When tested for the loading of GTTR into HCs after 24 hour exposure to 13150, there was a 
complete block of its loading (Figure 4.17F-H). The average cellular fluorescence in the control 
condition, after 24 hour incubation in 0.5% DMSO followed by 20 minutes exposure to GTTR, 
was 113.3 (± 2.6) (n=10, from one animal). When treated with 13150 for 24 hours prior to 
GTTR exposure, the average cell fluorescence reduced by 97% to 3.1 (± 0.2) (n=10, from one 
animal). An unpaired t test revealed that this difference was statistically significant (p < 0.001).  
Taken together, these data imply that there was full inhibition of MET channel function after 
24 hour exposure to the compound and that this is what underlay the protective ability of the 
compound. 
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Figure 4.17: 24 hour incubation with 50 μM 13150 led to hair bundle disruption, a reduction in 
GTTR loading into HCs, and subsequent complete protection from OHC loss following washout 
and 48 hours, 5 μM gentamicin exposure. 
Cultures were treated with 50 μM 13150 for 24 hours. The compound was then washed off 
and the culture was tested for (A-E) protection against subsequent 5 μM gentamicin 
incubation for 48 hours or (F-H) reduction of GTTR loading. (A-E) Cultures incubated with (A) 
0.5% DMSO for 24 hours followed by HBHBSS for 48 hours, (B) 0.5% DMSO for 24 hours 
followed by 5 μM gentamicin for 48 hours, (C-E) 50 μM 13150 for 24 hours followed by (C) 
fixation or 48 hour incubation with (D) 5 μM gentamicin or (E) HBHBSS. (F-H) Live imaging of 
fluorescent dye loading into cochlear culture HCs, incubated with HBHBSS or 50 μM 13150 for 
24 hours. GTTR loading into HCs following 24 hour incubation with (F) HBHBSS or (G) 50 μM 
13150. (H) Quantification of HC fluorescence. Scale bars are 50 μm. 
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4.2.5.5.3 UoS 13170 - ZK 93423 HCl 
 
When treated with 50 μM 13170 for 24 hours, the morphology of the mechanosensory hair 
bundle was greatly disrupted, with no evidence of the characteristic V-shaped OHC bundles 
along the length of the cochlear culture (Figure 4.18C). When 13170 was washed off of the 
cochlear culture after 24 hours and 5 μM gentamicin applied for 48 hours, the compound 
provided no protection against the gentamicin-induced loss of OHCs, but rather exacerbated 
the damage, leading to IHC loss as well as the characteristic OHC loss (Figure 4.18D). This also 
occurred when the compound was washed off after 24 hours and then HBHBSS (a control 
saline solution in which gentamicin is dissolved) was incubated for 48 hours. 
When tested for the loading of GTTR or FM 1-43 into HCs after 24 hour exposure, there was a 
complete block of the loading of both fluorescent compounds (Figure 4.18F-J). The average 
cellular fluorescence in the control condition, after 24 hour incubation in 0.5% DMSO followed 
by 20 minutes exposure to GTTR, was 70.94 (± 3.1) (n=10, from one animal). When treated 
with 13170 for 24 hours prior to GTTR exposure, the average cell fluorescence reduced by 99% 
to 0.7 (± 0.2) (n=10, from one animal). An unpaired t test revealed that this difference was 
statistically significant (p < 0.001). The average cellular fluorescence in the control condition, 
after 24 hour incubation in 0.5% DMSO followed by 15 minutes exposure to FM 1-43, was 
101.4 (± 4.7) (n=10, from one animal). When treated with 13170 for 24 hours prior to FM 1-43 
exposure, the average cell fluorescence reduced by 96% to 3.6 (± 0.6) (n=10, from one animal). 
Again, an unpaired t test revealed that this difference was significant (p < 0.001). 
Taken together, these data imply that 13170 caused dysfunction of the MET channel after 24 
hours incubation, and over time, even in the absence of the compound or gentamicin, caused 
HC toxicity. 
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Figure 4.18: 24 hour incubation with 50 μM 13170 led to hair bundle disruption and a reduction 
of FM 1-43 and GTTR loading into HCs. However, no protection from OHC loss was observed 
following washout and 48 hours, 5 μM gentamicin exposure. 
Cultures were treated with 50 μM 13170 for 24 hours. The compound was then washed off 
and the culture was tested for (A-E) protection against 5 μM gentamicin incubation for 48 
hours or (F-J) reduction of FM 1-43 or GTTR loading. (A-E) Cultures incubated with (A) 0.5% 
DMSO for 24 hours followed by HBHBSS for 48 hours, (B) 0.5% DMSO for 24 hours followed by 
5 μM gentamicin for 48 hours, (C-E) 50 μM 13170 for 24 hours followed by (C) fixation or 48 
hour incubation with (D) 5 μM gentamicin or (E) HBHBSS. (F-J) Live imaging of fluorescent dye 
loading into cochlear culture HCs, incubated with HBHBSS or 50 μM 13170 for 24 hours.  
Control (F) FM 1-43 or (H) GTTR loading. 24 hours incubation with 50 μM 13170 followed by 
(G) FM 1-43 or (I) GTTR exposure. (J) Quantification of HC fluorescence.  Scale bars are 50 μm. 
 
95 
 
4.3 Summary 
Screening of the Tocris Ion Channel library has led to the identification of several novel 
otoprotectants. Of the 160 compounds tested in zebrafish, 78 were taken forward to mouse 
cochlear cultures. Of these 78, 13 provided protection against the 48 hours, 5 μM gentamicin-
induced loss of HCs when tested at 50 μM, and 3 of these were still protective at 10 μM. When 
tested at 50 μM in the presence of 5 μM gentamicin, 8 caused disruption to sensory hair 
bundle morphology, and 1 when tested at 10 μM. When tested alone at 50 μM in the absence 
of gentamicin, 5 caused hair bundle disruption; alone at 100 μM, 4 were generally cytotoxic 
and 4 caused bundle disruption. Our 2 most effective otoprotectants both provided half-
protection in the nanomolar range. Our most effective compound (13097) was protective 
when tested at a high concentration (300 μM) against 10 μM gentamicin for 48 hours; 
however, when tested (≤ 50 μM) against 5 μM gentamicin for 72 hours, it failed to protect. 
Modification of 2 Tocris compounds of interest failed to yield more effective otoprotectants.  
After the exclusion of any compounds that caused adverse effects on the morphology of the 
mechanosensory hair bundle or displayed any intrinsic toxicity, 5 potential otoprotectants 
remained. When all 13 compounds were tested for their effect on MET channel currents 6 
compounds showed an interaction with the channel, all displaying voltage-dependent, 
permeant blocking characteristics. When tested for their effect on the basolateral potassium 
channel currents, 11 showed block of the channel, with varying degrees of current inhibition.  
Despite the potassium channel block, none of the 5 lead compounds caused any shift in the 
resting membrane potential of HCs. When tested for their ability to block GTTR loading into 
HCs in a short time assay, only 1 compound reduced its loading. 
Five of the 8 compounds that caused hair bundle damage when tested at 50 μM in the 
presence of gentamicin were tested to see if they caused a reduction in GTTR loading 24 hours 
after the onset of application, and if such pre-treatment provided anterograde protection to 
subsequent gentamicin exposure. After 24 hours, all 5 compounds significantly reduced GTTR 
loading to varying degrees, and all but 1 provided some level of anterograde HC protection. 
 
 
96 
 
4.4 Discussion 
Our screening of the Tocris Ion Channel library has further reinforced the usefulness and 
viability of zebrafish pre-screening when conducting large otoprotectant drug screening 
projects. By using zebrafish as a preliminary screening tool we have more than doubled the 
number of mammalian otoprotectants previously identified using this approach (Chiu et al., 
2008; Owens et al., 2008; Ou et al., 2009, 2012; Vlasits et al., 2012; Thomas et al., 2015; Hirose 
et al., 2016; Kruger et al., 2016). Furthermore, we have identified 2 compounds that protect in 
a mammalian system in the nanomolar range - an unparalleled protective efficacy reported to 
date. Due to the restrictions on the number of viable cochlear cultures that can be produced 
on a regular basis, we would not have been able to achieve these results with mammalian 
system screening alone. By comparing the number of compounds that were protective in each 
different zebrafish screen and subsequently found to also be protective in cochlear cultures, 
the zebrafish screening process has the potential to be refined to have a greater transferable 
efficiency to mammalian systems. Of the three zebrafish screens, the assay that tested 
protection against neomycin-induced HC damage yielded the highest number of compounds 
that were also protective in mouse cochlear cultures. Ten of the 13 compounds were 
protective in this assay, relative to 2 that reduced FM 1-43FX loading and 5 that reduced the 
loading of neomycin-Texas Red. Only 1 of the 19 compounds that were successful in each of 
the three zebrafish assays was protective in mouse cochlear cultures. Ten of the 13 
compounds would have been identified in the neomycin protection assay alone, so the added 
value of the FM 1-43FX and neomycin-Texas Red loading assays in these large-scale screens is 
questionable. 
Despite the usefulness of zebrafish pre-screening, caution must be executed when relying 
solely on zebrafish protection assays to determine which compounds are selected for further 
screening in mammalian systems. Of the 72 that were protective in zebrafish, 12 were 
consistently protective in mouse cochlear cultures. This signifies a 17% transferrable efficacy. 
Of the 6 compounds that were selected that did not protect in zebrafish, but had a similar 
chemical structure to some of those that did, 1 was consistently protective. This again signifies 
a 17% transferable efficacy. Although these numbers are small, it is evident that zebrafish 
screening alone would lead to a number of false negatives, with potentially effective 
mammalian otoprotectants being missed in this screening process. One way to avoid this issue 
is to refine and improve the procedure, by identifying the most effective zebrafish assay in 
terms of transferable efficacy and primarily using the results of this assay to select structurally 
similar compounds for mammalian screening. 
97 
 
The cochlear culture screening conducted in this chapter revealed the need for an extensive 
screening procedure in mammalian systems. When the 12 compounds that consistently 
protected HCs were put through rigorous additional screening for adverse effects on bundle 
morphology or any intrinsic toxicity at higher concentrations, only 3 remained (compounds 
13097, 13142 and 13143). This means that the majority of identified protectants had the 
potential to cause adverse effects in the cochlea if transferred directly to an in vivo model, 
reinforcing the notion that a thorough screening regime should be adhered to when searching 
for clinically-viable compounds. It is vital that compounds are assessed for any adverse effect 
on bundle morphology, especially due to the disruptive effect this may have on auditory 
transduction and consequent hearing ability. 
Of the 13 compounds that provided protection, almost half blocked the MET channel. We 
therefore assumed that they were providing protection against AG damage by preventing 
antibiotic entry into the HCs. However, when half of the MET channel blockers were tested for 
their ability to block the entry of GTTR into HCs, all failed to reduce its loading. Noteworthy 
here is that native (un-tagged) gentamicin was also unable to reduce GTTR loading (data not 
shown). Several conclusions can be made from this observation. Firstly, evident interaction 
with the MET channel current is not indicative of the compound’s ability to prevent AG entry 
through this ion channel. Secondly, precaution should be taken when using GTTR as a 
surrogate for gentamicin trafficking through the cochlea and into HCs, despite its ongoing use 
for this purpose (Steyger et al., 2003). The MET channel-blocking compounds may prevent the 
entry of native gentamicin into HCs, however it could be that GTTR has a higher affinity for the 
channel and is therefore able to compete for entry more efficiently, reducing the likelihood of 
compounds being able to prevent its loading. To note here, all of the Tocris compounds 
showed maximal block at the intermediate potentials and displayed a release of block at both 
extremes of depolarisation and hyperpolarisation, indicative of them behaving as permeant 
blockers. The fact that they are readily reversible and do not remain in the channel to block it 
continuously could explain the somewhat surprising GTTR result. 
Interestingly, the two most effective otoprotectants identified in this chapter (13097 and 
13143) have both been identified in the literature as Kv7 potassium channel inhibitors. The 
Kv7.4 potassium channel subunit is encoded by the KCNQ4 gene and is known to play a role in 
the regulation of neuronal excitability, particularly in the sensory cells of the cochlea. For this 
reason we hypothesised that these two compounds may be protecting by blocking the 
outward potassium channels in the OHCs of our cochlear cultures, thereby depolarising the cell 
and reducing the entry of the positively charged AGs. However, when tested for their influence 
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on the resting membrane potential both had no effect, thereby eliminating depolarisation, at 
least in the short term, as a potential mechanism of protection. In this study 13143 was shown 
to reduce GTTR loading however it displayed no interaction with the MET channel and did not 
shift the resting potential of the cell, implying that its block of GTTR loading was irrespective of 
its mechanism of protection. Later chapters in this thesis also elucidate an effect of 13143 on 
AG-induced mitochondrial dysfunction. However this will be discussed later, in Chapter 8. 
The issue with our lead compounds being Kv7 channel blockers arises from our use of postnatal 
day 2 mouse cochlear cultures. Around postnatal day 8, a mature OHC K+ current starts to be 
expressed (IK,n) and this coincides with a decrease of Ik,neo (Marcotti and Kros, 1999) – the 
potassium current that we investigated in our experiments. If we had tested our compounds 
on cultures made from a later developmental stage (˃ postnatal day 8), our lead compounds 
may have caused a block of the more mature potassium channels and consequent damage to 
HCs as a result of continuous depolarisation (Oliver et al., 2003), due to the strong influence of 
plasma membrane K+ efflux channels in the regulation of apoptosis (Kondratskyi et al., 2015). 
For this reason, we should have tested them at a later developmental stage. However, 
dissecting the cochlea from ˃ P8 mice and keeping the basal coil intact is notoriously difficult. 
As we are trying to replicate the clinical manifestation of AG ototoxicity, with HC loss primarily 
from the basal section, it is important to experiment on this cochlear region. We therefore had 
to compromise between the cochlear region of interest and the developmental expression of 
relevant ion channels. However, the concentration at which our lead compound (13097) 
protects 50% of basal-coil HCs from 5 μM gentamicin is an order of magnitude below its IC50 
for KCNQ4-encoded K+ channels (Oliver et al., 2003), so channel block may not be an issue. We 
are now awaiting in vivo confirmation of the otoprotective ability of 13097. 
Somewhat surprisingly, our most effective compound (13097), protective at nanomolar 
concentrations, was unable to provide any protection when tested against a longer time 
exposure to gentamicin. Furthermore, it was only protective against a higher gentamicin 
concentration when tested at a high molar excess of its minimum protective concentration in 
our standard protection assay, and even then it did not protect against AG-induced bundle 
damage. This highlights the complexity of the AG-induced cell-death process and also adds 
ambiguity to the mechanism by which the compound is protecting. Ideally, 13097 should have 
been tested at a higher concentration in the 72 hour assay however this was not possible due 
to stock limitations. 
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Lastly, experiments assessing the effect of hair bundle morphological disruption on GTTR 
loading and consequent protection provided some interesting results. All of the compounds 
that were incubated for 24 hours caused a significant reduction in GTTR loading, even if there 
was no obvious damage to the morphology of the hair bundle. Four of the 5 compounds then 
provided anterograde protection from subsequent gentamicin exposure, to varying degrees. 
The fifth compound caused generalised cytotoxicity after 72 hours even in the absence of 
gentamicin, so conclusions cannot be made regarding its subsequent protective ability. These 
results suggest that in our protection assay, any compounds that do cause an observable 
disruption to hair bundle morphology after 48 hours should be excluded from further 
screening, as they render the function of the MET channel compromised to some degree and 
this potentially underlies at least part of its protective ability. Moreover, high-resolution 
microscopy should be used to ascertain the effect of these compounds on hair bundle 
morphology, due to the limitations of detection with lower-resolution imaging. Preserving MET 
channel function is a vital task when searching for otoprotectants, so this part of the screening 
procedure should be considered imperative.  
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5   Assessing the Otoprotective Potential of d-Tubocurarine 
and Berbamine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101 
 
5.1 Introduction 
5.1.1 Compound Choice 
 
Historically, d-Tubocurarine (dTC) is known to be the main active ingredient of the arrow 
poison curare. It is an alkaloid that can be obtained from the bark of the plant Chondrodendron 
tomentosum (Perotti, 1977). Characterised as a nicotinic antagonist, studies have shown that it 
blocks the acetylcholine receptor response in guinea-pig OHCs (Housley and Ashmore, 1991; 
Eróstegui et al., 1994) and also MET channels in the cochlear HCs of neonatal mice (Glowatzki 
et al., 1997). A study investigating the MET channel pore identified curare as being a non-
permeant blocker of these channels in turtle sensory HCs (Farris et al., 2004); a quality that we 
sought to identify in a potential otoprotectant throughout this project. Other studies have 
shown that 1 mM curare can block 3 μM GTTR loading into HCs and that co-incubation of 1 
mM curare and 0.1 mM gentamicin prevents AG-induced HC death (Alharazneh et al., 2011), 
suggesting a MET channel-blocking mechanism of protection. These characteristics rendered 
dTC an interesting compound to investigate in our search for otoprotectants, as a potential 
candidate for compound modification. 
In the search for other MET channel-blocking compounds we identified berbamine, another 
naturally occurring alkaloid present in many plant species of the Berberidaceae family 
(Rahmatullah et al., 2014). Berbamine has an extremely similar chemical structure to dTC 
(Kirkwood et al., 2017). In Eastern medicine it has been used for centuries and is still of current 
interest due to its potential anti-cancer properties (Ji et al., 2009; Meng et al., 2013; Zhao et 
al., 2016). Zebrafish lateral line studies have revealed that 25 μM berbamine can protect 
neuromast HCs from the damage induced by both neomycin and gentamicin, tested at a 
concentration range of 50-400 μM (Kruger et al., 2016). This study also revealed that 
berbamine was able to block the loading of GTTR and FM 1-43 into zebrafish lateral line HCs, 
leading to the conclusion that berbamine protects similarly by acting as a competitive blocker 
of the MET channel, thereby preventing AG entry into HCs. 
 
5.1.2 Aims 
 
We investigated both dTC and berbamine for their otoprotective abilities in zebrafish and 
mouse cochlear cultures, assessing whether dTC also provides protection in zebrafish models 
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and whether berbamine is able to provide protection in mammalian systems. Comparing 
compound protection of neuromast and cochlear HCs provides further evidence of the viability 
of zebrafish pre-screening when searching for mammalian otoprotectants. We also provided 
full characterisation of the interaction of both compounds with the MET channel by 
performing electrophysiological experiments on mouse cochlear culture HCs. Comparative 
studies like this allow us to further ascertain what characteristics of a compound determine 
their otoprotective, MET channel-blocking abilities, thereby informing future studies and the 
design of potential otoprotectants.  
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5.2 Results 
5.2.1 Screening for Otoprotection 
 
5.2.1.1 Zebrafish Pre-Screening 
 
*The zebrafish research presented in this section was collected by Emma Kenyon, University of 
Sussex. I performed the statistical analysis of the data. 
 
The protective abilities of dTC and berbamine were initially assessed using a zebrafish lateral 
line protection assay, investigating whether the two compounds of interest could prevent the 
loss of neuromast HCs caused by exposure to either neomycin or gentamicin. These results are 
thoroughly documented in Kirkwood et al., 2017, however, in brief: dTC was found to provide 
complete protection against the damage induced by 1 hour exposure to 6.25 μM neomycin at 
concentrations ≥ 12.5 μM, with partial protection observed at 6.25 μM. Full protection against 
the damage induced by 6 hour exposure to 10 μM gentamicin was only observed at dTC 
concentrations ≥ 50 μM, with partial protection at 25 μM. Berbamine consistently provided 
protection at lower concentrations against both AGs. It provided full protection against the 
neomycin-induced neuromast damage at concentrations ≥ 12.5 μM, with partial protection 
even down to 1.55 μM, the lowest concentration tested. Berbamine offered full protection 
against 10 μM gentamicin damage at ≥ 25 μM, with partial protection at 12.5 μM. Noteworthy, 
no signs of toxicity due to either compound were observed at the highest concentration tested 
(200 μM). 
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5.2.1.2 Cochlear Culture Screening 
 
dTC and berbamine were subsequently screened in mouse cochlear cultures to test if they 
would protect mammalian cochlear HCs from the damage induced by exposure to 5 μM 
gentamicin for 48 hours (Figure 5.1A–D). Such treatment results in the average loss of 88% of 
OHCs from the mid-basal region of the cochlea, with little effect if any on the survival of IHCs 
and apical OHCs (see Chapter 3). dTC and berbamine were found to be protective against the 
gentamicin-induced loss of OHCs (Figure 5.1A and B) at minimum concentrations of 25 μM and 
20 μM respectively (Figure 5.1C and D), as quantified in Figure 5.1G and H, which show graphs 
of OHC counts from a 220 μm-long segment of the mid-basal region of mouse cochlear 
cultures.  
 
As a further criterion to assess the suitability of a compound for use as an otoprotectant we 
examined the hair bundle morphology. No hair bundle damage was observed during exposure 
to either compound (Figure 5.1C and D). To determine if either compound had any adverse 
effects on HCs in the absence of gentamicin, they were tested alone at a higher concentration 
of 50 μM. Berbamine was found to be generally cytotoxic and killed all cell types in the 
cochlear culture (Figure 5.1H), whereas dTC had no adverse effect at this concentration (Figure 
5.1E and G). Berbamine was tested alone at the lower concentrations of 20 and 30 μM and 
found to be equally toxic at 30 μM as it was at 50 μM but not at 20 μM, the concentration at 
which it showed protection (Figure 5.1F and H). When 30 μM berbamine was tested together 
with 5 μM gentamicin the same cytotoxic effect was observed as with 30μM berbamine alone 
(Figure 5.1H), highlighting the extremely narrow protective concentration range of this 
compound in cochlear cultures. 
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Figure 5.1:  d-Tubocurarine and berbamine protect mouse OHCs from gentamicin damage. 
 
 (A) A control culture incubated for 48 hours in the presence of 0.5% DMSO. The sensory HC 
loss shown in (B), caused by 48 hours incubation with 5 μM gentamicin and 0.5% DMSO can be 
prevented by co-incubation with 25 μM dTC (C) or 20 μM berbamine (D). Cells incubated in 50 
μM dTC in the absence of gentamicin were not damaged (E), whereas 30 μM berbamine 
resulted in widespread loss of all cell types (F). Scale bar is 50 μm. (G-H) Quantification of OHC 
survival in the control, 5 μM gentamicin, 5 μM gentamicin plus different concentrations of 
compounds and in compound alone-treated conditions. 
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5.2.2 Mechanism of Protection 
 
5.2.2.1 The Effect of dTC and Berbamine on MET Channel Currents 
 
* The electrophysiology presented in Figures 5.2E, 5.3 and 5.6G was performed by Nerissa 
Kirkwood, University of Sussex.  
 
To ascertain whether the otoprotective nature of dTC and berbamine may be a result of their 
MET channel-blocking abilities, due to the consequent impedance of AG entry into HCs, we 
investigated their interaction with the MET channel using P2 mouse cochlear cultures. All 
recordings were performed on basal-coil HCs; the cells most susceptible to AG damage. dTC 
had previously been reported to behave as a MET channel blocker (Glowatski et al., 1997; 
Farris et al., 2004), however no such study had been conducted for berbamine. MET currents 
were recorded from OHCs as their membrane potential was stepped from -164 to +96 mV, 
before, during and after the local superfusion of dTC or berbamine, tested at concentrations 
ranging from 300 nM to 100 μM (dTC) or 1 to 30 μM (berbamine). When exposed to either 
compound, there was a reduction in MET current size when the cell was stepped to 
hyperpolarised potentials. At depolarised potentials this reduction was less pronounced and 
was dependent on the concentration of the compound. Examples of MET channel block by 30 
μM dTC and berbamine can be seen in Figures 5.2A-C and 5.3A-C respectively. During 
superfusion of the compounds when the cell was held at negative potentials, on each cycle of 
the sine-wave there was an initial inward current peak, after which the current rapidly 
declined. This characteristic is indicative of an open-channel mechanism of block, as the 
compounds can only block the channel and reduce the current size once it is in the open 
conformation. This is a postulation further supported by investigation of MET current size in 
response to large step stimuli, which revealed an adaptation-like decline in the current sizes 
when exposed to the compounds; a response not observed in the controls, as detailed in 
Kirkwood et al., 2017. MET channel block and subsequent washout were very rapid, with 
current sizes making a complete recovery following re-superfusion of the control solution, 
suggesting that the block by both of these compounds is completely reversible.  
The current-voltage curves displayed in Figure 5.2D and 5.3D, generated from the raw data in 
A-C, highlight the voltage-dependency of MET channel block by both compounds. Fractional 
block curves were generated from the extracellular block of the MET channel by both dTC and 
berbamine across a range of concentrations (Figures 5.2E and 5.3E). These graphs serve to 
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further highlight the voltage and concentration-dependency of MET channel block by both of 
the compounds. Furthermore, the block of the channels is released at both extreme 
hyperpolarised and depolarised potentials, indicative of dTC and berbamine acting as 
permeant blockers of the channel. Release of block at hyperpolarised potentials was more 
pronounced for berbamine than it was for dTC, suggesting that berbamine would more readily 
permeate through the channel and enter into the cell cytoplasm. Maximal block was seen at a 
membrane potential of -118 mV for dTC and -94 mV for berbamine. 
Further investigation revealed that the half-blocking concentration, KD, of the MET channel is 
extremely similar for both compounds, found to be 2.2 μM for dTC and 2.8 μM for berbamine 
(Kirkwood et al., 2017). Investigation of the intracellular block of the channel, established by 
including the compounds in the patch pipette-filling solution, revealed that berbamine caused 
no block of the channel when tested at ≤ 300 μM. When tested at a much higher 
concentration of 1 mM, berbamine had an adverse effect on the cells and their ability to be 
patched. With intracellular dTC, however, when tested at concentrations ranging from 100 μM 
to 1 mM we observed current reduction when cells were stepped to depolarised, but not 
hyperpolarised, membrane potentials. Again this block was both voltage and concentration- 
dependent, as detailed in Kirkwood et al., 2017. 
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Figure 5.2: The interaction of d-Tubocurarine with the MET channel. 
(A-C) Representative MET currents from OHCs in cultures prepared from P2 pups recorded 
before, during, and after exposure to 30 μM dTC. MET currents were recorded at membrane 
potentials from -164 mV to +96 mV in response to a sine-wave stimulus. (D) Current-voltage 
curve for the peak MET currents derived from the recordings shown in A-C demonstrates the 
voltage-dependency of the block by dTC. (E) Fractional block of the MET currents at all 
membrane potentials revealed that block is strongest at negative potentials and is released at 
the extremes, at every concentration tested. Data in E obtained from Nerissa Kirkwood. 
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Figure 5.3: The interaction of berbamine with the MET channel. 
(A-C) Representative MET currents from OHCs in cultures prepared from P2 pups recorded 
before, during, and after exposure to 30 μM berbamine. MET currents were recorded at 
membrane potentials from -164 mV to +96 mV in response to a sine-wave stimulus. (D) 
Current-voltage curve for the peak MET currents derived from the recordings shown in A-C 
demonstrates the voltage-dependency of the block by berbamine. (E) Fractional block of the 
MET currents at all membrane potentials revealed that block is strongest at negative potentials 
and is released at the extremes, at every concentration tested. Data obtained from Nerissa 
Kirkwood, figure prepared by myself. 
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5.2.2.2 The Effect of dTC and Berbamine on K+ Channel Currents and the 
Resting Potential of the Cell 
 
dTC has been shown to block a number of potassium channels, including neuronal apamin-
sensitive potassium currents (Goh and Pennefather, 1987) and various calcium-dependent 
potassium channels in other cell types (Ishii et al., 1997; Vacher et al., 1998). During the first 
postnatal week, cochlear OHCs express a slow outward K+ current (IK,neo), as detailed in chapter 
4 (section 4.2.5.2) (Marcotti and Kros, 1999). We therefore tested whether dTC and berbamine 
had any interaction with this channel. In addition to MET channel block, the compounds could 
inhibit this current and thereby potentially depolarise the resting cell membrane potential. 
This would lead to a further reduction in AG entry due to a reduction in the electrical driving 
force pulling the positively charged AGs into the cell, thereby providing an additional 
mechanism of protection. The results of these experiments are thoroughly documented in 
Kirkwood et al., 2017, however will be described here in brief. 
Basolateral K+ channels were investigated in whole-cell voltage clamp mode, with currents 
elicited by applying a series of hyperpolarising and depolarising voltage steps from a holding 
potential of -84 mV. Currents were recorded before, during and after the superfusion of 30 μM 
dTC or berbamine. At this concentration berbamine caused a large reduction in K+ current size, 
however dTC had no effect. The effect on the resting membrane potential was subsequently 
investigated in current-clamp mode. Neither compound caused a depolarisation in the resting 
membrane potential when tested at 30 μM.  Conversely, both berbamine and dTC caused a 
hyperpolarisation of the resting membrane potential. This hyperpolarisation would increase 
AG entry rates into HCs due to the increased electrical driving force, thus eliminating 
membrane depolarisation as a potential mechanism of protection. 
 
 
5.2.2.3 The Effect of dTC and Berbamine on GTTR Loading into HCs 
 
In order to test whether dTC and berbamine reduced the accumulation of gentamicin into 
OHCs by blocking the MET channel, mouse cochlear cultures were exposed to a low 
concentration (0.2 μM) of GTTR in the presence of a large molar excess (100 μM) of each 
compound for a short period of time to enable a quantification of AG uptake into HCs (Steyger 
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et al., 2003). For a negative control, cultures were incubated in 0.2 μM GTTR and 1% DMSO 
alone – the solvent in which the compounds were dissolved. Following 5 minutes pre-
incubation with dTC, berbamine or DMSO and subsequently 10 minutes co-incubation with 0.2 
μM GTTR, a one-way ANOVA revealed that a significant decrease in GTTR loading was seen in 
OHCs that were pre-exposed to either dTC (p = 0.001) or berbamine (p < 0.001) compared to 
the DMSO vehicle controls (Figures 5.4A–D). The reduction in GTTR labelling observed with the 
two compounds was very similar and not significantly different. In the control, the average 
intracellular fluorescence 12 minutes after GTTR washout was 75.5 (± 3.7) (arbitrary units) 
(n=30). In the dTC treated condition it was 36.8 (± 4.6) (n=30, from 3 animals) and in the 
berbamine treated condition it was 32.4 (± 3.2) (n=30, from 3 animals). 
 
 
Figure 5.4: d-Tubocurarine and berbamine reduce the loading of GTTR into HCs. 
(A) Quantification of intracellular fluorescence in cochlear culture HCs pre-treated for 5 
minutes with 100 μM dTC, berbamine or 1% DMSO, followed by 10 minutes co-incubation with 
0.2 μM GTTR. (B–D) Representative images captured 12 minutes after GTTR washout. (C) dTC 
(**p = 0.001) and (D) berbamine (***p < 0.001) significantly reduced the intracellular 
fluorescence intensity of GTTR compared to the DMSO vehicle controls. No significant 
difference was observed between the reduction caused by dTC and berbamine. Scale bar is 50 
μm. 
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5.2.3 Compound Modification  
 
5.2.3.1 dTC-related Compounds 
 
Following the success of the screening procedure, reinforcing that both dTC and berbamine 
protect against AG ototoxicity by blocking the MET channel, compounds that share a similar 
mechanism of action to dTC (other neuromuscular blockers) were bought for testing. This was 
in an attempt to identify a compound with similar otoprotective abilities - maintaining, and 
ideally enhancing, the desirable characteristics of MET channel block and otoprotection, whilst 
also reducing the concurrent permeation properties. This investigation would inform us of 
what parts of the dTC molecule are integral to its interaction with the MET channel, enhancing 
our knowledge and informing the future design of otoprotectants. 
Four compounds were commercially available (14916, 16297, 16298 and 16299) that share the 
same mechanism of action of dTC but differ slightly chemically. Compound 14916 is the dTC 
molecule cut in half. Compounds 16297 and 16298 are structurally identical but 16297 has two 
fixed positive charges (quaternary nitrogens) whilst 16298 has only one fixed positive charge 
and one that is pH-dependent. Compound 16299 consists of two 14916 linked together via a 
chemical linker and has two fixed positive charges. 
Shown in Figure 5.6A-F is the cochlear culture protection assay displaying the protective 
efficacy of each compound. Figure 5.6G shows their interaction with the MET channel. When 
tested at 50 μM, only one of the four compounds provided protection against the AG-induced 
OHC loss (16297), two showed no protection (14916 and 16298) and one displayed a toxic 
effect on the sensory epithelium (16299), causing an enlargement of the apical surface of all 
OHCs and a deformity of the hair bundle along the entire length of the cochlear coil (Figure 
5.6A-F). When tested at lower concentrations (25 and 12.5 μM) 16297 failed to protect, 
suggesting that there was no improvement of the protective efficacy compared to dTC itself 
(data not shown). Moreover, when tested electrophysiologically all but one compound 
retained the MET channel blocking ability, however none blocked as strongly as dTC (Figure 
5.6G). The one compound that had no interaction with the channel (14916) was the dTC 
structure that was cut in half, so it was perhaps not surprising that it did not show any block of 
the channel. 
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Figure 5.6: One of the four d-Tubocurarine-related compounds protected against gentamicin 
damage and three showed a voltage-dependent block of the MET channel. 
(A-F) Cochlear culture protection assay. (A) A control culture incubated for 48 hours in the 
presence of 0.5% DMSO. The sensory HC loss shown in (B), caused by 48 hours incubation with 
5 μM gentamicin and 0.5% DMSO can be prevented by co-incubation with 50 μM 16297 (n=3) 
(D), but not with 14916 (n=1) (C) or 16298 (n=1) (E). Cells incubated with 50 μM 16299 (n=1) 
showed toxicity symptoms (F). Scale bar is 50 μm. (G) The average fractional block curves 
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reveal that all but one compound (14916) display a voltage-dependent, permeant block of the 
MET channel, similar to dTC. Data in G obtained from Nerissa Kirkwood. 
 
 
5.2.3.2 d-Tubocurarine-Texas Red 
 
A previous study into the MET channel interacting properties of dTC revealed that it is a non-
permeant blocker, however here we have found evidence to contradict this. 
Electrophysiological recordings revealed a release of channel block at extreme hyperpolarised 
potentials (Figure 5.2), indicative of the dTC molecule being drawn into the HC. To further 
assess this postulation we conjugated dTC to a fluorescent dye, Texas Red, and investigated its 
loading into HCs using live cell imaging. I incubated cochlear cultures with 50 nM of either 
Texas Red or dTC-Texas Red (dTC-TR) for 4 hours, washed the compound away with three 1 
minute washes in HBHBSS and then performed live imaging of HC fluorescence. By comparing 
the intracellular fluorescence of Texas Red, a dye that would not selectively enter HCs over this 
time course (Steyger et al., 2003; Wang and Steyger, 2009; Alharazneh et al., 2011), with the 
loading of dTC-TR, comparisons can be made as to whether dTC enhances its specific loading 
into HCs. 
As shown in Figure 5.7A, Texas Red alone does not enter HCs over a 4 hour time course when 
tested at 50 nM. When conjugated with dTC, however, selective HC loading is observed (Figure 
5.7B). The average HC fluorescence in the Texas Red-treated culture was 6.5 (±0.7) (n=10, from 
one animal) and in the dTC-Texas Red culture it was 64.7 (±1.7) (n=10, from one animal) 
(Figure 5.7C). A two-tailed t test revealed that this difference was significant (p ˂ 0.001). This 
provides additional evidence in support of our hypothesis that dTC is a permeant MET channel 
blocker and does enter HCs following its block of the channel, consistent with the 
electrophysiological evidence presented in this chapter. 
Additionally, I performed a cochlear culture protection assay to ascertain whether dTC-TR 
retained the same protective ability of the parent compound. As seen in Figure 5.7D-G, myosin 
VIIa staining of HC bodies reveals that both compounds protect HCs similarly when tested at 
50 μM (Figure 5.7F and G), suggesting that the conjugation of the fluorophore did not cause a 
change in the otoprotective characteristics of dTC. 
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Figure 5.7: d-Tubocurarine-Texas Red loads into HCs specifically over a 4 hour time period, and 
protects cochlear HCs similarly to dTC. 
(A-C) Live cell imaging of OHC fluorescence. Cultures incubated with 50 nM Texas Red for 4 
hours (A) displayed no specific labelling, whereas those incubated with dTC-TR (B) showed 
granular fluorescence labelling within HCs specifically. (C) Quantification shows that the 
difference in cytoplasmic fluorescence is statistically significant (p ˂ 0.001). (D-G) Cochlear 
culture protection assay, stained with myosin VIIa primary antibody. (D) A control culture 
incubated for 48 hours in the presence of 0.5% DMSO. The sensory HC loss shown in (E), 
caused by 48 hour incubation with 5 μM gentamicin and 0.5% DMSO, can be completely 
prevented by co-incubation with 50 μM d-TC (F) or dTC-TR (G). Scale bars are 50 μm. 
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5.3 Summary 
 
Our screening of the structurally-related compounds dTC and berbamine has further 
highlighted their otoprotective similarities. Here we show that dTC also protects against 
neomycin and gentamicin damage in zebrafish neuromasts and that berbamine also protects 
against gentamicin damage in mouse cochlear cultures. In cochlear cultures, we show that the 
protective range of berbamine is extremely narrow; it provides protection against 5 μM 
gentamicin damage when tested at 20 μM, however when tested at ≥ 30 μM both alone and in 
the presence of gentamicin, cytotoxicity and a complete loss of all cell types in the cochlear 
culture is observed. dTC does not share these toxicity characteristics when tested ≤ 50 μM. 
Characterisation of their MET channel-blocking abilities shows that they both interact with the 
channel in an extremely similar way. Both display a voltage-dependent, permeant block of the 
channel, with maximum block at negative potentials around -80 mV and release of block at the 
extreme hyperpolarised and depolarised potentials. dTC and berbamine have a similar half-
blocking KD, 2.2 and 2.8 μM respectively (Kirkwood et al., 2017), showing that they have a 
similar affinity for the channel. Their block of basolateral potassium channels is different, 
however, in that berbamine blocks these channels whereas dTC does not. Neither causes a 
positive shift in the resting cell membrane potential, eliminating depolarisation as a potential, 
additional mechanism of protection. 
The postulation that the compounds may be protecting by blocking MET channels and 
impeding AG entry is further supported by our evidence of the reduction of GTTR loading into 
HCs, both by dTC and berbamine, consistent with the results published by other researchers 
(Alharazneh et al., 2011; Kruger et al., 2016). Contrary to what is found in the literature (Farris 
et al., 2004), however, here we show that dTC is itself a permeant blocker of the MET channel. 
This is evident from electrophysiological recordings showing release of MET channel block at 
extreme hyperpolarised potentials, and is further supported by my investigation of the loading 
of dTC-TR into HCs. Over a 4 hour time course dTC-TR selectively enters sensory HCs, whereas 
Texas Red alone does not.  
Lastly, of the 4 compounds with a similar mechanism of action to dTC that were commercially 
available, only one provided protection and this was at a reduced efficacy compared to dTC 
itself. Furthermore, all 3 that blocked the MET channel retained the undesirable characteristic 
of channel permeation. 
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Figure 5.8: d-Tubocurarine and berbamine share similar chemical structures. 
(A-B) Energy-minimized structures showing the distance between the positive charges for dTC 
(8.89 Å; yellow) (A) and berbamine (10.18 Å; magenta) (B) respectively. (C) A flexible alignment 
with the structures not minimized reveals dTC and berbamine share striking structural 
similarities. Figure taken from Kirkwood et al., 2017. 
 
5.4 Discussion 
 
The research conducted in this chapter, into the protective and mechanistic characterisation of 
dTC and berbamine, has further reinforced the usefulness of zebrafish pre-screening in the 
search for clinically-relevant otoprotectants. If these compounds had been blindly screened in 
the zebrafish assays they would have been selected and taken forward to mouse cochlear 
cultures for additional screening. This again suggests that zebrafish provide a useful pre-
screening tool in the search for mammalian otoprotectants. 
From the cochlear culture screening section of this chapter, we have gained further evidence 
of the importance of a thorough, comprehensive screening procedure. Berbamine was found 
to be protective at 20 μM but extremely toxic when tested ≥ 30 μM. Evidently, it is vital to 
screen compounds at a series of concentrations outside of their protective range, to ensure no 
adverse effects at higher concentrations. Furthermore, it is vital that this thorough screening is 
conducted in mammalian systems as berbamine showed no signs of toxicity when tested 
against either AG in the zebrafish assays, even at the highest concentration tested (200 μM). 
Consequently, any compound put forward as a potential otoprotectant to be used in a clinical 
setting should be screened thoroughly in mammalian models to ensure a broad protective, 
non-toxic range and also no inherent intrinsic toxicity when tested alone. To this end, the 
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current use of berbamine for this very purpose should be exercised with some caution, as it 
has been identified as an otoprotectant in the literature (Kruger et al., 2016; Neveux et al., 
2017) and reported to protect against a range of other ailments (Zhnag et al., 2012; Wang et 
al., 2016; Jia et al., 2017) however reports of its striking toxicity profile are lacking. 
Our electrophysiological investigation of MET channel interaction revealed that dTC is a 
permeant blocker of the channel, contrary to what has been reported elsewhere (Farris et al., 
2004). This is further supported by my live imaging of the loading of a fluorescently-tagged 
version of dTC (dTC-TR) into HCs specifically. This literature-contradicting evidence highlights 
that when investigating compounds electrophysiologically for their permeation properties the 
cell membrane should be stepped to all possible physiologically-relevant potentials, to ensure 
any potential permeation is detected. 
Investigation of the dTC-related compounds informed us that it is not sufficient for a 
compound to interact with the MET channel in order for it to provide protection from AG-
induced ototoxicity. Although all but one of the derivatives interacted with the MET channel 
similarly to dTC, only one conferred any protection against gentamicin damage. Alongside 
channel interaction, other factors underlying a compound’s ability to block AG entry through 
the MET channel include: the compound’s affinity for the channel, dictating the force of its 
binding within the channel pore; the permeation properties of the compound, determining 
how easily the compound is drawn into the HC and the duration of time it spends bound inside 
the vestibule; and lastly the structure, determining whether the compound is bulky enough to 
prevent AG entry or compact enough to allow AGs to pass through.  
What can be concluded from the dTC-related compounds is that in this case, two fixed positive 
charges are necessary for otoprotection. The compound that protected (16297) and one 
compound that did not (16298) were structurally identical, aside from 16297 having a fixed 
and 16298 having a pH-dependent positive charge. For this set of compounds, the two fixed 
positive charges may be vital to the compound’s protective ability – potentially due to the 
electrically expelling force this would have on any AGs encountering the MET channel.  
Another issue for consideration, as a result of the channel-blocking nature of dTC’s mechanism 
of protection, is in regards to the lack of effect on stereociliary morphology. After 48 hours 
incubation with dTC, known to block HC MET channels, the morphology of the stereociliary 
hair bundle appeared unperturbed; at least through the low-resolution microscopy that we 
used for our screening procedures. A study investigating the effect of the MET current on the 
dynamic control of stereocilial morphology (Vélez-Ortega et al., 2017) highlighted that MET 
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channel blockers can alter the shape and height of the sterociliary rows, shortening the second 
and third rows specifically, and that this effect can be reversed following washout of the MET 
blocker. This suggests that any prolonged block of the MET channel will lead to bundle 
disfiguration, and that there may be a morphological difference in the cultures treated with 
MET blockers that we are not detecting in our low-resolution microscopy. 
Lastly, the evidence collected in regards to the HC loading of dTC-TR poses several questions. 
The evident granular nature of the fluorescence within the HCs would suggest an endocytosis-
driven, vesicle-bound intracellular accumulation of the dye. If the Texas Red was simply 
funnelling through the MET channel when conjugated to dTC then we would expect an 
equally-dispersed fluorescence signal within the cell. However, if this were the case and the 
compound was being brought into the cell via endocytic mechanisms then we would also 
expect to see the same pattern of granular fluorescence in the HCs exposed to Texas Red 
alone, which is not what we observed. An alternative explanation of the granular labelling is 
that once inside the cell, the fluorescently-tagged dTC is being internalised by other 
intracellular structures such as lysosomes or mitochondria, leading to the punctate 
fluorescence signal that we observed. In order to test this we could incubate for a reduced 
time frame in order to see if the fluorescence is intracellularly dispersed before aggregating 
into punctate clusters. Another way in which we could test this hypothesis is by using myosin 
VIIa mouse mutants (Myo7aSh6J mice) - mice with a mutation in a protein that is crucial to MET 
channel function (Richardson et al., 1997; Kros et al., 2002) and renders all MET channels 
closed at rest. Consequently, if we tested dTC-TR loading in these mutants and did not observe 
the same punctate fluorescence within the cell, this would provide compelling evidence that 
dTC does enter HCs through the MET channel. 
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6   Assessing the Otoprotective Potential of Carvedilol, an 
FDA-Approved Drug used to treat Hypertension 
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6.1 Introduction 
6.1.1 Compound Choice 
 
Carvedilol is an FDA-approved beta-2 adrenergic blocker, used clinically for the treatment of 
hypertension, angina and symptomatic chronic heart failure (Al-Ghamdi, 2011; Akbar and 
Alorainy, 2014). Carvedilol had previously been reported to protect against neomycin damage 
in zebrafish, when tested at 10-100 μM against 200 µM neomycin (Ou et al., 2009). This study 
also reported its block of GTTR loading into zebrafish neuromast HCs. However, its protective 
abilities in mammalian systems had not yet been documented. For this reason, I sought to 
characterise the protective efficacy of carvedilol in mouse cochlear cultures, whilst also 
establishing the mechanism by which it protects through use of electrophysiology and 
fluorescence imaging studies. 
6.1.2 Aims 
 
In this chapter I aimed to assess whether carvedilol also protected zebrafish lateral line HCs 
against gentamicin damage and whether it behaved as an otoprotectant when tested in mouse 
cochlear cultures. This would provide further evidence of the similarity between zebrafish and 
mammalian models and further highlight the transferable efficacy from zebrafish pre-
screening into mammalian systems. 
As carvedilol is already FDA-approved, the transition from scientific screening to use in a 
clinical setting would be greatly reduced, depending on the method of administration. If the 
administrative procedure when the drug is used to treat hypertension (usually oral 
administration (Stafylas and Sarafidis, 2008)) was suitable for its additional use as an 
otoprotectant, it is possible that no additional testing would be necessary. Carvedilol has been 
shown to cross the blood brain barrier, so this is a possibility (Elsinga et al., 2004). 
I also aimed to assess carvedilol’s mechanism of protection - investigating whether it had a 
MET channel-blocking mechanism of protection or otherwise. Lastly, derivatives of carvedilol 
were designed and synthesised in order to further assess structure-activity relationships and 
potentially synthesise a more effective otoprotectant than the parent compound. Testing 
these derivatives electrophysiologically would provide additional information concerning 
which aspects of a compound’s chemical composition are vital to enabling MET channel 
interaction. 
122 
 
6.2 Results 
6.2.1 Screening for Otoprotection 
 
6.2.1.1 Zebrafish Pre-Screening 
 
*The zebrafish research presented in this section was collected by Emma Kenyon, University of 
Sussex. I performed the statistical analysis of the data. 
 
In order to assess the protective capability of carvedilol against AG damage, an initial 
protection assay was performed using the sensory HCs of the lateral line organs of zebrafish 
larvae at 4 dpf, a time point that ensures the reliable loading of Yo-Pro 1 (Santos et al., 2006; 
Kindt et al., 2012).  
Carvedilol was found to provide complete protection against the damage induced by 6.25 μM 
neomycin over the course of 1 hour when tested at concentrations ≥ 6.25 μM (Figures 6.1A-G 
and graph O). Complete protection against the damage induced by 10 μM gentamicin over the 
course of 6 hours was only observed at concentrations ≥ 25 μM, with partial protection at 12.5 
μM (Figures 6.1H-N, graph P). Complete protection is defined here as the HC counts from the 
carvedilol-treated conditions being significantly higher than the AG-alone treatments and also 
not significantly different from the control. Partial protection is defined here as being 
significantly different to both the control and the AG-treated conditions. 
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Figure 6.1: Carvedilol protects zebrafish lateral line HCs against 6.25 μM neomycin and 10 μM 
gentamicin when tested at a concentration of 6.25 and 25 μM respectively. 
 
Zebrafish were treated with: (A, H) E3 alone (B) 6.25 μM neomycin, or (C-G) 50 μM, 25 μM, 
12.5 μM, 6.25 μM, or 3.1 μM of carvedilol plus 6.25 μM neomycin for 1 hour, (I) 10 μM 
gentamicin, (J-N) 50 μM, 25 μM, 12.5 μM, 6.25 μM, or 3.1 μM of carvedilol plus 10 μM 
gentamicin for 6 hours. Neuromasts were pre-stained with 3 μM Yo-Pro1. n=3 independent 
experiments with at least 3 fish per well. Images were obtained with a 40x objective. Scale bar 
is 25 μm. (O-P) Quantification of neuromast HC survival when exposed to (O) neomycin or (P) 
gentamicin together with selected concentrations of carvedilol. Numbers above bars are the 
number of experimental replicates. 
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6.2.1.2 Cochlear Culture Screening 
 
Following zebrafish trials, mouse cochlear cultures were used to assess whether carvedilol 
could protect against the HC death caused by exposure to 5 µM gentamicin over a 48 hour 
time course. As detailed in Chapter 3, incubation with 5 µM gentamicin alone caused a loss of 
88% of OHCs from the mid-basal region of mouse cochlear cultures (Figures 3.1, 6.2A and B). 
When co-incubated together with gentamicin, 5 μM carvedilol provided partial protection, 
with OHC survival being significantly different from both the control and gentamicin-treated 
cultures (p < 0.001 in both cases) (Figure 6.2C). The average number of HCs in a 300 μm-long 
segment of the mid-basal region of the control was 109.8 (± 2.2) (26), in the gentamicin-
treated condition it was 15.3 (± 2.2) (n=26) and in the 5 μM carvedilol condition it was 69.7 (± 
12.9) (n=7). This highlights the partial protectiveness at this concentration, suggesting that this 
is the lower limit of carvedilol’s protective efficacy. Consistently complete protection against 
the gentamicin-induced loss of OHCs was observed with both 10 μM and 20 μM carvedilol (p ˂ 
0.001) (Figures 6.2D and E). Higher concentrations of carvedilol, from 30 to 50 μM, proved to 
be generally cytotoxic to cochlear cultures, causing widespread, non-specific cell death (Figure 
6.2F and G). 
When carvedilol was tested alone no OHC death was observed at either 10 μM or 20 μM, 
similar to control conditions (Figure 6.3C and D). However when tested both alone at 20 μM 
and alongside 5 μM gentamicin, some degree of IHC damage and disruption to hair bundle 
morphology in both IHCs and OHCs can be observed (Figure 6.2E, Figure 6.3D-F). Figure 6.3E 
and F shows confocal images of IHC stereocilia bundles in both control conditions (Figure 6.3E) 
and during exposure to 20 μM carvedilol (Figure 6.3F), revealing the damage caused to the hair 
bundle morphology by carvedilol exposure. When used in a clinical setting carvedilol is known 
to cause hearing loss in a small percentage of treated patients (eHealthMe, 2017). The 
sporadic toxicity to IHCs could potentially underlie this finding, with the incidence explained by 
the individual differences in carvedilol’s accumulation within the endolymphatic compartment 
of the inner ear. At concentrations ≥ 30 µM, carvedilol is generally cytotoxic to all cell types in 
the cochlear culture, both alone and in the presence of 5 µM gentamicin (Figure 6.2F and G, 
Figure 6.3G and H). 
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Figure 6.2: When exposed to 5 µM gentamicin for 48 hours, co-incubation with 10 or 20 µM 
carvedilol completely protects against OHC loss. 5 μM provides partial protection. ≥ 30 µM 
carvedilol is generally cytotoxic.  
(A) A control culture exposed to 0.5% DMSO for 48 hours. (B) A culture exposed to 5 μM 
gentamicin and 0.5% DMSO for 48 hours. (C-F) A culture exposed to 5 μM gentamicin for 48 
hours plus (C) 5 µM, (D) 10 µM, (E) 20 µM or (F) 30 µM carvedilol. The asterisk in (E) shows an 
example of IHC disruption. Scale bar is 50 µm. (G) Quantification of HC survival in a 300 µm-
long segment of the mid-basal region of cochlear cultures treated with 5 µM gentamicin alone, 
5 µM gentamicin together with carvedilol (5 – 50 µM) or carvedilol alone (10 – 50 µM). 
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Figure 6.3: When tested in the absence of gentamicin carvedilol is selectively toxic to 
mechanosensory hair bundles at 20 µM and generally cytotoxic at ≥ 30 µM.  
(A) A control culture exposed to 0.5% DMSO for 48 hours. (B) A culture exposed to 5 μM 
gentamicin and 0.5% DMSO for 48 hours. (C-D) Cultures exposed to (C) 10 or (D) 20 µM 
carvedilol in the absence of gentamicin for 48 hours. (E-F) Magnification of a region of IHCs in 
(E) a control culture or (F) a culture treated with 20 µM carvedilol. (G-H) Cultures exposed to 
(G) 30 or (H) 40 µM carvedilol 48 hours. Scale bar in (F) is 5 μm, scale bar in (H) is 50 μm. 
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6.2.2 Mechanism of Protection 
 
6.2.2.1 The Effect of Carvedilol on MET Channel Currents 
 
* The electrophysiology presented in Figures 6.5, 6.7 and 6.9 was performed by Nerissa 
Kirkwood, University of Sussex.  
 
In order to assess whether carvedilol provides otoprotection by blocking MET channels and 
preventing AG entry into HCs, we investigated its effect on OHC MET currents in P2 mouse 
cochlear cultures. Whole-cell voltage clamp procedures were used to step the cell membrane 
between potentials ranging from -164 to +96 mV, whilst MET currents were elicited by a sine-
wave stimulus and recorded before, during and after the extracellular superfusion of 1, 3 and 
10 μM carvedilol.  Shown in Figure 6.4 (A-C) is an example of MET channel block by 3 μM 
carvedilol. Carvedilol reduces MET current sizes at all membrane potentials tested. Current-
voltage (Figure 6.4D) and fractional block curves (Figure 6.4E) revealed that the reduction in 
current size is voltage-dependent, with maximal block at the intermediate and depolarised 
potentials (maximum block is seen at +16 mV). Following re-superfusion of control solution I 
observed full recovery of the MET channel current (Figure 6.4C), suggesting that the block of 
the channels is completely reversible.  
Averaged current-voltage curves from multiple cells (Figure 6.5A) highlight the concentration-
dependency of the block, with increasing carvedilol concentrations leading to stronger block of 
the channel at all membrane potentials tested. Fractional block curves showing the current 
recorded during carvedilol superfusion relative to that during control solution (Figure 6.5B) 
reveal that there is a modest release of the channel block at the extreme depolarised 
potentials and a large release of block at the extreme hyperpolarised potentials. This is a 
characteristic of a permeant MET channel blocker, with the release of block evident at 
hyperpolarised potentials being due to the compound entering into the cell driven by the 
electrical potential present across the MET channel. 
 
 
 
 
128 
 
 
Figure 6.4: Extracellular exposure to 3 µM carvedilol reduces OHC MET currents at all 
potentials, with the reduction most pronounced at intermediate and depolarized potentials. 
(A-C) MET currents recorded from a P2 basal OHC between -164 and +96 mV in response to a 
sine-wave stimulus delivered by a fluid jet (45 Hz sinusoid, ± 40V driver voltage, DV shown 
above each trace), before, during and after exposure to 3 µM carvedilol. Carvedilol reduces the 
current size at all potentials. Full recovery is seen following re-exposure to the control solution. 
(D) Current-voltage curves of the currents shown in (A-C) reveal the current block at all 
potentials during carvedilol exposure and the reversibility of the block following washout. (E) 
Fractional block of the MET currents at all membrane potentials reveals that block is strongest 
at the intermediate and depolarised potentials and is released at the extremes. 
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Figure 6.5: Carvedilol acts as a voltage-dependent, permeant blocker of the MET channel with 
maximum block observed at +16 mV. 
(A) Average normalized current-voltage curves for the peak MET currents recorded before and 
during exposure to 1, 3 and 10 µM carvedilol. Currents for each cell were normalized to the 
peak control current measured at +96 mV. The block is strongest at the intermediate and 
depolarized potentials and the level of block increases with increasing carvedilol 
concentration. Number of cells; Control: 17, 1 µM: 4, 3 µM: 6, 10 µM: 7. (B) Fractional block 
curves of the current during carvedilol exposure (1-10 µM) relative to the control current at 
each membrane potential demonstrate a release of the block at the extreme hyperpolarized 
potentials, indicative of a permeant blocker. Data collected by Nerissa Kirkwood. 
 
 
 
Electrophysiological evidence of MET channel block suggested this to be the mechanism of 
protection of carvedilol, by way of preventing AG entry into HCs. GTTR studies were conducted 
to further investigate this postulation; however, this will be detailed in a later section of this 
chapter (6.2.4). 
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6.2.3 Compound Modification  
6.2.3.1 Carvedilol Derivatives: Protective Abilities and MET Channel Block 
 
Our results demonstrated that carvedilol is a voltage-dependent blocker of the MET channel 
and consistently protects OHCs from AG damage at 10 and 20 µM; however, it is toxic at 
higher concentrations and is itself a permeant blocker, entering the HCs via their MET channels 
once the cell is stepped to a sufficiently negative potential. In an attempt to identify a 
compound with reduced toxicity and improved blocking and protective properties, 7 carvedilol 
derivatives were initially synthesised (14953, 14958, 14970, 14971, 14972, 15173 and 15174). 
Each derivative was screened at 20 µM to assess its protective ability against 5 µM gentamicin 
with each screen repeated ≥ 3 times. At this concentration 1 of the derivatives was generally 
cytotoxic (14971), 3 provided no protection (14953, 14958 and 15173), 1 showed partial 
protection (14970) and 2 of the 7 derivatives consistently protected against OHC loss (14972 
and 15174) (Figure 6.6 A-J). Both 14972 and 15174 caused disruption of the mechanosensory 
hair bundle morphology when tested at this concentration together with gentamicin.  
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Figure 6.6: When exposed to 5 µM gentamicin for 48 hours, co-incubation with certain 
carvedilol derivatives can prevent the mid-basal OHC loss. At 20 µM, 2 out of the 7 derivatives 
protected and 1 derivative showed partial protection. 
(A) A control culture exposed to 0.5% DMSO for 48 hours. (B) A culture exposed to 5 μM 
gentamicin and 0.5% DMSO for 48 hours. (C-I) Cultures exposed to 5 μM gentamicin for 48 
hours plus 20 µM: (C) 14953, (D) 14958, (E) 14970, (F) 14971, (G) 14972, (H) 15173, (I) 15174. 
132 
 
Scale bar is 50 µm. (J) Quantification of HC survival revealed that 2 derivatives protected at 20 
µM against 5 µM gentamicin (14972 and 15174) and 1 derivative offered partial protection 
(14970), with the HC survival significantly different from both the control and gentamicin 
exposed cultures (p < 0.001 in both cases). 
 
The three derivatives that showed partial or full protection at 20 µM were subsequently tested 
against 5 µM gentamicin at 10 and 5 µM. At these concentrations, only 14972 remained 
protective, providing full protection at 5 µM in 6 out of 7 screens. Carvedilol itself showed full 
protection at 5 µM in 4 out of 8 screens, suggesting that 14972 had slightly improved 
protective properties (Figure 6.7). The average HC number in the control conditions was 109.8 
(± 2.2) (n=24) and in the gentamicin-treated conditions it was 15.3 (± 2.2) (n=26). When 
gentamicin was co-incubated with 5 µM carvedilol the HC count was 66.1 (± 12.4) (n=7), and 
when co-incubated with 14972 it was 98.9 (± 8.2) (n=7). A one-way ANOVA followed by 
Tukey’s multiple comparisons test revealed that the difference in HC survival between the 
carvedilol and 14972-treated cultures was significant (p = 0.0016) (Figure 6.7). 
When tested alone 14972 showed similar toxicity characteristics to carvedilol, proving toxic to 
OHCs at concentrations ≥ 30 µM and affecting the IHC and OHC bundle morphology at 20 µM. 
Unlike carvedilol, however, 14972 was not toxic at 30 µM when tested together with 5 µM 
gentamicin. At this concentration 14972 provided protection but did affect IHC and OHC 
bundle morphology (data not shown).  
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Figure 6.7: When exposed to 5 µM gentamicin for 48 hours, co-incubation with 5 µM 14972 
was more effective at preventing OHC loss than co-incubation with 5 µM carvedilol. 
(A) A control culture exposed to 0.5% DMSO for 48 hours. (B) A culture exposed to 5 μM 
gentamicin and 0.5% DMSO for 48 hours. (C-D) Cultures exposed to 5 μM gentamicin for 48 
hours plus 5 µM: (C) carvedilol or (D) 14972. Scale bar is 50 µm. (J) Quantification of HC 
survival reveals that 14972 is completely protective when tested at  5 μM however carvedilol is 
only partially protective, with HC survival significantly different from both the control and 
gentamicin exposed cultures (p < 0.001 in both cases). 
 
 
 
134 
 
In conjunction with assessing the protective abilities of the 7 carvedilol derivatives, potential 
interactions with the MET channel were investigated by recording MET currents from OHCs 
before and during exposure to 10 µM of each compound. Fractional block curves of the 
currents during compound exposure relative to the control currents at each membrane 
potential show that 2 of the derivatives have limited interaction with the channel at this 
concentration (14958 and 15173; Figure 6.8). These derivatives were among the three that 
showed no protection at 20 µM, providing further evidence that the protection offered by 
carvedilol is a result of MET channel block. The third derivative showing no protection at 20 
µM (14953) did reduce the MET currents across all membrane potentials; however, the level of 
block was greatly reduced compared to carvedilol suggesting that this derivative has a far 
lower affinity for the channel (Figure 6.8). Similar levels of block to 14953 were observed with 
14970 (Figure 6.8), with no release of the block at extreme hyperpolarized potentials 
suggesting this compound is non-permeant. However, this derivative only offered partial 
protection against 5 µM gentamicin, possibly due to its lower affinity for the channel. Three of 
the derivatives were strong MET channel blockers at 10 µM (14971, 14972 and 15174; Figure 
6.8). Compound 14971 was generally cytotoxic at 20 µM, however 14972 and 15174 offered 
consistent protection, with 14972 protecting OHCs from gentamicin damage at concentrations 
down to 5 µM. This result again suggests that the protection observed is brought about by a 
block of the MET channels, reducing the entry and accumulation of gentamicin into the cells. 
Both 15174 and 14972 appeared to be permeant blockers of the MET channel, indicated by 
the release of the block at the extreme hyperpolarized potentials (Figure 6.8).  
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Figure 6.8: Fractional block curves revealed varying degrees of interaction between the 7 
carvedilol derivatives and the MET channel. 
Fractional block curves of the currents recorded during 10 µM derivative exposure relative to 
the control currents at each membrane potential (between -164 and +96 mV). Two of the 
derivatives showed limited interaction with the channel (14958 and 15173), two showed a 
partial block of the currents (14953 and 14970) and three acted as strong MET channel 
blockers (14971, 14972 and 15174). Number of cells; 14970: 3, 14971: 5, 14972: 2, 14953: 8, 
14958: 5, 15173: 2, 15174: 4. Data collected by Nerissa Kirkwood. 
 
Combining the desired characteristics of a non-permeant MET channel blocker (14970) and a 
higher-affinity blocker (14972) a further derivative was synthesised (31036) and the protective 
and channel-blocking abilities determined. Compound 31036 showed limited interaction with 
the MET channel at both 3 and 10 µM (data not shown). It protected against 5 µM gentamicin 
in only one out of three trials when tested at 20 µM (Figure 6.9A-C) and provided no 
protection at 10 µM (3 repeats; data not shown). However solubility problems were identified 
with this derivative hindering any meaningful interpretation of the results.  
A further 6 derivatives were synthesised in an attempt to improve the protective abilities and 
eliminate the solubility problems of previous compounds (31833, 32528, 32536, 32546, 32639 
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and 32663). Of these derivatives, 2 were generally cytotoxic when tested at 20 µM against 5 
µM gentamicin (32639 and 32633) for 48 hours, 2 offered no protection (32528 and 32546) 1 
showed partial protection (31833) and 1 was consistently protective (32536) (Figure 6.9D-J). 
When tested at 10 µM, 31833 no longer offered any protection and 32536 was protective in 2 
out of 4 screens but offered no protection at 5 µM (data not shown).  
 
137 
 
 
Figure 6.9: When exposed to 5 µM gentamicin for 48 hours, co-incubation with certain 
carvedilol derivatives can prevent mid-basal OHC loss. At 20 µM, 1 out of the 7 derivatives 
protected and 2 showed partial protection. At 10 μM, none maintained their protective ability 
(data not shown). 
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(A) A control culture exposed to 0.5% DMSO for 48 hours. (B) A culture exposed to 5 μM 
gentamicin and 0.5% DMSO for 48 hours. (C-I) Cultures exposed to 5 μM gentamicin for 48 
hours + 20 µM: (C) 31036, (D) 31833, (E) 32528, (F) 32536, (G) 32546, (H) 32639 or (I) 32663. 
Scale bar is 50 µm.  (J) Quantification of HC survival reveals one derivative protects at 20 µM 
against 5 µM gentamicin (32536) and two derivatives offer partial protection (31036 and 
31833) with the HC survival significantly different from both the control (p ˂ 0.001 and p = 
0.0087, respectively) and gentamicin exposed cultures (p < 0.001). 
 
MET channel interactions were investigated for the two derivatives that showed protection or 
partial protection at 20 µM (31833 and 32536). Fractional block curves revealed that both 
compounds, at a concentration of 10 µM, blocked the MET channel at all membrane 
potentials, however the degree of block was far less than for both carvedilol and 14972 (Figure 
6.10) suggesting these derivatives had a reduced affinity for the channel. 
 
Figure 6.10: Fractional block curves revealed that the carvedilol derivatives 31833 and 32536 
had a far lower affinity for the MET channel than carvedilol itself. 
Fractional block curves of the currents recorded during 10 µM derivative exposure relative to 
the control currents at each membrane potential (between -164 and +96 mV). Both 31833 and 
32536 show a limited interaction with the MET channel across all membrane potentials. 
Number of cells; 31833: 5, 32536: 5. Data collected by Nerissa Kirkwood. 
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6.2.4 Mechanism of Protection (continued) 
To further assess whether carvedilol and the most protective derivative 14972 protected 
sensory HCs against AG damage by blocking the MET channel and thereby preventing the entry 
of the antibiotics into the cells, a fluorescent gentamicin analogue (GTTR) was used to quantify 
gentamicin uptake (Steyger et al., 2003). Pre-incubation with either 1% DMSO, 100 µM 
carvedilol or 100 µM 14972 for 5 minutes prior to 0.2 µM GTTR application resulted in 
significantly reduced loading of GTTR in the presence of both carvedilol and 14972 relative to 
the DMSO control (p < 0.001 in both cases) (Figure 6.11). No significant difference was 
observed between the GTTR loading in the presence of carvedilol or 14972. These findings 
further suggested that both carvedilol and 14972 protected against AG damage by 
competitively blocking the MET channel and thereby preventing AG entry into HCs, minimising 
accumulation and consequent apoptosis induction. 
 
 
Figure 6.11: Carvedilol and 14972 significantly block the entry of GTTR into mouse cochlear 
culture HCs. 
(A) Quantification of GTTR fluorescence intensity in a control culture pre-treated with 1% 
DMSO before the addition of 0.2 μM GTTR, compared to cultures pre-treated with 100 μM 
carvedilol or 14972. Both compounds significantly reduced GTTR loading (p < 0.001). No 
significant difference in reduction was seen between the two compounds. (B-D) A 
representative fluorescence image from which intensity values were measured and a DIC 
image for: (B and B’) the control (C and C’) carvedilol and (D and D’) 14972. Asterisks indicate 
the first row of OHCs, from which fluorescence intensity values were taken. Scale bar is 50 μm. 
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6.3 Summary 
The screening process detailed in this chapter has enabled a full characterisation of carvedilol’s 
otoprotective profile, both in terms of its protective ability and also its mechanism of 
protection. Here we confirm that it is protective against neomycin damage to the HCs of the 
zebrafish lateral line (Ou et al., 2009) and we extended this knowledge to show that it also 
protects neuromast HCs against 10 μM gentamicin damage when tested at ≥ 25 μM. We also 
provided evidence of its protection against 5 μM gentamicin damage in mouse cochlear 
cultures when tested at 10 and 20 μM. Extensive screening and confocal imaging revealed that 
at 20 μM, carvedilol caused selective damage to the IHC mechanosensory hair bundles in 
cochlear cultures, both when tested alone and in the presence of gentamicin. Furthermore, 
when tested at ≥ 30 μM both in the absence and presence of gentamicin, carvedilol is 
generally cytotoxic to all cell types in cochlear cultures.  
Electrophysiological recordings revealed that carvedilol is a relatively high-affinity blocker of 
the MET channel (KD = 1.5 μM at +96 mV; data not shown), displaying a voltage-dependent, 
permeant block of the channel similarly to the compounds previously identified in Chapters 4 
and 5. Block of the channel was strongest at intermediate and depolarised potentials, was 
released at both extremes of depolarisation and hyperpolarisation, and was completely 
reversible. 
We synthesised 7 carvedilol derivatives, 2 of which provided complete protection against 
gentamicin damage in cochlear cultures when tested at 20 μM. Both of these were found to be 
strong MET channel blockers. We then synthesised 6 more derivatives, only one of which was 
protective. Although it did block the MET channel, it was with a much lower affinity than 
carvedilol. Of all of the synthesised derivatives only one (14972) showed improved protection 
characteristics relative to carvedilol, more frequently providing protection when tested at a 
concentration of 5 μM. 
As a final confirmation of the relation between MET block and protective ability, GTTR 
experiments were conducted to assess if carvedilol and 14972 blocked GTTR uptake into HCs. 
Both significantly reduced its loading, adding further confirmation to the identified mechanism 
of protection. 
 
 
 
141 
 
6.4 Discussion  
Within this chapter, evidence is provided of the otoprotective profile of carvedilol, for both 
zebrafish lateral line and mouse cochlear culture HCs. We have clearly demonstrated the 
mechanism of protection of the compound, linking carvedilol’s protective nature to its ability 
to block the MET channel and thereby reduce AG entry and consequent accumulation within 
sensory HCs. This screening process has further highlighted the usefulness and applicability of 
zebrafish pre-screening in the search for mammalian otoprotectants. If blindly screened in our 
zebrafish assay, carvedilol would have been taken forward to mouse cochlear cultures for 
additional testing – thus reinforcing the viability of our two-model screening procedure. 
The results of the cochlear culture screening process detailed in this chapter have again 
reinforced the proposition that we need to adhere to a thorough screening procedure in 
mammalian systems when searching for potential clinically-viable otoprotectants. Despite 
being protective at 10 and 20 μM, carvedilol caused severe IHC bundle disruption at 20 μM 
and was generally cytotoxic when tested ≥ 30 μM, both in the presence and absence of 
gentamicin. Similarly to the extremely narrow protective range that was found for the alkaloid 
berbamine (Chapter 5), these toxicity characteristics had not been picked up on when 
previously screened in zebrafish alone (Ou et al., 2009). However, it is possible that 
compounds that would not be toxic in vivo may appear toxic in vitro due to the experimental 
assay conditions. Consequently, this criterion should not be used to eliminate compounds as 
this could result in the rejection of possibly useful drugs. Mammalian in vivo screening is 
necessary to address this concern. 
The screening of carvedilol derivatives offered further confirmation that the otoprotective 
nature of the compound is attributable to its block of the MET channel, as the three 
compounds that did protect all displayed a voltage-dependent block of the channel, similarly 
to the parent compound. Interestingly, the one compound that did strongly block the MET 
channel but did not protect (14971; shown to be toxic at 20 μM (Figure 6.8)), was also the 
most permeant of all of the compounds tested, displaying a large release of the block once the 
cell was stepped to -84 mV or below, indicative of the compound being drawn into the cell. 
This result suggests that the permeation and accumulation of the compound may underlie its 
evident toxicity, similarly to the AGs themselves. Although toxic to the basal section, 14971 
caused no toxicity to the HCs in the apical region (data not shown); adding further 
confirmation to this postulation. This idea of permeation underlying toxicity could also 
underlie the disparity in the dTC and berbamine toxicity profiles, with berbamine found to be 
toxic at higher concentrations whereas dTC was not. As berbamine is a more permeant blocker 
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of the MET channel, it would enter the HCs more readily.  This greater permeation would lead 
to greater intracellular accumulation and consequently a greater likelihood of initiating 
intracellular apoptotic pathways. 
The improved protective ability of one compound (14972) relative to carvedilol itself suggests 
that we are capable of modifying compounds based on their mechanism of protection in order 
to improve their protective efficacy. Although a labour-intensive procedure, here we have 
shown that modifying compounds based on structure-activity relationships is a viable method 
for the generation of otoprotectants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
 
7   Assessing the Otoprotective Potential and MET Channel 
Interaction Abilities of FM 1-43 and its Derivatives 
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7.1 Introduction 
 
7.1.1 Compound Choice 
 
The styryl dye FM 1-43 is a water-soluble, cationic dye that has classically been a useful tool for 
the study of endo- and exo- cytosis (Betz et al., 1996; Amaral et al., 2011). It has been shown 
to behave as a permeant blocker of the MET channels in cochlear sensory HCs (Gale et al., 
2001) and also in neurons (Drew and Wood, 2007). The dye rapidly loads into HCs via the 
apical surface, exhibits a voltage-dependent block of the MET channel and its loading is 
reduced by increasing the extracellular calcium concentration (leading to greater adaptation in 
the HC tip links). These data suggest that FM 1-43 primarily enters HCs in the same way as the 
AGs – through the MET channel. This postulation is further supported by the evidence that FM 
1-43 co-administration alongside AG exposure reduced the ototoxic effects of the antibiotics 
(Gale et al., 2001), implying a common, competitive mode of entry into cells. The dye therefore 
provides a useful marker of MET channel function in the sensory HCs of the cochlea. 
 
7.1.2 Aims 
 
Due to its obvious interaction with the MET channel we chose to investigate this compound 
further, chemically synthesising 15 derivatives in order to assess the structure-activity 
relationships and gain a better understanding of which moieties of the compound are integral 
to its interaction with the MET channel and also its otoprotective abilities. This work is done on 
the premise that understanding what is required to block the MET channel will help with the 
future design of otoprotective compounds capable of blocking the channel and preventing AG 
entry and the associated ototoxicity.  All derivatives were tested for their ability to protect 
against gentamicin damage in mouse cochlear cultures. They were also tested for their ability 
to load into the neuromast HCs of the zebrafish lateral line in a short time assay. Their block of 
the MET channel was subsequently investigated electrophysiologically as the focus of this 
study. The overarching aim was to better understand the components of the FM 1-43 molecule 
that enable it to behave as a permeant blocker of the MET channel, whilst also attempting to 
synthesise a non-permeant MET channel blocker. 
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7.2 Results 
7.2.1 The Structural Modifications made to FM 1-43 in the Synthesising of 
Derivatives 
 
Figure 7.1: The structure of FM 1-43 and the 15 derivative modifications synthesised in house. 
FM 1-43 has three distinct moieties: a lipophilic tail (red), a central core (green) and a 
hydrophilic head (orange and blue). Modifications were made to each moiety, as depicted. 
 
 
The FM 1-43 molecule has a chemical structure consisting of three distinct moieties, as 
depicted in Figure 7.1. These are: a lipophilic tail (red circle), exemplified by two linear alkyl 
chains; a central core consisting of a pyridine ring conjugated via a double bond linker to a 
phenyl ring (green circle); and a hydrophilic head usually consisting of a quaternary nitrogen 
(orange circle) linked to the piridinium nitrogen via an alkyl chain (blue circle).  
Chemical modifications were made to each of these three separate moieties to produce 15 FM 
1-43 derivatives (13248, 13547, 13551, 13666, 13667, 13668, 13669, 13670, 13695, 13696, 
13698, 14885, 14957, 16327 and 28552), with their structures as depicted in Figure 7.1.  
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7.2.2 Screening for Otoprotection in Mouse Cochlear Cultures 
 
7.2.2.1 Protection at 5 μM 
 
For the purposes of the experiments detailed in this chapter, FM 1-43 is denoted on graphical 
representations as 13550 – made in house by the chemist assigned to this project (Marco 
Derudas, University of Sussex). When tested at a concentration of 5 μM for their ability to 
protect against 48 hours exposure to 5 μM gentamicin, 9 of the FM 1-43 derivatives were 
found to be generally cytotoxic to the entire cochlear culture (13551, 13667, 13668, 13669, 
13696, 14885, 14957, 16327 and 28552), killing not only the sensory HCs but also the other 
supporting cell types in the cochlear explant, similar to what I observed with FM 1-43 (13550) 
itself (Figure 7.2). Previously, FM 1-43 had been reported to be only mildly toxic when tested 
on mouse cochlear cultures at 30 μM, causing blebbing, or membrane externalisation, of the 
apical surface of basal-coil HCs (Gale et al., 2001; Chung et al., 2007). However, this was when 
tested in a relatively short 70 minutes exposure assay, much shorter than our 48 hours 
incubation assay. Two of the derivatives were not protective (13248 and 13547), 3 provided 
full protection from the gentamicin-induced loss of OHCs (13666, 13670 and 13695) and 1 
(13698) provided partial protection in this initial trial. The 4 that provided at least some degree 
of protection were re-screened to confirm their protective abilities. Compounds 13666 and 
13695 failed on these subsequent trials however 13670 and 13698 were successful, providing 
complete protection across three independent trials (Figure 7.2). 
In terms of disruption to the morphology of the mechanosensory hair bundle, when tested at 5 
μM the 2 derivatives that were consistently protective (13670 and 13698) both caused some 
degree of bundle disruption in all 3 independent trials. However, this could be due to the 
gentamicin as opposed to the derivatives. Compounds should be tested alone in the absence 
of gentamicin to further investigate this. 
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Figure 7.2: When tested at 5 μM against 5 μM gentamicin for 48 hours, FM 1-43 and 9 of its 
derivatives were cytotoxic to mouse cochlear cultures, 4 were not protective and 2 were 
consistently protective. 
Cochlear cultures were treated with either (A) 0.5% DMSO, (B) 5 μM gentamicin and 0.5% 
DMSO, or (C–O) 5 μM gentamicin and 5 μM compound: (C) 13248 (n=1), (D) 13547(n=1), (E) 
13550 (n=1), (F) 13551 (n=1), (G) 13666 (n=3), (H) 13667 (n=1), (I) 13668 (n=1), (J) 13669 (n=1), 
(K) 13670 (n=3), (L) 13695 (n=3), (M) 13696 (n=1), (N) 13698 (n=4), (O) 14885 (n=1), (P) 14957 
(n=1), (Q) 16327 (n=1) or (R) 28552 (n=1) for 48 hours. Images in A and B are representative of 
17 experiments. Images in C–R are representative of 1-4 experiments each. Scale bar is 50 μm. 
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7.2.2.2 Protection at 0.5 μM 
 
When the compound concentration was reduced to 0.5 μM, still in the presence of 5 µM 
gentamicin, no toxicity was observed with any of the 15 derivatives or from the parent 
compound, 13550. In the initial trial, 10 were not protective (13248, 13547, 13550, 13666, 
13667, 13668, 13669, 13695, 13696 and 14885), 2 were partially protective (13698 and 14957) 
and 4 were found to be protective (13551, 13670, 16327 and 28552); however, 2 of these 
(13670 and 16327) then failed to provide protection on subsequent trials, and only 2 (13551 
and 28552) consistently provided complete protection across 3 independent trials (Figure 7.3). 
No compound was consistently protective when tested at 0.1 μM (only one, 16327, protected 
on 1 of 3 occasions (data not shown)). 
When tested at 0.5 μM, the 2 derivatives that were protective (13551 and 28552) both caused 
some degree of bundle disruption in all three independent trials. Again, however, this could be 
due to the gentamicin as opposed to the derivatives. Compounds should be tested alone in the 
absence of gentamicin to further investigate this. 
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Figure 7.3: When tested at 0.5 μM against 5 μM gentamicin for 48 hours, 2 FM 1-43 derivatives 
were consistently protective whilst the remaining 13 and FM 1-43 itself were not protective. 
Cochlear cultures were treated with either (A) 0.5% DMSO, (B) 5 μM gentamicin and 0.5% 
DMSO, or (C–O) 5 μM gentamicin and 0.5 μM compound: (C) 13248 (n=1), (D) 13547 (n=1), (E) 
13550 (n=1), (F) 13551 (n=3), (G) 13666 (n=1), (H) 13667 (n=1), (I) 13668 (n=1), (J) 13669 (n=1), 
(K) 13670 (n=3), (L) 13695 (n=1), (M) 13696 (n=1), (N) 13698 (n=1), (O) 14885 (n=2), (P) 14957 
(n=1), (Q) 16327 (n=3) or (R) 28552 (n=3) for 48 hours. Images in A and B are representative of 
17 experiments. Images in C–R are representative of 1-3 experiments. Scale bar is 50 μm. 
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7.2.3 Assessing MET Channel Interaction 
 
7.2.3.1 Zebrafish Loading Assay 
 
*The zebrafish research presented in this section was collected by Emma Kenyon, University of 
Sussex. 
 
All derivatives were initially screened for their ability to load into the HCs of zebrafish lateral 
line neuromasts. This gave an initial indication of whether the compounds still behaved as 
permeant MET channel blockers and entered into sensory HCs, similar to FM 1-43 itself. 
Compounds were tested at a range of concentrations: 300 nM, 1 μM, 3 μM or 10 μM and 
images were taken at a range of time intervals: 1, 2.5, 5 or 10 minutes.  
Only one compound (14885) did not load into neuromast HCs at any concentration, over any 
time period. Compound 13666 showed extremely weak loading into HCs, however some slight 
loading was detected after 10 minutes incubation at 10 μM, potentially as a result of endocytic 
processes as opposed to MET channel permeation (Figure 7.4). 
Of the remaining 13 derivatives, in comparison to the parent compound (13550), 4 showed a 
greatly reduced loading pattern (13547, 13667, 13669, and 13670), 2 showed a moderately 
reduced loading pattern (13698 and 16327), 4 showed a similar level of loading (13551, 13695, 
13696 and 28552) and 2 showed enhanced loading into neuromast HCs (13668 and 14957) 
(Figure 7.4). Compound 13248 was not tested for its loading ability as it does not bear any 
chromophore so cannot be seen in these assays. 
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Figure 7.4: Comparison of loading of FM 1-43 derivatives into zebrafish lateral line HCs. 
4 days post fertilisation zebrafish embryos were treated with FM 1-43 derivatives at a 
concentration of 300 nM, 1 μM, 3 μM or 10 μM for either 1 minute, 2.5 minutes, 5 minutes or 
10 minutes before washing and imaging. Derivative loading is compared to that of the parent 
compound, 13550. Neuromast 4 was imaged in every instance. Scale bar is 25 μm. 
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7.2.3.2 Electrophysiological Recordings of MET Channel Currents 
 
* The electrophysiology presented in Figure 7.6 was performed by Nerissa Kirkwood, 
University of Sussex. 
 
7.2.3.2.1 FM 1-43 (13550) 
 
FM 1-43 and all of its derivatives were tested for their ability to block the OHC MET channels of 
P2 mouse cochlear cultures. MET channel currents were recorded in whole-cell voltage clamp 
mode before, during and after the superfusion of each compound, tested at 10 μM. The cell 
was clamped at a holding potential of -84 mV and stepped to hyperpolarising voltages down to 
-164 mV and up to depolarising voltages of +96 mV, in 20 mV increments, in order to assess 
the voltage-dependency of any observed channel block.  
Shown in Figure 7.5A-C is an example of the MET current recordings from a third row OHC, 
before (black), during (red) and after (blue) the superfusion of 10 μM 13550. Also shown is the 
current-voltage curve derived from the traces in A-C (Figure 7.5D) and the fractional block 
curve generated from 3 different cells (Figure 7.5E). The transformed data highlights the 
voltage-dependency of the observed MET channel block. Block of the MET channel by 13550 is 
strongest at slightly depolarised potentials (+16 mV). The block of the channel is released at 
the extreme depolarised and hyperpolarised potentials, which is indicative of 13550 behaving 
as a permeant blocker of the MET channel, as has been reported elsewhere (Gale et al., 2001). 
This notion is further supported by the zebrafish loading assay presented herein (Figure 7.4), 
which showed the loading of 13550 into neuromast HCs after 1 minute at 3 of the 4 
concentrations tested. 
Interestingly, FM 1-43 had previously been reported to have otoprotective abilities against 
neomycin-induced HC damage in mouse cochlear cultures when tested in a short-time assay 
(Gale et al., 2001), and the mechanism of protection was assumed to be due to MET channel 
block. Here, however, I found that despite the observed channel block, in the 48 hours 
cochlear culture protection assay FM 1-43 provided no protection when tested at 0.5 μM 
(Figure 7.3E) and was generally cytotoxic when tested at 5 μM (Figure 7.2E). Gale et al. (2001) 
did report a blebbing effect on the apical membranes of cochlear HCs after 70 minutes of 
prolonged exposure to FM 1-43, so this result is perhaps not surprising.  
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Figure 7.5: Extracellular exposure to 10 μM FM 1-43 (13550) reduced OHC MET currents at all 
membrane potentials, with the reduction most pronounced at slightly depolarised potentials. 
(A-C) MET currents recorded from a P2 basal OHC between -164 and +96 mV in response to a 
sine-wave stimulus delivered by a fluid jet (45 Hz sinusoid, ±40V driver voltage, DV) shown 
above each trace, before (black), during (red) and after (blue) exposure to 10 µM 13550. 
Compound 13550 caused a reduction of the current size at all potentials. Full recovery is seen 
following re-exposure to the control solution. (D) Current-voltage curves of the currents shown 
in (A-C) reveal the current block at all potentials during 13550 exposure and the reversibility of 
the block following washout. (E) Fractional block curve reveals the voltage-dependency of the 
block, with maximal block observed at slightly depolarised potentials (n=3 OHCs). 
 
 
 
 
 
 
 
154 
 
7.2.3.2.2 Derivatives with Lipophilic Tail Modifications - 13695, 13696 and 14885 
 
Lipophilic tail alterations were made to the FM 1-43 molecule based on the assumption that 
we could potentially design a compound that did not permeate the MET channel following its 
block, due to the altered size of the lipophilic tail moiety. This is because, in theory, the 
positively charged head moiety of the molecule would interact with the MET channel as usual 
however the lipophilic tail moiety might be too big to permeate into the HC, thereby creating a 
non-permeant blocker of the channel.  
Three derivatives were designed with lipophilic tail modifications (13695, 13696 and 14885) 
and investigated for their interaction with the channel: compounds 13695 (a C-8 derivative), 
13696 (a C-4 Obenzyl derivative, with the introduction of oxygen assumed to increase 
solubility) and 14885 (ethyl acetate), which shares the same moiety as the calcium chelator 
BAPTA, known to abolish mechano-electrical transduction by way of tip-link degeneration 
(Assad et al., 1991; Goodyear and Richardson, 2003; Marcotti et al., 2014).  
When tested electrophysiologically, there was a mixture of MET channel interactions. 
Compound 13695 gave a moderate block of the channel, as shown by the exemplar MET 
current traces in Figure 7.6, showing the currents recorded before (black), during (red) and 
after (blue) 10 μM 13695 superfusion (Figure 7.6A-C). A current-voltage curve is shown in 
Figure 7.6D and the average fractional block curve from 3 cells is shown in Figure 7.6E, further 
highlighting the voltage-dependency of the observed channel block. Compound 13696 was not 
tested at 10 μM due to time limitations, however when tested at 3 μM it displayed a strong, 
voltage-dependent block of the MET channel, as shown by the fractional block curve presented 
in Figure 7.6F (n=2 OHCs). Compound 14885 displayed no interaction with the channel. Its 
average fractional block is presented later, in Figure 7.11B. Compound 14885’s lack of 
interaction is perhaps not surprising following the result of the zebrafish loading assay (Figure 
7.4), which showed that this compound did not load into neuromast HCs at any concentration 
over any time course tested. Both 13695 and 13696 loaded similarly into neuromast HCs when 
tested in the zebrafish assay, confirming that they still behave as permeant blockers of the 
channel (Figure 7.4). 
Interestingly, all 3 compounds were toxic when tested in cochlear cultures at 5 µM (Figure 7.2) 
and none of the compounds provided any protection against the gentamicin-induced loss of 
OHCs when tested at 0.5 µM (Figure 7.3), similarly to FM 1-43 itself. 
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Figure 7.6: Extracellular exposure to 10 μM 13695 and 3 μM 13696, two of the three FM 1-43 
derivatives with lipophilic tail modifications.  
(A-C) MET currents recorded from a P2 basal OHC between -164 and +96 mV in response to a 
sinewave stimulus delivered by a fluid jet (45 Hz sinusoid, ±40V driver voltage, DV) shown 
above each trace, before (black), during (red) and after (blue) exposure to 10 µM 13695. 
Compound 13695 caused a reduction of the current size at all membrane potentials. No 
recovery is seen following re-exposure to the control solution. (D) Current-voltage curves of 
the currents shown in (A-C) reveal the current block at all potentials during 13695 exposure 
and the irreversibility of the block following washout. (E) Fractional block curve reveals the 
voltage-dependency of the block, with maximal block observed at slightly depolarised 
potentials (n=3 OHCs). (F) Fractional block curve for 3 μM 13696 shows the strong, voltage-
dependent block of the MET channel (n=2 OHCs). Data obtained from Nerissa Kirkwood, figure 
prepared by myself. 
 
 
 
 
 
 
156 
 
7.2.3.2.3 Derivatives with Central Core Modifications – 13248 and 13547 
 
The 2 compounds synthesised with alterations to their central core were compounds 13248 
and 13547. The FM 1-43 parent molecule was cut into two halves, with the positive charges 
contained in one molecule (13248) and the lipophilic moiety in the other (13547). Due to the 
lack of positive charges in the lipophilic compound 13547, it was not expected to interact with 
the MET channel. Compound 13248 was expected to show an interaction due to the existence 
of two positive charges contained within the molecule. 
When tested electrophysiologically, neither compound blocked the MET current at any 
membrane potential (-164 to +96 mV) when tested at 10 µM, indicating no interaction with 
the channel. Shown in Figure 7.7A-C is an example of the MET currents obtained from a third 
row OHC before (black), during (red) and after (blue) the superfusion of 10 µM 13547. The 
current-voltage (Figure 7.7D) and fractional block curves (figure 7.7E) generated from the raw 
data further highlight the lack of interaction of the compound with the MET channel. The 
average fractional block curve for 13248 is presented later, in Figure 7.11B. 
When tested in zebrafish, 13547 did display some loading into neuromast HCs after 
approximately 5 minutes at the higher concentrations tested; however this could potentially 
be due to endocytic processes. Compound 13248 was not tested in the zebrafish loading assay 
due to it not bearing any chromophore. 
Interestingly, neither compound with central core modifications provided any protection 
against the gentamicin-induced OHC loss when screened in cochlear culture assays (Figures 7.2 
and 7.3), reinforcing the notion that the mechanism of otoprotection of FM 1-43 is due to its 
block of the MET channel. Furthermore, they also showed no toxicity at either concentration 
tested, implying that FM 1-43’s toxic properties are due to its block of the MET channel and 
subsequent permeation into HCs. These data reveal that the central core and lipophilic moiety 
of the FM 1-43 molecule are integral to MET channel block and consequent otoprotection. 
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Figure 7.7: Extracellular exposure to 10 μM compound 13547, one of the two FM 1-43 
derivatives with central core modifications. 
(A-C) MET currents recorded from a P2 basal OHC between -164 and +96 mV in response to a 
sinewave stimulus delivered by a fluid jet (45 Hz sinusoid, ±40V driver voltage, DV) shown 
above each trace, before (black), during (red) and after (blue) exposure to 10 µM 13547. 
Compound 13547 caused no reduction in MET current size at any membrane potential tested. 
(D) The current-voltage and (E) fractional block curves further highlight the lack of interaction 
of 13547 with the MET channel (n=3 OHCs). 
 
 
 
 
 
 
 
 
 
 
 
158 
 
7.2.3.2.4 Derivatives with Hydrophilic Head, Quaternary Nitrogen Modifications – 13551, 
13670 and 14957 
 
Three derivatives were designed with altered hydrophilic heads based on quaternary nitrogen 
modifications (13551, 13670 and 14957). With compounds 13551 and 14957, one of the two 
positive charges was substituted for a neutral moiety to test if two positive charges are 
required for MET channel interaction. Compound 13670 had a substitution of the terminal 
positive charge with a negative moiety (free acid).  
The 3 compounds were tested for their MET channel blocking abilities. All 3 blocked the MET 
channel to varying degrees. Compounds 13551 and 14957 showed strong block of the channel 
whereas 13670 showed a modest block. Shown in Figure 7.8A-C is an example of the currents 
obtained from a third row OHC before (black), during (red) and after (blue) the superfusion of 
10 µM 14957. The current-voltage (Figure 7.8D) and fractional block curves (Figure 7.8E) 
generated from the raw data highlight the voltage-dependency of the observed channel block. 
The strongest block of the MET channel by 10 µM 14957 was observed at slightly depolarised 
potentials (+16 mV). Release of the block occurred at the extreme hyperpolarised potentials 
and slightly at the extreme depolarised potentials, indicating that the compound still behaved 
as a permeant blocker of the MET channel. The average fractional block curves for 13551 and 
13670 are presented later, in Figure 7.11D and C respectively. 
The electrophysiological data correlates well with what was observed in the zebrafish loading 
assay – both 13551 and 14957 loaded strongly into neuromast HCs, whereas 13670 displayed a 
much weaker pattern of loading (Figure 7.4). 
Of the 3 compounds, 2 were protective in the cochlear culture assays. Compound 13551 
protected against the gentamicin-induced loss of OHCs when tested at 0.5 μM (Figure 7.3) and 
13670 when tested at 5 μM (Figure 7.2). The difference in protective concentration could be 
directly correlated with their MET channel blocking abilities – with 13551 acting as a strong 
MET channel blocker whereas 13670 displayed only modest block. The third compound, 
14957, was highly toxic to cochlear cultures so comparisons of MET channel block and 
otoprotection cannot be made (Figures 7.2 and 7.3). Convincingly, we can confirm that only 
one positive charge is needed for MET channel block by the FM 1-43 compound, and 
substitution of a positive for a negative charge unsurprisingly reduced the observed channel 
interaction. 
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Figure 7.8: Extracellular exposure to 10 μM compound 14957, one of the three FM 1-43 
derivatives with quaternary nitrogen modifications in the hydrophilic head. 
(A-C) MET currents recorded from a P2 basal OHC between -164 and +96 mV in response to a 
sinewave stimulus delivered by a fluid jet (45 Hz sinusoid, ±40V driver voltage, DV) shown 
above each trace, before (black), during (red) and after (blue) exposure to 10 µM 14957. 
Compound 14957 caused a large reduction of the current size at all membrane potentials. Full 
recovery is seen following re-exposure to the control solution. (D) Current-voltage curves of 
the currents shown in (A-C) reveal the current block at all potentials during 14957 exposure 
and the reversibility of the block following washout. (E) Fractional block curve reveals the 
voltage-dependency of the block, with maximal block observed at slightly depolarised 
potentials (n=3 OHCs). 
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7.2.3.2.5 Derivatives with Hydrophilic Head, Alkyl Chain Modifications - 13667, 13668, 
13669 
 
Three derivatives were designed with modifications to the alkyl chain portion of their 
hydrophilic heads (13667, 13668 and 13669). The modifications were made to influence the 
space between the two positive charges. The spacer for the FM 1-43 molecule consists of three 
carbon atoms. Here we designed compounds bearing a spacer of 4 (13669), 5 (13667) and 6 
(13668) carbons, in order to investigate how the distance between the positive charges may 
influence the interaction of the compound with the MET channel. 
The derivatives were tested electrophysiologically for their interaction with the MET channel. 
When tested at 10 µM, all 3 derivatives strongly blocked the MET current, suggesting they all 
still interact with the channel. Shown in Figure 7.9A-C is an example of the currents obtained 
from a third row OHC before (black), during (red) and after (blue) the superfusion of 10 µM 
13669. The current-voltage (Figure 7.9D) and fractional block curves (Figure 7.9E) generated 
from the raw data highlight the voltage-dependency of the observed channel block. The 
strongest block of the MET channel by 10 µM 13669 is observed at slightly depolarised 
potentials (+16 mV), and release of the block occurs at the extreme hyperpolarised and 
depolarised potentials, indicating that the compound is a permeant blocker of the channel. 
The average fractional block curves for 13667 and 13668 are presented later, in Figure 7.11D. 
These results suggest that the spacing between the positive charges on the FM 1-43 molecule 
is not integral to its interaction with the MET channel. Interestingly, when tested in zebrafish 
all 3 compounds loaded into neuromast HCs however the loading patterns were different for 
13668 (Figure 7.4). Compound 13668 loaded very strongly into neuromast HCs, whereas the 
other 2 loaded relatively weakly. As shown in Figure 7.11D, when tested electrophysiologically 
13668 was also shown to be the strongest blocker of the MET channel. As 13668 had the 
largest spacing between its positive charges, it can be concluded that a reduced spacing may 
reduce the binding of the compound to the channel pore, and vice versa. 
Interestingly, despite their shared block of the MET channel, none of the 3 derivatives 
provided any protection from the gentamicin-induced loss of OHCs when tested at 0.5 µM 
(Figure 7.3). When tested at 5 µM, all 3 derivatives were extremely toxic to the cochlear 
cultures (Figure 7.2), similarly to FM 1-43 itself. 
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Figure 7.9: Extracellular exposure to 10 μM compound 13669, one of the three FM 1-43 
derivatives with alkyl chain modifications in the hydrophilic head  
(A-C) MET currents recorded from a P2 basal OHC between -164 and +96 mV in response to a 
sinewave stimulus delivered by a fluid jet (45 Hz sinusoid, ±40V driver voltage, DV) shown 
above each trace, before (black), during (red) and after (blue) exposure to 10 µM 13669. 
Compound 13669 caused a large reduction of the current size at all membrane potentials. Full 
recovery is seen following re-exposure to the control solution. (D) Current-voltage curves of 
the currents shown in (A-C) reveal the current block at all potentials during 13669 exposure 
and the reversibility of the block following washout. (E) Fractional block curve reveals the 
voltage-dependency of the block, with maximal block observed at slightly hyperpolarised 
potentials (n=4 OHCs). 
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7.2.3.2.6 Additional FM 1-43 Derivatives – 13666, 13698, 16327 and 28552 
 
Four additional derivatives were synthesised based on those previously tested (7.2.3.2.2 - 
7.2.3.2.5) (13666, 13698, 16327 and 28552). Compound 13666 is the zwitterionic form of 
13670. Compound 13698 corresponds to bis-FM 1-43, having two lipophilic moieties, linked by 
a 3 carbon spacer and bearing two positive charges. The compound was designed because the 
Hill Coefficient, which quantifies the degree of interaction between a ligand and its binding site 
or the cooperativity of binding, suggests that the MET channel is able to accommodate two FM 
1-43 molecules (Gale et al., 2001). Compound 16327 is a photo affinity-labelled FM 1-43 
derivative. Compound 28552 was designed based on the results obtained with compounds 
13696 and 13551, and is a combination of their structures.  
Compounds 13666, 13698, 16327 and 28552 were tested electrophysiologically for their 
interaction with the MET channel.  Compound 13698 was extremely hard to get into solution 
and prevented the possibility of current recordings due to its crystallization on the cochlear 
cultures following superfusion. However, when 13698 was tested in the zebrafish loading 
assay it did load into neuromast HCs (Figure 7.4), suggesting it does interact with, and 
permeate through, the MET channel.  
When tested electrophysiologically, compounds 13666 and 16327 displayed a modest voltage-
dependent block of the MET channel. An example of MET channel block by 10 µM 16327 is 
shown in Figure 7.10, with the currents recorded before (black), during (red) and after (blue) 
compound superfusion displayed in Figure 7.10A-C, the current-voltage curve in Figure 7.10D 
and the fractional block in Figure 7.10E. The average fractional block curve for 13666 is 
displayed later, in Figure 7.11C. When compound 28552 was superfused on top of the cochlear 
cultures, this ruptured the cells and current recordings could not be obtained. In the zebrafish 
assay all 3 compounds loaded into neuromast HCs, suggesting all still behave as permeant 
blockers. However, 13666 loaded very weakly – only displaying neuromast labelling when 
incubated at 10 µM for 10 minutes (Figure 7.4). 
In mouse cochlear cultures, a wide variety of responses were observed. Compound 13666 
provided no protection at either concentration tested; 13698 provided protection at both 
concentrations; 16327 was toxic at 5 µM and not protective at 0.5 µM; and 28552 was toxic at 
5 µM and protective at 0.5 µM (Figures 7.2 and 7.3). 
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Figure 7.10: Extracellular exposure to 10 μM compound 16327, one of the four additional FM 1-
43 derivatives. 
(A-C) MET currents recorded from a P2 basal OHC between -164 and +96 mV in response to a 
sinewave stimulus delivered by a fluid jet (45 Hz sinusoid, ±40V driver voltage, DV) shown 
above each trace, before (black), during (red) and after (blue) exposure to 10 µM 16327. 
Compound 16327 caused a large reduction of the current size at all membrane potentials. Full 
recovery is seen following re-exposure to the control solution. (D) Current-voltage curves of 
the currents shown in (A-C) reveal the current block at all potentials during 16327 exposure 
and the reversibility of the block following washout. (E) Fractional block curve reveals the 
voltage-dependency of the block, with maximal block observed at slightly hyperpolarised 
potentials (n=4 OHCs). 
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7.2.3.2.7 Fractional Block Curves for all of the FM 1-43 Derivatives 
 
The fractional block curves for all of the tested FM derivatives were compiled based on their 
level of MET channel block. Figure 7.11 shows the average fractional block curves for 13550 
(Figure 7.11A) and also the derivatives that showed no interaction (Figure 7.11B), weak block 
(Figure 7.11C) or strong block (Figure 7.11D) of the MET channel. Three compounds are not 
shown in Figure 7.11 (13696, 13698 and 28552). Time limitations prevented 13696 from being 
able to be tested at 10 µM, 13698 had solubility issues and 28552 caused cell death upon 
application.  
 
Figure 7.11: The average fractional block curves for FM 1-43 and all but three of its derivatives 
at 10 µM, split in to no block, weak block and strong block of the MET channel. 
(A-D) Fractional block curves reveal that (A) FM 1-43 (13550) caused modest block of the MET 
channel. (B) 3 derivatives (13248, 13547 and 14885) showed no interaction. (C) 4 derivatives 
(13666, 13695, 13670 and 16327) gave a modest block and (D) 5 derivatives (13551, 13667, 
13668, 13669 and 14957) displayed a strong block of the channel. All compounds that blocked 
displayed a voltage-dependent block that was greatest at intermediate and often slightly 
depolarised potentials. They also showed a release of block at the extreme hyperpolarised 
potentials, indicative of them all behaving as permeant blockers of the MET channel. 
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7.3 Summary 
 
The results of this chapter have highlighted which aspects of the chemical composition of FM 
1-43 are vital to its previously-documented interaction with the MET channel. FM 1-43 has 
three distinct structural moieties: a lipophilic tail, a central core and a hydrophilic head. 
Modifications were made to each moiety and we assessed the effect this had on the two 
aforementioned characteristics of MET channel block and reported otoprotection.  
In the cochlear culture protection assay, FM 1-43 itself was toxic at 5 µM and not protective 
when tested at 0.5 µM. Electrophysiological recordings revealed that it behaves as a voltage-
dependent blocker of the MET channel, blocking most strongly at slightly depolarised 
potentials and displaying a release of block when the cell membrane was stepped to extreme 
hyperpolarised potentials, indicating that it is a permeant blocker of the channel.   
Of the 3 derivatives with modifications to their lipophilic tail (13695, 13696 and 14885), all 
three were toxic to cochlear cultures when tested at 5 µM and provided no protection when 
tested at 0.5 µM. When tested electrophysiologically, there was a variety of responses 
observed. Compound 13695 showed a weak, and 13696 showed a strong, voltage-dependent 
block of the MET channel. Compound 14885 showed no block of the channel, indicating a lack 
of interaction.  
Both of the derivatives with modifications to their central core (13248 and 13547) did not 
block the MET channel and provided no protection or toxicity at either concentration tested, 
indicating that the central core is integral to MET channel interaction and consequent 
otoprotection. 
Derivatives with modifications to their hydrophobic head can be divided into two classes: 
those missing the quaternary nitrogen and those with an extended alkyl chain spacer. Those 
with quaternary nitrogen modifications (13551, 13670 and 14957) all blocked the MET channel 
to some degree. Compound 13351 blocked strongly and protected against the gentamicin-
induced loss of OHCs when tested at 0.5 μM. Compound 13670 displayed modest block of the 
channel and protected when tested at 5 μM. Compound 14957 strongly blocked the MET 
channel but was found to be highly toxic in cochlear cultures at both concentrations tested. 
The three derivatives with alkyl chain modifications (13667, 13668 and 13669) all strongly 
blocked the MET channel. When tested in cochlear cultures, however, they provided no 
protection at 0.5 μM and were highly toxic when tested at 5 μM. 
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7.4 Discussion 
 
The results presented in this chapter serve to further indicate that the mechanism of 
otoprotection of FM 1-43 that had been previously reported (Gale et al., 2001), was due to its 
block of the MET channel and the consequent prevention of AG entry into sensory HCs. None 
of the FM 1-43 derivatives that showed a lack of interaction with the MET channel conferred 
any protection against the gentamicin-induced loss of OHCs, reinforcing that MET channel 
block is the mechanism of reported otoprotection of the styryl dye. 
It is evident that the central core of the FM 1-43 molecule is integral to its ability to interact 
with the MET channel, as any modification made to this moiety prevented any observable 
interaction. Furthermore, the evidence presented herein surprisingly suggests that the 
hydrophobic head component of the molecule is less integral to MET channel interaction than 
the lipophilic tail. This is because all six modifications made to the hydrophobic head still 
allowed the derivatives to display some degree of MET channel block, whereas one of the 
three modifications made to the lipophilic tail prevented MET channel interaction. Moreover, 
when modifications were made to the central core separating the charged head from the 
lipophilic tail (section 7.2.3.2.3), the charged head compound did not interact with the channel 
without the lipophilic tail component. 
Electrophysiological investigations revealed that FM 1-43 and all of its derivatives that 
interacted with the MET channel showed maximum block at the intermediate potentials, most 
often at +16 mV. Moreover, only one positive charge is needed for channel interaction, as 
shown by compounds 13551 and 14957 still behaving as channel blockers, and a substitution 
of a positive for a negative charge (13670) reduced the level of block, most likely due to 
electrostatic repulsion of the molecule from the negative charges within the channel’s pore. 
The spacing between the positive charges affects the permeation of the compound, in that the 
compound with the longer space between the two charges (13668) loaded most strongly into 
zebrafish neuromast HCs compared to those with lesser spacing. 
In regards to the cochlear protection assays, toxicity was observed with a large number of the 
FM 1-43 derivative compounds (9 of the 15 when tested at 5 μM), and only few conferred 
protection at either concentration tested (0.5 or 5 μM). This is perhaps not surprising, as 
previous studies have reported that when applied to cochlear cultures, FM 1-43 caused 
blebbing of the apical surface of sensory HCs after only 70 minutes (Gale et al., 2001). Due to 
the 48 hours duration of the cochlear culture protection assay used herein, the derivatives 
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would have had a much longer time to potentially permeate into HCs and exert their toxic 
effect, thereby explaining the result. To further assess any intrinsic toxicity of the compounds, 
they should have been tested alone in the absence of gentamicin to determine whether it was 
the gentamicin or the compound that induced the toxic effects. This would have made the 
interpretation of their toxicity much easier. These experiments were not completed due to 
time limitations. Future studies should address this concern.  
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8   Assessing the Effects of Aminoglycoside Antibiotics on 
Mitochondrial Function 
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8.1 Introduction 
 
Following the entry of the AGs into sensory HCs they are believed to interact with intracellular 
targets such as ribosomes, the endoplasmic reticulum (ER) and mitochondria (Jiang et al., 
2017; O’Sullivan et al., 2017), causing their dysfunction and the consequent induction of 
apoptotic cell death pathways. The assumed mitochondrial involvement in the apoptotic 
process has manifested as a result of several indirect lines of evidence, including: the structural 
similarity of bacteria (the target of AGs) and mitochondria, as well as their proposed bacterial 
origin (Margulis et al., 1970; Gray et al., 2001; Gray et al., 2012); the co-localisation of GTTR 
with mitochondrial stains such as Mitotracker (Ding et al., 1995; Steyger et al., 2003); the 
enhanced susceptibility to AG-induced ototoxicity resulting from mitochondrial genetic 
mutations (Prezant et al., 1993); and the rise in ROS levels following AG exposure – cell 
signalling molecules that are primarily produced by mitochondria (Clerici et al., 1996; Hirose et 
al., 1997; Sha and Schacht, 1999a). 
Although compelling, these lines of evidence for mitochondrial involvement in the AG-induced 
cell death process are somewhat indirect. The aim of this chapter was to investigate the effect 
that the AGs may directly induce when they encounter these organelles. In order to examine 
this I initially used isolated rat liver mitochondria, due to the ease of isolation and the high 
yield that can be obtained from a single liver dissection. Following preliminary investigations, I 
repeated the experiments in isolated rat kidney mitochondria – an organ that is susceptible to 
AG damage in the form of nephrotoxicity (Mingeot-Leclerq and Tulkens, 1999; Mouedden et 
al., 2000). Lastly, we also investigated the effect of the AGs on intact sensory HC mitochondria, 
in the same mouse cochlear cultures that have been used for compound screening throughout 
this thesis. 
As a brief introduction to the way in which mitochondrial function can be investigated; all 
mitochondria have five protein complexes embedded in their inner membranes, known 
collectively as the electron transport chain (ETC). These complexes serve to move electrons 
along the chain, from complex I to V (CI-V), with oxygen as the final electron acceptor. This 
electron flow simultaneously generates a proton gradient which manifests as a membrane 
potential and a pH gradient. Adenosine triphosphate (ATP) synthase utilises this proton 
gradient in order to produce ATP, which is then harnessed by the cell. Under usual conditions, 
mitochondria have a basal respiratory rate known as state 4 respiration. The maximal 
respiratory capacity of mitochondria is known as state 3 (or state 3U, if maximal respiration is 
induced by uncoupler addition as opposed to an abundance of ADP), and the ratio of the basal 
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to maximal respiratory rates is termed the respiratory control ratio (RCR), which gives an 
indication of the integrity of mitochondria by conveying how coupled the consumption of 
oxygen is to ATP production. The ETC is also crucially involved in the production of ROS – cell 
signalling molecules that are directly involved in the survival of a cell.  
 
Figure 8.1: Illustration of the mitochondrial electron transport chain, taken from Polyzos and 
Mcmurray, 2016. 
The ETC is the target of a large number of drugs, including several anti-cancer compounds 
(Rohlena et al., 2011; Olszewska and Szewczyk, 2013; Kluckova et al., 2013). Cisplatin, another 
nephro- and ototoxicity-inducing compound used to treat several forms of cancer (Skinner et 
al., 1998; Knight et al., 2005), had been reported to cause mitochondrial dysfunction as a 
crucial pathogenic event in its induction of nephrotoxicity (Simmons and Humes, 1979). 
Furthermore, previous studies investigating the effect of gentamicin on renal tissue 
mitochondria had reported an effect on their state 3 and state 4 respiratory activities, 
potentially underlying the associated nephrotoxicity (Bendirdjian et al., 1975; 1978; Simmons 
et al., 1980). However, documentation of the mechanism underlying this observation is 
lacking. Moreover, the effect of the AGs on sensory HC mitochondria is not fully understood. 
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Studies have reported that AGs trigger the opening of the permeability transition pore and 
dissipate the mitochondrial membrane potential (MtMP) (Dehne et al., 2002). AGs have also 
been shown to cause a rapid alteration of mitochondrial metabolism, particularly in basal 
OHCs when compared to IHCs and their apically-located counterparts (Jensen-Smith et al., 
2012). This evidence directly correlates with the AG-induced ototoxicity pattern that I have 
observed throughout this thesis, suggesting a direct link between mitochondrial dysfunction 
and AG-induced HC death.   
For this reason, I investigated whether gentamicin affected the function of the ETC in isolated 
mitochondria, through a series of measurements of oxygen consumption using an Oroboros 
Oxygraph-2K oxygen electrode. The MtMP and mitochondrial ROS (MtROS) production in 
isolated kidney and liver mitochondria were also investigated, as was the MtMP in intact 
sensory HC mitochondria using a selection of fluorescent indicators. The overarching, 
predominant aim of this chapter was to identify the effect that the AGs have on mitochondria 
and establish an assay system, so that I could then subsequently screen any identified 
otoprotectants against this effect, thereby investigating an additional mechanistic avenue. The 
mechanism of otoprotection of several compounds that I have identified herein (including the 
two most efficacious; see Chapter 4) remained unknown, as they do not block the HC MET 
channels or affect the RP, so are unlikely to prevent AG entry into the cell. By conducting this 
research, I was able to investigate whether these compounds may have protected sensory HCs 
by preventing AG-induced mitochondrial dysfunction. 
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8.2 Results 
 
8.2.1 Gentamicin Stimulates State 4 and Inhibits State 3U Respiratory 
Activities of Isolated Rat Liver Mitochondria 
 
Overall mitochondrial activity was assessed by measuring oxygen consumption of isolated 
mitochondria using an Oroboros Oxygraph-2K oxygen electrode, with the dual chamber set-up 
proving ideal for running control experiments simultaneously. The ETC complexes (I-V) were 
investigated independently, to assess any complex-dependent effect. Mitochondrial samples 
were equilibrated in reaction media with or without 5 mM gentamicin for 10 minutes prior to 
the addition of 10 mM succinate to stimulate CII, in the presence of 2.5 µM rotenone to ensure 
NADH generated within the tricarboxylic acid cycle did not become a confounding factor. Upon 
addition of the substrate, oxygen uptake increased to 240 (± 22) pmol O2 s
-1 ml-1 (n=26) within 
the control samples and 419 (± 48) pmol O2s
-1ml-1(n=14) in the gentamicin-treated conditions, 
demonstrating a significant (p = 0.0496) stimulation of CII-dependent state 4 respiration, as 
has previously been reported (Bendirdjian et al., 1975; 1978) (Figure 8.2). Subsequent addition 
of 1 µM CCCP, to uncouple oxygen consumption rates from the proton-motive force, increased 
the rate to 807 (± 57.43) pmol O2 s
-1 ml-1 (n=26) within the control sample. However, the 
gentamicin rate remained relatively stable at 406 (± 40) pmol O2 s
-1 ml-1 (n=14), demonstrating 
no significant change to its coupled state (Figure 8.2). 
To ensure the effect was not limited to CII-dependent respiration, the same set of experiments 
were repeated using 5 mM pyruvate and 2 mM malate to stimulate NADH generation via 
pyruvate dehydrogenase and malate dehydrogenase respectively, thereby assessing CI-
dependent state 4 respiration. As with the previous set of experiments, the gentamicin-treated 
mitochondria presented a significant (p = 0.0059) increase in state 4 respiration, increasing the 
rate from 149.8 (± 15.39) pmol s-1 ml-1 (n=4) in the controls to 502 (± 72) pmol O2 s
-1 ml-1 (n=4) 
in the gentamicin-treated conditions, but demonstrated no significant increase when treated 
with CCCP, 402 (± 84) pmol O2 s
-1 ml-1 (n=4) (Figure 8.2).   
Furthermore, there was a significant difference in the state 3U respiratory rates between the 
control and gentamicin-treated conditions, both for CI (p = 0.0375) and CII-mediated (p < 
0.0001) respiration (Figure 8.2). This implied that gentamicin reduces state 3U respiratory 
rates, as had previously been reported elsewhere in the literature (Simmons et al., 1980). All 
statistical comparisons in this section were made using a one-way ANOVA, followed by Tukey’s 
multiple comparisons test.  
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Figure 8.2: Pre-incubation with 5 mM gentamicin for 10 minutes caused stimulation of complex 
I and complex II respiration (state 4) and inhibition of the maximal respiratory rates (state 3U). 
A respiratory flux trace for CII (A) respiration, with (red) and without (green) 5 mM gentamicin 
pre-incubation for 10 minutes, alongside quantification of the CI (B) and CII (C) response. 
(A) Succinate addition (10 mM) (*) in the gentamicin condition caused a much larger O2 flux 
response than in the control. Subsequent addition of CCCP (1μM) (**), an uncoupler of the 
ETC, caused O2 flux to rise significantly in the control, whereas a greatly reduced rise was 
observed when pre-incubated with gentamicin. (B) Quantification of the CI response. Pyruvate 
(5 mM) and malate (2 mM) addition in the gentamicin condition caused a much larger O2 flux 
response than in the control. Subsequent addition of CCCP caused O2 flux to rise significantly in 
the control, whereas no such rise was seen when pre-incubated with gentamicin. (C) Shows 
quantification of the CII response, presented in (A). 
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8.2.2 Gentamicin Reduces the Respiratory Control Ratio (RCR) of Isolated 
Mitochondria   
 
Given that gentamicin stimulates state 4 and causes a concurrent reduction of state 3U 
respiratory rates (Figure 8.2) (Bendirdjian et al., 1975; 1978; Simmons et al., 1980), I 
investigated its effect upon the RCR of isolated mitochondria. The RCR is a measure of the 
integrity of mitochondria and the extent of the coupling between oxygen consumption and 
ATP production. Initial dose-response experiments were performed at a fixed 10 minutes 
incubation time point, with the data displaying a clear concentration-dependent increase in 
state 4 respiratory activities (Figure 8.3A). While the data for uncoupled (state 3U) respiration 
does initially appear somewhat erratic, this is likely due to the non-homogeneous nature of the 
mitochondrial samples, causing uniform protein addition to be extremely challenging. 
However, once the data is transformed into RCR values a typical dose-response effect can be 
observed (Figure 8.3B).  
The extent to which incubation time was a factor was also investigated (Figure 8.3C), with all 
three concentrations tested demonstrating a linear reduction in the RCR as the length of AG-
incubation time increased. Dose response curves (Figure 8.3D) were generated for state 4 
respiration and an IC50 of 7.5 (±2.5) mM (n=2) was determined, with a Hill coefficient of 1.54 
(1.24 – 1.84 95% CI). 
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Figure 8.3: Gentamicin reduced the respiratory control ratio (RCR) of isolated mitochondria in a 
dose and time-dependent manner. 
(A) Shows the increase in succinate-induced O2 flux (state 4) with increasing gentamicin 
concentrations, and a simultaneous reduction in the CCCP-induced O2 flux (state 3U). 
Experiments were done in the presence of 2.5 μM rotenone, to inhibit CI respiration. Lines are 
fit to a linear regression model, displaying 95% confidence intervals.  (B) Shows the 
transformed data, with RCRs derived by dividing the CCCP state 3U rates by the succinate state 
4 rates. (C) Shows the decrease in the RCR with increasing gentamicin incubation times, for 
three different concentrations (2.5, 5 and 7.5 mM). (D) A dose-response curve for gentamicin’s 
effect on state 4 respiration. 
 
 
 
 
 
 
 
176 
 
8.2.3 Gentamicin Depolarises the Mitochondrial Membrane Potential 
(MtMP) 
 
Given the observed effect of gentamicin on the mitochondrial RCR, I investigated its effect on 
the mitochondrial membrane potential (MtMP) using safranin (Krumschnabel et al., 2014). 
Safranin (2 μM) is a fluorescent dye that indicates the MtMP using a quenching mechanism, 
accumulating in mitochondria due to the negative potential inside, generated across the inner 
mitochondrial membrane (IMM). The MtMP is the transmembrane potential that is directly 
responsible for ATP production (Zorova et al., 2017); it underlies the coupling, or the RCR, of 
mitochondria. Previous studies have reported a loss of the MtMP in OHCs before cell death 
occurs (Dehne et al., 2002), further highlighting the involvement of mitochondrial dysfunction 
in the AG-induced cell death process.  
Initial addition of safranin to the chambers generated a fluorescent signal (Figure 8.4A). Upon 
subsequent addition of succinate to initiate respiration a proton gradient was formed, the dye 
entered mitochondria and was quenched. This reduced the fluorescent signal (Figure 8.4A*), 
which was indicative of an MtMP being generated. Upon subsequent addition of 2.5 mM 
gentamicin, the signal increased, indicating a decrease in the MtMP, with successive 2.5 mM 
titrations further decreasing the membrane potential (Figure 8.4A↓).  
Figure 8.4B shows quantification of the results. A one-way ANOVA followed by Dunnett’s 
multiple comparisons test revealed that a significant shift in safranin signal relative to 
succinate only was evident at gentamicin concentrations ≥ 1 mM (p = 0.009) (n=5). As shown in 
Figure 8.4A, complete dissipation of the gradient was seen when using quick, successive 
additions of gentamicin up to a concentration of 15 mM. However, if lower concentrations of 
gentamicin were added (≥ 1 mM) and left incubating in the chamber then we saw a 
progressive depolarisation of the MtMP over time (data not shown), possibly suggesting that 
gentamicin must first cross the outer mitochondrial membrane (OMM) in order to exert its 
effect on the proteins embedded within the IMM. Alternatively, the binding of gentamicin to 
mitochondria has been shown to be persistent and not readily reversible when tested in vitro 
(Kornguth et al., 1980), so perhaps a certain amount of gentamicin must bind before it can 
exert its detrimental effect on mitochondrial function.  
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Figure 8.4: Gentamicin depolarised the mitochondrial membrane potential (MtMP). 
(A) Succinate was added to the chamber to initiate respiration (*), generating a proton 
gradient and consequent polarisation of the mitochondrial membrane. This is indicated by the 
quenching of the safranin signal, which is indicative of the MtMP being generated. When 2.5 
mM gentamicin was added to the chamber (↓) there was a sudden, direct increase in safranin 
signal, suggesting that gentamicin was dissipating the proton gradient and depolarising the 
MtMP.  (B) Shows quantification of the results. A significant shift in safranin signal relative to 
succinate only was evident at gentamicin concentrations ≥ 1 mM. 
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8.2.4 Gentamicin Reduces Mitochondrial ROS (MtROS) Production with 
Succinate as the Substrate 
 
MtROS production can be measured using Amplex Red, a dye that fluoresces dependent on 
hydrogen peroxide (H₂O₂) levels. Previous studies have suggested excessive ROS production to 
be the cause of sensory HC death, as a result of AG treatment or otherwise, with many 
protective approaches aimed at applying antioxidants to reduce ROS accumulation within the 
cell (Sha and Schacht, 2000; Wu et al., 2002; Sergi et al., 2004; Rybak and Whitworth, 2005; Xie 
et al., 2011; Kim et al., 2015; Negrette-Guzmán et al., 2015). 
Here, endogenous ROS production was measured following the addition of succinate (*) to the 
Oroboros Oxygraph chambers. In Figure 8.5A, the rates of ROS production and overall 
concentrations in the chamber are plotted. Solid lines display overall ROS concentrations and 
dashed lines display ROS production rates. Green is the control and red is the gentamicin-
treated condition. Evidently, 5 mM gentamicin incubation reduced the amount of ROS 
produced over time (Figure 8.5A). Antimycin A (2.5 µM) is an inhibitor of CIII that causes 
electron backflow through CI, thereby inducing ROS production. It was added as a positive 
control (**), and an increase in ROS was observed following its addition. 
Quantification of the increase in ROS concentrations over time are plotted in Figure 8.5B. 
When compared to the control, a one-way ANOVA followed by Dunnett’s multiple 
comparisons test revealed that there was a significant reduction in the amount of ROS 
produced over a period of 10 minutes when mitochondria were incubated with 1 (p = 0.0167) 
(n=3) or 5 (p = 0.0080) (n=3) mM gentamicin. Evidently, gentamicin reduces ROS production; a 
result which is consistent with our proposal that it acts as a mitochondrial uncoupler. This is 
because in order for MtROS to be produced there must be a backflow of electrons along the 
ETC. Uncoupling of the mitochondrial membrane prevents electron backflow, thus preventing 
the formation of ROS.  
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Figure 8.5: Gentamicin reduced endogenous mitochondrial ROS (MtROS) production, consistent 
with our hypothesis that it behaves as a mitochondrial uncoupler. 
(A) Shows H₂O₂ levels detected over a period of 10 minutes, with the rates of production and 
overall concentrations plotted. Solid lines display concentrations, dashed lines display rates. 
Green is control, red is gentamicin. Following succinate addition (10 mM) (*), the endogenous 
formation of ROS was inhibited by 5 mM gentamicin. Antimycin A (2.5 µM), a known inhibitor 
of CIII, was added (**) as a positive control. (B) Shows quantification of the increase in ROS 
concentration over a 10 minute period. Gentamicin reduced endogenous ROS production 
when tested ≥ 1 mM (n=3), consistent with our proposal that it acts as a mitochondrial 
uncoupler. 
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8.2.5 Gentamicin causes State 4 Stimulation and State 3U Inhibition, RCR 
Reduction, MtMP Depolarisation and a Reduction in MtROS Production in 
Isolated Rat Kidney Mitochondria  
 
Isolated rat liver mitochondria were used for all of the initial experiments due to the ease of 
isolation and the high yield of mitochondria per dissection. However, as this is not an organ 
that is damaged by AGs, all experiments were subsequently repeated using rat kidney 
mitochondria to ensure that the same effect was seen. As shown in Figure 8.6A, the same 
stimulation of state 4 and reduction of state 3U respiratory rates was observed, with a 
concurrent reduction in the RCR of kidney mitochondria (Figure 8.6B). To note, the RCR of 
kidney mitochondria is much lower than that of liver mitochondria, with an average RCR of 
5.28 (± 0.83) (n=4) relative to that of the liver, which was 9.04 (± 0.56) (n=8). This observation 
has been reported elsewhere (Lash and Jones, 1993). 
Depolarisation of the MtMP occurred with serial gentamicin additions (Figure 8.6C), with a 
complete collapse of the MtMP at gentamicin concentrations ≥ 5 mM. The lower 
concentration of gentamicin needed to collapse the MtMP relative to liver mitochondria is 
likely due to there being fewer mitochondria in the tissue sample, due to less experience in the 
dissection and isolation technique and the smaller size of the tissue sample meaning greater 
dilution by assay media throughout the isolation process. Alternatively, it could reflect the 
lower RCR and the smaller amount of gentamicin required to disrupt the membrane. 
Moreover, the time between each addition was slightly longer, perhaps giving gentamicin 
more time to bind or to cross the OMM and exert its effect on the IMM, if this is indeed how 
the antibiotic is having its effect. 
Lastly, gentamicin was found to reduce ROS production in kidney mitochondria also (Figure 
8.6D), with endogenous ROS levels following succinate addition (*) being greatly reduced in 
the gentamicin-treated condition relative to the control. 
Taken together these data suggest that all mitochondria are susceptible to AG insult; however, 
it is the existence of suitable entry routes into specific tissue types that determines their 
susceptibility to AG-induced toxicity. An alternative possibility is a lack of suitable exit routes, 
leading to the enhanced accumulation in certain tissue types specifically. 
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Figure 8.6: In kidney mitochondria, gentamicin stimulated state 4 and reduced state 3U 
respiratory activities, reduced the RCR, depolarised the MtMP and reduced ROS production. 
All experiments detailed were replicated using kidney mitochondria, as the kidney is an organ 
susceptible to AG-induced (nephro-) toxicity. (A) Succinate addition (*) in the 5 mM gentamicin 
condition caused a larger O2 flux response than in the control. Subsequent addition of CCCP (1 
μM) (**) caused O2 flux to rise significantly in the control, whereas a greatly reduced rise was 
seen when pre-incubated with gentamicin. (B) Quantification of the results shows that 
gentamicin caused a concentration-dependent decrease in the RCR of isolated kidney 
mitochondria. (C) Succinate was added to the chamber to initiate respiration (*), generating a 
proton gradient and consequent polarisation of the mitochondrial membrane. When 
gentamicin was added to the chamber (↓) there was a sudden, direct increase in safranin 
signal, suggesting that gentamicin was dissipating the proton gradient and depolarising the 
MtMP.  (D) Shows H₂O₂ levels detected over a period of 10 minutes, with the rates of 
production and overall concentrations plotted. Solid lines display concentrations, dashed lines 
display rates. Green is control, red is gentamicin. Following succinate addition (10 mM) (*), the 
endogenous formation of ROS was inhibited by gentamicin. 
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8.2.6 Gentamicin causes MtMP Depolarisation in Sensory HC Mitochondria 
 
*This research was conducted by Nerissa Kirkwood, University of Sussex. 
 
To further confirm that the effect I had observed in isolated mitochondria would also occur in 
intact cell systems, we investigated the effect of gentamicin on the MtMP in the mitochondria 
of HCs in mouse cochlear cultures. Previous studies had shown a location-dependent effect of 
gentamicin on cochlear culture HCs; with basal OHCs losing their mitochondrial metabolic 
activity more rapidly than those located in the apical coil (Jensen-Smith et al., 2012). 
Cells were pre-loaded with Rhodamine-123, a fluorescent dye that stains mitochondria based 
on an active MtMP. If the MtMP is dissipated, the fluorescence signal diminishes (Rahn et al., 
1991). Cells were bathed in extracellular solution and gentamicin was added to a final 
concentration of 5 mM. Figure 8.7 shows the HC fluorescence over a period of 26 minutes. 
Between 0 and 14 minutes, there was no change in the fluorescence detected (Figure 8.7A-D). 
By 16 minutes incubation time, however, the MtMP in some HCs had dissipated, as indicated 
by the asterisk in Figure 8.7E. By 26 minutes, almost all of the HCs in the cochlear region under 
investigation showed a loss of their MtMPs (Figure 8.7J). This directly correlates with what we 
had observed previously in the isolated mitochondrial assay systems, adding further 
confirmation that this may be the process underlying AG-induced ototoxicity.   
 
Figure 8.7: Extracellular exposure to 5 mM gentamicin caused a loss of MtMPs in mouse 
cochlear culture HCs after ≥ 16 minutes incubation time. 
(A-J) Rhodamine-123 fluorescence in cochlear culture OHCs at differing time points following 
extracellular exposure to 5 mM gentamicin. Loss of fluorescence begins at 16 minutes post-
exposure, with complete loss visible in one OHC (*). The decrease in fluorescence indicates a 
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collapse of the MtMP. By 26 minutes post-exposure the majority of OHCs in the ROI had 
reduced Rhodamine-123 fluorescence indicating a widespread loss of MtMP. Experiment was 
performed at room temperature (20 -22 °C). Scale bar is 25 μm. 
 
 
8.2.7 Tocris Library Otoprotectant 13143 Prevents the Gentamicin-Induced 
Stimulation of State 4 Respiration 
 
One of the most effective otoprotectants that I identified in this thesis, 13143 (see Chapter 4), 
was shown to have no interaction with the HC MET channel or affect the RP of the cell. 
Although shown to reduce GTTR entry into HCs, this was assumed to be independent of its 
mechanism of protection due to the lack of effect on the MET channel current or the RP of the 
cell; the two processes that could influence the AG-uptake process. This meant that the 
mechanism of protection of this compound remained unknown. For this reason, I investigated 
whether 13143 was able to prevent the gentamicin-induced effect on the respiratory activities 
of isolated mitochondria. Using an Oroboros Oxygraph I compared the state 4 respiratory rates 
of isolated mitochondria when incubated with 5 mM gentamicin alone or 5 mM gentamicin 
alongside 25 μM 13143. 
In Figure 8.8A-D the otoprotective effect of 13143 is shown. Partial protection against the 48 
hours, 5 μM gentamicin-induced loss of OHCs is observed with co-incubation of 0.5 μM 13143, 
and complete protection is seen with 1 μM. Shown in Figure 8.8E is the stimulation of CII-
driven state 4 respiration caused by 5 mM gentamicin (red), and also the reduction of this 
stimulatory effect as a result of co-incubation with 25 μM 13143 (purple). Quantification of the 
response is shown in Figure 8.8F. A one-way ANOVA followed by Tukey’s post hoc test 
revealed a significant difference in the gentamicin-induced stimulation of CII-driven state 4 
oxygen consumption rates when mitochondria were co-incubated with 25 μM 13143 (p = 
0.0039) (n=3). The average state 4 respiratory rate of the mitochondria treated with 5 mM 
gentamicin was 712 (± 68.4) pmol O2 s
-1 ml-1 (n=3) and in those co-treated with 13143 it was 
396 (± 13.9) pmol O2 s
-1 ml-1 (n=3). However, the maximal respiratory rate (state 3U) was 
greatly reduced, measuring 907.3 (± 33.9) pmol O2 s
-1 ml-1 (n=3) in the gentamicin-treated 
conditions and 600.7 (± 39.0) pmol O2 s
-1 ml-1 (n=3) in those co-incubated with 13143. 
Consequently, RCR conversions revealed the resulting RCR of gentamicin-treated mitochondria 
to be 1.31 (± 0.19) and 1.51 (± 0.05) when co-incubated with 13143. The difference was not 
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significant. However, dissimilarly to what was observed with gentamicin alone, 13143 co-
incubation did restore a significant difference between the state 4 and state 3U respiratory 
activities (p = 0.0042) (n=3). 
Taken together, these data implied that this may be the mechanism of protection of 13143 – 
protecting by preventing the gentamicin-induced dysfunction of mitochondrial activity that 
subsequently leads to HC apoptosis induction. However, the mitochondrial RCR is still reduced 
to approximately the same value and the overall activity is considerably lower, suggesting that 
13143 may simply be exacerbating the ETC disruption caused by gentamicin.  
 
Figure 8.8: Compound 13143 protected sensory HCs against gentamicin damage in mouse 
cochlear cultures and also prevented the gentamicin-induced stimulation of mitochondrial 
state 4 respiration in isolated rat liver mitochondria. 
Cochlear cultures were treated for 48 hours with either (A) 0.5% DMSO, (B) 5 μM gentamicin 
and 0.5% DMSO, 5 μM gentamicin and (C) 1 μM or (D) 0.5 μM 13143. Scale bar is 50 μm. (E) 
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Oroboros Oxygraph recordings of oxygen consumption showed that co-incubation of 25 μM 
13143 (purple) reduced the 5 mM gentamicin-induced stimulation of CII-driven state 4 
respiration. (F) Quantification revealed that 25 μM 13143 co-incubation significantly reduced 
gentamicin’s stimulation of state 4 respiration (p = 0.0081) and also caused an increase in state 
3U activity, relative to state 4 (n=3). 
 
 
8.2.8 Tocris Library Otoprotectant 13097 does not Prevent AG-Induced 
Mitochondrial Dysfunction 
 
The most effective otoprotectant that I identified in this thesis, 13097 (see Chapter 4), was 
shown to protect with a remarkable efficacy. However, mechanistic investigations revealed 
that it had no effect on the MET channel current or the RP of the cell, and was also shown to 
have no effect on the loading of GTTR into cochlear HCs. Consequently, the mechanism of 
protection was assumed to be intracellular. For this reason, I investigated whether 13097 was 
able to prevent the gentamicin-induced effect on the respiratory activities of isolated 
mitochondria. 
Figure 8.9A-D shows the protective effect of 13097, completely protecting against the 5 μM 
gentamicin-induced OHC damage when co-incubated at a concentration of 10 nM. In Figure 
8.9E the gentamicin-induced stimulation of state 4 and inhibition of state 3U respiratory 
activities is shown (red). Also shown is evidence that 13097 does not prevent this effect 
(purple), at any concentration tested (≤ 200 μM). Figure 8.9F shows quantification of the state 
4 response and Figure 8.9G shows quantification of the state 3U response. A one-way ANOVA 
followed by Dunnett’s multiple comparison’s test revealed that no significant difference 
between the gentamicin alone and gentamicin alongside 13097 conditions were detected with 
either gentamicin-induced effect. 
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Figure 8.9: Compound 13097 protected sensory HCs against gentamicin damage in mouse 
cochlear cultures but did not prevent gentamicin’s effects on isolated rat liver mitochondria. 
Cochlear cultures were treated for 48 hours with either (A) 0.5% DMSO, (B) 5 μM gentamicin 
and 0.5% DMSO, 5 μM gentamicin and (C) 10 nM or (D) 3 nM 13097. Scale bar is 50 μm. (E) 
Oroboros Oxygraph recordings of oxygen consumption rates revealed that co-incubation of 
200 μM 13097 (purple) did not prevent the 5 mM gentamicin-induced stimulation of CII-driven 
state 4 respiration (red). (F-G) Quantification of the respiratory rates revealed no significant 
difference in the oxygen fluxes of mitochondria treated with 5 mM gentamicin alone or 
gentamicin alongside 200 μM 13097. 
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8.3 Summary 
 
Here I have presented evidence of the direct effect of gentamicin on the respiratory activities 
of isolated rat liver and kidney mitochondria, showing that it stimulated state 4 and inhibited 
state 3U respiratory rates, thereby reducing the mitochondrial RCR. I have also demonstrated 
that gentamicin caused a collapse of the MtMP, which would lead to a reduction in ATP 
production. I propose that the AGs behave as uncouplers of the mitochondrial ETC; increasing 
the permeability of the membrane and thus preventing the tight coupling of oxygen 
consumption to ATP production. This working hypothesis is supported by evidence that it 
reduces the production of MtROS (Figure 8.5 and 8.5D), which is only produced by electron 
backflow - a process requiring coupled mitochondria. I also showed the gentamicin-induced 
reduction of the MtMP in sensory HCs of mouse cochlear cultures, confirming that the effects 
observed in isolated mitochondria are also applicable to those in intact cell systems. Lastly, I 
tested the two most effective otoprotectants that I identified within this thesis to see if they 
prevented the observed effect of gentamicin on mitochondria, as their mechanism of 
protection remained unknown. One compound (13143) prevented the gentamicin-induced 
stimulation of state 4 respiration and one (13097) did not.  
To summarise on the effect of AGs on mitochondria, it is my working hypothesis that once the 
AGs have accumulated inside a cell at a high enough concentration, they begin to cause the 
dysfunction of mitochondria. They potentially form holes in mitochondrial membranes 
similarly to how they attack bacteria (Kadurugamuwa et al., 1993), or perhaps in a similar way 
to classic mitochondrial uncouplers such as CCCP, which work as protonophores by 
translocating protons across the lipid membrane (Lim et al., 2001); leading to the opening of 
the permeability transition pore that underlies the characteristic mitochondrial swelling 
associated with apoptosis (Ganote and Armstrong, 2003). The increased permeability causes 
the dissipation of the proton gradient and MtMP (Dehne et al., 2002; Miyazono et al., 2018) 
that is tightly regulated in order to allow the correct production of ATP required by the cell. 
Consequently, mitochondria will be unable to produce as much ATP on demand – for instance, 
in the event of AG damage and the need for additional ATP to aid its clearance. Studies have 
shown reduced ATP levels in whole kidneys following in vivo gentamicin treatment (Simmons 
et al., 1980), supporting this postulation.  
This hypothesis is further supported by evidence that valinomycin, another antibiotic, induces 
the same effect as classic mitochondrial uncouplers – increasing mitochondrial membrane 
permeability to K+ ions, thereby reducing the MtMP (Safiulina et al., 2006). 
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8.4 Discussion 
 
The evidence that I have presented in this chapter is important in that I show a potentially 
direct effect of the AGs on the functional activities of mitochondria and propose a mechanism 
of action underlying the effect. Although often assumed to interact with mitochondria and 
affect their respiratory activities, most lines of evidence for this postulation are indirect and a 
unified process has not yet been established. If this research is validated by future studies, this 
could represent a direct line of evidence to reveal how the AGs induce mitochondrial 
dysfunction once inside a cell, thereby enabling screening for otoprotection mechanisms in 
terms of intracellular, mitochondrial dysfunction.  
Doubt in the validity of the experimental results presented in this chapter arises from the 
concentration of gentamicin used in the experiments. In order to see an effect on 
mitochondria, gentamicin had to be incubated in the millimolar range for at least 2 to 3 
minutes. When compared to the cochlear culture gentamicin-kill assay used throughout this 
thesis, which used 5 μM gentamicin for 48 hours, concerns for the discrepancy in 
concentration arise. Ideally, mitochondria would have been incubated with a much lower 
concentration for a much longer time, to mimic the cochlear culture assay conditions. 
However, when using the Oroboros Oxygraph machinery, mitochondria left spinning in the 
chambers lose their integrity and begin to uncouple as soon as 15 minutes post-incubation. 
This is because a magnetic stirrer bar is used to keep the mitochondria in suspension in the 
solution; however, the mechanical damage induced by this setup caused the mitochondria to 
uncouple over time, resulting in a reduction in the RCR which then skewed meaningful 
interpretation of the results. Consequently, it was not possible to extend the incubation time 
and reduce the AG concentration to make the two assay types more comparable.  
Although the concentration discrepancy poses a valid concern, a previous study investigating 
the effect of gentamicin on renal cells in vivo revealed a very similar response (Simmons et al., 
1980). The researchers gave daily administrations of gentamicin to rats for 7 days, after which 
they harvested their kidneys and performed similar experiments on mitochondria isolated 
from the organ. They also observed a gentamicin-induced stimulation of state 4 and inhibition 
of state 3U respiration, which adds validity to the results obtained herein.  Moreover, the 
researchers found a very high concentration of gentamicin had accumulated in the kidney 
cortex (damage to which underlies nephrotoxicity) relative to the hepatic concentrations 
(Simmons et al., 1980); thus further supporting the argument that it is the tissue-selective 
enhanced accumulation that underlies the specificity of AG toxicity. 
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Further validation of the effects I observed in isolated mitochondria comes from the 
investigation of MtMP changes in the HCs of cochlear cultures. All of the effects seen in 
isolated mitochondria (respiratory state stimulations and inhibitions, RCR and MtMP 
reductions and the prevention of ROS production) are tightly linked to the collapse of the 
MtMP. In cochlear cultures, the evident MtMP collapse therefore implies that each of the 
documented effects would be applicable to mitochondria in whole-cells also. We observed the 
collapse of HC MtMPs after 16 minutes extracellular exposure to 5 mM gentamicin. What 
remains to be determined is what concentration of gentamicin would accumulate 
intracellularly when this MtMP collapse is observed. Because the cochlear cultures are 
stripped of their SV during the dissection process, the EP would not be present to act as a 
driving force for AG entry, as is usually the case in vivo. Moreover, the EP only starts to develop 
in mice in vivo around P7, so it would not be present in the cochlear cultures irrespective of SV 
removal. Electrophysiological experiments would need to be conducted to assess the HC’s 
resting potential, so as to establish what driving force would exist across the MET channel, in 
order to determine the entry rates of the antibiotics and their consequent accumulation within 
the cell. Volumetric calculations of the HC size would also be required for this calculation. 
Furthermore, the speed at which HCs lose their MtMP may be quicker in vivo due to the 
differing temperatures. The experiments were performed at room temperature (20-22°C); 
however, if performed at body temperature (37°C), due to the kinetics involved in the entry 
rates, AGs might have entered more rapidly and caused a loss of the MtMPs more rapidly also. 
Another intriguing factor emerging from this research concerns the lack of MtROS production. 
After exposure to AGs, large spikes of ROS are observed in cochlear HCs before they undergo 
apoptosis (Clerici et al., 1996; Hirose et al., 1997; Sha and Schacht, 1999a). This was one line of 
evidence that suggested mitochondrial involvement in the AG-induced cell death process, as 
mitochondria are the main source of ROS within the cell. However, there are other sources of 
ROS production (Brand, 2010; Phaniendra et al., 2015), so this issue remains to be further 
investigated. Given the results presented within this chapter, it would suggest that AG-induced 
ROS production is not mitochondrial in nature. Perhaps if one could block MtROS production, 
by way of uncoupler addition, for example, and then investigate whether ROS spikes still occur 
in cells before apoptosis, this would add confirmation to our hypothesis of AG-induced 
mitochondrial uncoupling preventing MtROS formation. 
Interestingly, past researchers investigating the effect of gentamicin on mitochondrial activity 
found that after harvesting mitochondria from the kidney and liver of rats exposed to daily 
administration of gentamicin (Simmons et al., 1980), liver mitochondria showed no difference 
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when compared to controls, dissimilarly to what was found in those isolated from the kidney. 
This implied that only the mitochondria of organs susceptible to AG damage are affected by 
the antibiotics. However, here I have demonstrated the same effect of gentamicin on both 
kidney and liver mitochondria. What this suggests is that all mitochondria are susceptible to 
AG damage; however, it is the entry and exit rates into specific organs, and the consequent 
accumulation, that determines whether an organ’s mitochondria are affected by the 
antibiotics. 
The results presented herein confirm mitochondrial involvement in AG-induced ototoxicity 
whilst also potentially contesting the opposing postulation that it is the ER (or more 
specifically, its calcium signalling to mitochondria) that underlies the phenomenon, as other 
researchers have more recently suggested (Esterberg et al., 2013; 2014; 2016; Hailey et al., 
2017; O’Sullivan et al., 2017). Here we demonstrated that the same effects that have been 
observed in whole-cell systems, both kidney and cochlea, before the onset of AG-induced cell 
death occur in the isolated mitochondrial systems used in this chapter. Mitochondria in 
isolation receive no signalling input from the ER, which implies that mitochondria are 
susceptible to the reported AG effects independent of any input from the ER or its calcium 
signalling pathways. This is consistent with previous reports of mitochondrial alterations as the 
earliest and most predominant event observed in neomycin-induced cell death in zebrafish 
lateral line systems (Owens et al., 2007). 
The evident preventative effect of Tocris compound 13143 on gentamicin’s stimulation of 
state 4 respiration could be independent of its mechanism of protection, similarly to its effect 
on GTTR loading as presented in Chapter 4. This presumption arose due to the lack of any 
effect observed with 13097. Both compounds are Kv7 channel blockers, with 13097 (XE 991) 
identified as an improved version of 13143 (linopirdine) for use as a cognitive enhancer 
(Zaczek et al., 1998; Greene et al., 2017). Consequently, it was assumed that both compounds 
would protect HCs in a similar way. It therefore remains to be determined whether the 
preservation of mitochondrial function is indeed the mechanism of otoprotection of 13143. In 
order to investigate this further, assessment of MtMPs in cochlear culture sensory hair cells 
exposed to gentamicin alone (Figure 8.7) or gentamicin alongside 13143 would reveal whether 
this effect potentially underlay the identified HC protection.  
To conclude, the research presented in this chapter provides an exciting new prospect for the 
investigation of the mechanism of action of identified otoprotectants. If confirmed to be the 
true effect of the AGs, the potential for screening prospects is enormous. Although the 
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Oroboros Oxygraph only has two chambers, and so only allows the comparison of two 
mitochondrial samples at any one time, there are larger-scale versions of the machinery. 
Seahorse Biosciences have utilised the same principle of oxygen consumption assays for the 
assessment of mitochondria activity; however, their machines can hold up to 96 well plates 
and can be used both with isolated mitochondria and whole cells (Plitzko and Loesgen, 2018). 
If the effects I observed in the Oroboros Oxygraph could be replicated in Seahorse machinery, 
then we could use this for high-throughput screening of potential otoprotectants, especially 
when compared to the much lower throughput of our cochlear culture screening procedures. 
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9    Final Summary and Conclusions 
 
Within this thesis I present a number of potential novel otoprotectants, to the identification 
and validation of which I have contributed. These compounds are capable of protecting against 
the AG-induced loss of sensory hair cells that underlies the ototoxicity associated with the 
clinical use of the antibiotics. In terms of the identification of compounds that provide any 
otoprotective effect in mammalian models I discuss 25 novel compounds: 13 compounds from 
the Tocris Ion Channel library of ion channel interactors and 1 Tocris compound derivative 
(Chapter 4); the d-Tubocurarine-related alkaloid berbamine and a similar neuromuscular 
blocker that was commercially bought (Chapter 5); the FDA-approved drug carvedilol and 4 of 
its synthesised derivatives (Chapter 6); and 4 FM 1-43 derivatives synthesised in house 
(Chapter 7). Additionally, I have confirmed the protective nature of d-Tubocurarine and 
questioned that of FM 1-43, whilst extending the knowledge base of their otoprotective 
profiles.   
After thoroughly screening for any potentially adverse effects of all of the newly-identified 
otoprotectants investigated in this thesis, 5 compounds remained that have the potential to be 
used in a clinical setting. These 5 compounds emerged from the Tocris Ion Channel library 
screen (13097, 13142, 13143, 13154 and 13222), all of which displayed otoprotective 
properties and also no adverse effects throughout the comprehensive screening process. 
These compounds are now awaiting in vivo validation of their otoprotective abilities, for 
confirmation that they protect, and do not induce any off-target side-effects, when used in a 
whole mouse model. 
Of the 5 compounds with the potential for clinical application, 3 of them block sensory hair cell 
MET channels (13142, 13154 and 13222), suggesting block of AG entry to be their mechanism 
of protection. The remaining two (13097 and 13143) do not interact with the MET channel. 
They do interact with IK,neo, the other membrane channel that could influence the AG uptake 
process, however their modest block of this channel did not depolarise the OHCs, suggesting 
that they do not prevent AG entry but rather protect intracellularly. Although both avenues of 
otoprotection should thus continue to be investigated, I would argue that an intracellular, non-
MET blocking approach may be the most successful. Compounds 13097 (XE 991) and 13143 
(linopirdine) both protect mammalian hair cells at extremely low concentrations. Both 
protecting in the low nanomolar range, these compounds protect with a much greater efficacy 
than any other identified in this thesis and also reported elsewhere in the literature. It is 
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evident that they do not block the MET channel or prevent AG loading into hair cells. 
Extrapolating, this implies that they are likely to be working intracellularly, for example by way 
of preventing apoptosis induction in sensory hair cells. Compound 13143 may be protecting by 
preventing AG-induced mitochondrial dysfunction (Chapter 8), however this remains to be 
confirmed with additional experimentation. 
The research presented in this thesis has highlighted the importance of a thorough screening 
procedure when searching for otoprotectants with the potential for use in a clinical setting. A 
large number of the potential novel protectants identified herein (approximately 80%) were 
ineligible for testing in vivo due to the adverse side-effects they were shown to cause in mouse 
cochlear cultures, and therefore may induce in a whole mouse model. Consequently, it is vital 
that thorough screening procedures are always adhered to throughout this investigatory 
process. 
I have confirmed that the use of zebrafish pre-screening and a two-model system using the 
zebrafish lateral line and mouse cochlear cultures for otoprotectant discovery is a viable and 
successful procedure, with the majority of compounds shown to protect in mouse cochlear 
cultures also identified as protectors in the preliminary zebrafish screens. However, although 
useful for initial trials, follow-up experiments with extensive additional screening in 
mammalian systems should always be conducted. 
Lastly, I have shown that chemical compound modification based on the way in which a 
compound provides protection is a viable method for the production of alternative and 
additional otoprotectants. In each otoprotectant screening chapter presented herein, selected 
compounds were structurally modified and this led to the production of novel compounds 
capable of protecting against AG-induced sensory hair cell loss. Some of these modifications 
led to improved protective efficacy and also a reduction of unwanted, adverse side-effects. 
This confirms that the modification of compounds based on a compound’s mechanism of 
protection is a viable method for the generation of novel otoprotectants.  
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